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Abstract 
 
The basal forebrain, a grey matter region located in the medial and ventral aspects of the 
mammalian brain, consists of highly heterogeneous populations of cells including, but not 
limited to: cholinergic, GABAergic, glutamatergic and calbindin-positive neurons. The 
function of the basal forebrain has been linked to mediating reward-related behaviours, 
attention and, more recently, learning and memory in humans. In healthy aging, the basal 
forebrain undergoes slow, progressive degeneration over time. However in conditions 
such as Down-syndrome, Alzheimer’s disease and Parkinson’s disease this degenerative 
process is highly increased; why the basal forebrain is particularly vulnerable to 
neurodegeneration is unclear. 
Here we show that degeneration of the basal forebrain in Alzheimer’s disease occurs very 
early, even in patients diagnosed with a prodromal stage of the disease, called amnestic 
mild cognitive impairment. By imaging and measuring the basal forebrain volume non-
invasively through magnetic resonance imaging (MRI) in humans, the state of an 
individual’s basal forebrain can be assessed and might be predictive of future disease 
progression.  
We found that subjects with a basal forebrain volume below a certain cut-off value were at 
a 7 times higher risk of having a worse diagnosis within ~18 months. In addition, basal 
forebrain degeneration correlates with the two major hallmarks of Alzheimer’s disease 
pathology: amyloid beta and tau protein burden in the brain in living subjects. During the 
development of Alzheimer’s disease, degeneration of the basal forebrain follows a distinct 
posterior-to-anterior pattern, and the volume of posterior basal forebrain nuclei is 
correlated to amyloid beta level in asymptomatic subjects, whereas the volume of anterior 
basal forebrain nuclei is correlated to amyloid beta level in subjects suffering from 
amnestic mild cognitive impairment and Alzheimer’s disease.  
Furthermore, a strong correlation exists between basal forebrain atrophy, particularly of 
the posterior volume, and tau burden in brain regions that are typically affected by tau 
pathology and which are also anatomically connected to the posterior basal forebrain. In 
addition, we found that a weaker correlation exists between basal forebrain atrophy and 
amyloid burden, as compared to the correlation between basal forebrain atrophy and tau 
burden. Also, tau and basal forebrain atrophy were associated with cognitive measures in 
Alzheimer’s disease subjects and controls, whereas amyloid burden was not. Our findings 
therefore support the idea that Aβ accumulation is a necessary but insufficient cause for 
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progression to AD, with secondary, downstream or parallel events being required to trigger 
tau aggregation and BF degeneration, which then directly underpin cognitive decline. 
Based on these findings we suggest that an evaluation of basal forebrain atrophy should 
be included into routine MRI diagnostic procedures aimed at assessing the likelihood of 
development of dementia in elderly subjects. 
We further show, through selective ablation of a single population of cells (cholinergic 
neurons) of the basal forebrain in mice, that such subtle cell death in this region – similar 
to very early basal forebrain degeneration - does not affect the basal forebrain volume 
itself, but that MRI methods can still detect alterations in the diffusion of water molecules. 
This technique of diffusion MRI might offer an even more sensitive diagnostic method for 
Alzheimer’s disease risk.  
In order to conduct studies investigating degeneration of basal forebrain neurons in mice 
reliably and in greater detail in the future (through a combination of histological and MRI 
analysis), we are in the process of developing an average volume of the cholinergic nuclei 
of the basal forebrain from histological segmentation of three mice. The volumes are 
registered to MR images of the same mice and can therefore be used as a guide and 
reference by other researchers aiming to study basal forebrain pathology using mouse 
models recapitulating diseases such as Alzheimer’s disease and Parkinson’s disease. 
The work of this thesis will help to better understand the development of Alzheimer’s 
disease, further establish the role of basal forebrain dysfunction as a hallmark of 
Alzheimer’s disease pathology, and provide another important step towards an early 
diagnosis of this condition. 
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Chapter 1: Project rationale 
 
1.1 Introduction 
 
The cholinergic system in the human brain was discovered as one of the initial defective 
neurotransmitter systems in Alzheimer’s disease. Once the major source of acetylcholine 
in the brain, namely the cholinergic basal forebrain neurons, was identified (Whitehouse et 
al., 1981), a long quest to study their development, architecture, and function in health as 
well as dysfunction in disease began. At the same time, the so-called “cholinergic 
hypothesis” was born (Bartus et al., 1982), which postulated that loss of cholinergic basal 
forebrain neurons in aging and Alzheimer’s disease was a major contributor to the 
cognitive dysfunction observed in these subjects. A vast body of evidence accumulated 
over several decades of research starting from the early 1960s until today proving that the 
basal forebrain system is one of the most complex, functionally diverse but also vulnerable 
neurotransmitter systems in the brain. 
Motivated by the goal of finding the cause of Alzheimer’s disease and a cure for this 
condition several classes of drugs aimed at improving basal forebrain neuronal function 
and rescuing the death of cholinergic neurons were developed or are currently being 
developed. While the simplicity of the original form of the “cholinergic hypothesis” of 
Alzheimer’s disease is captivating, many aspects of this pathophysiological 
oversimplification have been disputed and questioned even by its initial discoverers and 
especially in light of recent evidence (Bartus, 2000; Baxter and Bucci, 2013; Burns et al., 
1997; Contestabile, 2011), such as the poor efficacy of cholinergic drugs, the finding that 
only mild cognitive effects are caused by cholinergic lesions in animal models and the fact 
that frank cholinergic cell loss only occurs in late stage Alzheimer’s disease. However 
there is no doubt that the initial dysfunction of cholinergic neurons, and hence dysfunction 
of the basal forebrain neuronal system overall, represents a central and early event in 
Alzheimer’s disease aetiology. Therefore studies of basal forebrain degeneration and its 
relationship to the major events in disease progression can give crucial insights in 
Alzheimer’s disease pathogenesis.  
Even though extensive research has been conducted studying the pathophysiology of the 
basal forebrain in Alzheimer’s disease, even today, it remains to be determined whether 
there is a relationship between degeneration of the basal forebrain and the accumulation 
of amyloid plaques as well as tau neurofibrillary tangles (the major pathological hallmarks 
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of Alzheimer’s disease) in the human brain in vivo. New advances in the imaging field now 
enable this potential interaction to be studied. Such methods in the future could also be 
applied to measure deterioration of connections of the basal forebrain network, and 
therefore give clues to how these factors manifest during the development of Alzheimer’s 
disease. Furthermore, imaging techniques have the potential to contribute invaluable non-
invasively acquired information that can aid in the diagnosis of neurological conditions 
including Alzheimer’s disease and its prodromal conditions.  
The aim of this thesis was to develop imaging methods to quantify basal forebrain neurons 
and their projections in mouse models of, and humans diagnosed with, Alzheimer’s 
disease, and its prodromal stages. These methods were also used to study the 
relationship between basal forebrain degeneration, amyloid and tau accumulation and 
cognition during the development of Alzheimer’s disease. 
 
1.2 Alzheimer’s disease 
 
Alzheimer’s disease is the most common form of aging dementia. Worldwide, the number 
of people with this condition is predicted to reach 66 million by 2030 and 115 million by 
2050 (Sui et al., 2014). The prevailing hypothesis of the cause of Alzheimer's disease is 
that the brain overproduces or fails to degrade an endogenously produced peptide known 
as amyloid beta (Hardy and Selkoe, 2002). Recent evidence has shown that soluble 
amyloid beta is toxic, causing inhibition of synaptic activity as well as neurodegeneration.  
Further aggregation of amyloid beta leads to extracellular deposits known as amyloid 
plaques, a histological hallmark of Alzheimer's disease from which the pathological 
diagnosis of the condition arose (Hardy and Selkoe, 2002; Masters and Beyreuther, 1991). 
Another hallmark of the disease is the aggregation of the microtubule-associated protein 
tau. The normal biological function of tau is to bind and stabilize microtubules in neurons 
but in Alzheimer’s disease, tau becomes hyperphosphorylated at multiple phosphorylation 
sites. This renders the protein unable to associate with microtubules and subsequently tau 
molecules aggregate and form intracellular inclusions termed neurofibrillary tangles 
(NFTs). 
Genetic screens have not been able to identify tau mutations in Alzheimer’s disease 
patients but there are a number of mutations that are known risk factors for conditions 
such as progressive supranuclear palsy and corticobasal degeneration. These mutations 
affect tau function either at the transcriptional level, causing a shift in the level of 
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expression of different tau isoforms, or at the protein level, increasing the propensity of tau 
to form aggregates (Goedert and Jakes, 2005). In contrast, several mutations affecting the 
protein cascade responsible for the production of amyloid beta have been found to be 
present in patients with early onset Alzheimer’s disease. The amyloid precursor protein 
(APP) is cleaved by the enzymatic complexes beta secretase and gamma secretase to 
produce amyloid beta. Presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are functional 
components of the gamma secretase complex and mutations in APP, PSEN1 and PSEN2 
genes are known risk factors for early onset Alzheimer’s disease. The majority of 
mutations identified in these genes cause an increased production of the 42 amino acid 
long amyloid beta peptide (Aβ42) vs. the 40 amino acid long (Aβ40) version. Although this 
does not affect total amyloid beta levels, it has been shown that in comparison to Aβ40, 
Aβ42 is more prone to aggregate and this may play a role in inducing Alzheimer’s disease 
(Bertram et al., 2010; Citron et al., 1997). 
In Alzheimer’s disease, cells within the basal forebrain might be particularly vulnerable to 
neurodegeneration, such as caused by the formation of protein aggregates consisting of 
Aβ and/or tau (Mufson et al., 2014; Vana et al., 2011). 
 
1.3 Cell types in the basal forebrain 
 
In general, the cellular architecture of the basal forebrain is highly complex and there 
appears to be no uniform distribution pattern of different cell types across its rostrocaudal 
extent. The basal forebrain is made up of a variety of cell types expressing different 
neurotransmitters and/or neurochemicals and neuropeptides. These include cholinergic, 
GABAergic and glutamatergic neurons, calcium binding protein (e.g. parvalbumin, 
calbindin, calretinin, secretagogin) -expressing neurons as well as neuropeptide (e.g. 
neuropeptide-Y, somatostatin, galanin) -expressing neurons. Cholinergic, GABAergic and 
glutamatergic neurons in the basal forebrain share common projection targets to cortical 
and subcortical areas (Gritti et al., 2003; Henny and Jones, 2008; Hur and Zaborszky, 
2005; Zaborszky et al., 1999).  
In addition to the heterogeneous neurochemical profile of basal forebrain cells, 
electrophysiological studies have shown differences in the membrane potential between 
cholinergic and non-cholinergic cells, as well as between cholinergic cells depending on 
their location within the basal forebrain (Unal et al., 2012). For example early firing 
cholinergic neurons might be more important contributors of phasic changes in cortical 
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acetylcholine release associated with attentional functions, whereas late firing cholinergic 
cells are more involved in tonic acetylcholine release mediating general arousal effects. 
The most well studied cells of the basal forebrain are the cholinergic neurons, as their 
degeneration was found to be the underlying factor causing a decrease in brain 
acetylcholine levels in Alzheimer’s disease patients (Whitehouse et al., 1981). Cholinergic 
neurons are found in all nuclei of the basal forebrain and the distribution of cholinergic 
cells does not appear to follow classically defined boundaries of nuclei (Zaborszky et al., 
2008). These neurons express the neurotrophin receptors TrkA and p75NTR and nearly 
all (>95%) of the p75NTR-expressing neurons are also ChAT-positive (Mesulam et al., 
1983a). In addition calbindin-D(28K) has been shown to be present in 72% of all ChAT-
positive basal forebrain neurons (Geula et al., 2003). Even though cholinergic neurons are 
located throughout the whole extent of the basal forebrain, relative cell numbers vary 
greatly between basal forebrain nuclei. It has been shown that, in the human brain, the 
nucleus basalis of Meynert is largely composed of cholinergic neurons (90%), as 
compared to Ch1/medial septum (10%), Ch2/horizontal diagonal band (70%) and 
Ch3/vertical diagonal band (1%) areas (Mesulam et al., 1983a). However more recent 
work in rodents (Gritti et al., 2006; Zaborszky et al., 2005)  has found that only a small 
population (~5%) of all neurons in the basal forebrain have the ability to synthesize 
acetylcholine, whereas 35% of neurons are GABAergic and 90% of all neurons synthesize 
glutamate. Moreover, the distribution of cholinergic-, calretinin-, calbindin- and 
parvalbumin-positive cells is not random. Indeed Zaborszky et al. (2005) found that the cell 
composition of clusters in the basal forebrain is regionally specific. For example, in the 
extended amygdala mostly calbindin-positive cells are present whereas the substantia 
innominata is rich in calbindin- and calretinin-positive cells. 
The basal forebrain is a cytoarchitectonically complex structure and different 
nomenclatures have been proposed. Mesulam et al. (1983) suggested a nomenclature 
according to target projection areas. However this nomenclature was not straightforward 
due to the lack of specific landmarks and recently a revised version of the original 
nomenclature was recently introduced (Zaborszky et al., 2008). New computational tools 
to analyse the clustering of cell populations in structures (Nadasdy et al., 2010) will 
provide helpful insight into the complicated organizational pattern of the basal forebrain, 
and detailed neuroanatomical tracer studies are now shedding new light into the functional 
organization of basal forebrain cells with respect of their projection targets (Zaborszky et 
al., 2013). 
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1.4 The role of the basal forebrain in Alzheimer’s disease 
 
The basal forebrain degenerates in Alzheimer’s disease (Mufson, 2003; Mufson et al., 
2008; Schliebs and Arendt, 2011; Whitehouse et al., 1981) and the number of cholinergic 
neurons within this region is severely reduced (Contestabile, 2011; Whitehouse et al., 
1981), which is believed to play a role in the cognitive dysfunction that occurrs in 
Alzheimer’s disease (Bartus, 2000; Bartus et al., 1982; Perry et al., 1978). To treat this 
dysfunction and to alleviate cognitive symptoms of Alzheimer’s disease a drug class called 
acetylcholine esterase inhibitors was developed. Acetylcholine esterase inhibitors inhibit 
the degrading enzyme of acetylcholine, acetylcholine esterase, in the synaptic cleft, 
thereby prolonging acetylcholine availability. Acetylcholine esterase inhibitors are 
efficacious for mild to moderate Alzheimer’s disease and have been shown to slightly 
improve attention and executive functions, communication, expressive language and 
mood stability; however the time period over which they exert their effect is relatively short 
(Martinez et al., 2009; Pepeu and Giovannini, 2009). 
Results on the effect of acetylcholine esterase inhibitors have been conflicting, with a 
recent study investigating long-term treatment using donepezil, rivistagmine and 
galantamine in patients with mild cognitive impairment showing no beneficial effect of 
these drugs to either reduce the risk or delay the onset of Alzheimer’s disease (Raschetti 
et al., 2007). Therefore it is evident that acetylcholine esterase inhibitors only have limited 
potential to treat cognitive dysfunction in Alzheimer’s disease and application in prodromal 
stages of the disease are not disease modifying i.e. do not prevent development of the 
condition. Thus there is a clear need for the development of new therapeutics that have 
the potential to alleviate neuronal degeneration in the basal forebrain, with one possibility 
being the application of molecules targeting neurotrophin receptors present on cholinergic 
basal forebrain neurons (Longo and Massa, 2013) which have been shown to rescue 
degeneration and improve cognition in an Alzheimer’s mouse model (Knowles et al., 
2013). 
 
1.4.1 Cholinergic neurons 
 
Cholinergic neurons degenerate in late-stage Alzheimer’s disease but there is no loss of 
cholinergic neurons in mild cognitive impairment (a prodromal stage of the disease) or 
early/mild Alzheimer’s disease (Contestabile, 2011; Gilmor et al., 1999) and no reduction 
in cortical levels of choline acetyl transferase (ChAT; the synthesizing enzyme of 
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acetylcholine expressed by cholinergic basal forebrain neurons) was found in patients with 
mild cognitive impairment or mild Alzheimer’s disease, whereas a severe reduction in 
cortical ChAT and the number of cholinergic basal forebrain neurons was found in late 
stage Alzheimer’s disease subjects (Contestabile, 2011; Davis et al., 1999; DeKosky et al., 
2002; Gilmor et al., 1999; Mufson, 2003; Tiraboschi et al., 2000). In addition there was no 
significant reduction of the vesicular acetylcholine transporter (VAChT) in the basal 
forebrain in mild cognitive impairment and mild Alzheimer’s disease patients compared to 
controls (Gilmor et al., 1999). The fact that significant cholinergic neuronal loss is only 
present at later stages of the disease became clear when reliable ways to categorize 
Alzheimer’s disease patients as belonging to either mild, moderate or late-stage 
categories were developed - with the help of cognitive tests such as the mini-mental state 
examination (MMSE).  
When post-mortem brain samples of the midfrontal area of patients with mild Alzheimer’s 
disease (MMSE=20), moderate Alzheimer’s disease (MMSE=10 to 19) and severe 
Alzheimer’s disease (MMSE=1 to 9) were stained for synaptophysin, a marker used to 
assess synaptic density, and ChAT, both markers were found to undergo asynchronous 
changes. Whereas synaptophysin reduction was most pronounced in patients with 
moderate Alzheimer’s disease, a significant decline in ChAT was only observed in patients 
with severe Alzheimer’s disease, and neither synaptophysin nor ChAT was reduced in 
patients with mild Alzheimer’s disease (Davis et al., 1999; Tiraboschi et al., 2000). Thus 
dysfunction occurs prior to synaptic loss and cholinergic neuron loss, which manifest 
during later stages of the disease. This finding has been further confirmed in various other 
cortical regions (superior frontal, inferior parietal, superior temporal and anterior cingulate) 
and the hippocampus (DeKosky et al., 2002).  
In contrast, ChAT activity has been shown to be increased in the hippocampus and 
superior frontal cortex of mild cognitively impaired subjects compared to controls (DeKosky 
et al., 2002), which might point towards a compensatory upregulation of ChAT activity in 
basal forebrain neurons in response to the onset of Alzheimer’s disease. In the case of the 
hippocampus it was hypothesized that early depletion of the entorhinal-hippocampal 
connection, which has been shown to occur in mild cognitive impairment (DeKosky et al., 
2002; Ikonomovic et al., 2003), could lead to increased sprouting of the septohippocampal 
connection (Stanfield and Cowan, 1982), producing an increase in ChAT within the 
hippocampus (Contestabile, 2011).  
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ChAT-positive neurons are present in all nuclei of the basal forebrain and also express the 
neurotrophin receptors p75 neurotrophin receptor (p75NTR) and tyrosine kinase A (TrkA), 
which bind nerve growth factor (NGF) and this process is involved in survival of cholinergic 
basal forebrain neurons. It has been shown that there is significant reduction in the 
expression of p75NTR and TrkA in basal forebrain neurons in Alzheimer’s disease patients 
compared to controls (Mufson et al., 2000; Mufson et al., 2002). Interestingly, in the same 
tissue samples of mild cognitively impaired subjects who displayed no reduction in 
cholinergic neuron number (Gilmor et al., 1999), a significant reduction of p75NTR- and 
TrkA- expression was found which was comparable to the reduction in Alzheimer’s 
disease patients (Mufson et al., 2000; Mufson et al., 2002). Reductions in neuronal 
expression of p75NTR and TrkA in the nucleus basalis of Meynert of Alzheimer’s disease 
and mild cognitively impaired subjects relative to controls were 56% (Alzheimer’s disease) 
and 46% (mild cognitive impairment) and 43% (Alzheimer’s disease) and 38% (mild 
cognitive impairment) for TrkA- and p75NTR- positive neurons respectively, and neuron 
numbers were also correlated with measures of cognitive function (Mufson et al., 2000; 
Mufson et al., 2002). These alterations in p75NTR and TrkA levels might indicate a severe 
neurotrophic defect and simultaneous dysfunction of cholinergic neurons before the 
occurrence of frank cell loss (Mufson, 2003). In line with this it was shown that the mRNA 
levels of TrkB and TrkC were also significantly reduced in Alzheimer’s disease patients, 
with changes in the mRNA levels of synaptic proteins, protein phosphatases and amyloid-
related proteins (Mufson, 2003).  
It has also been shown that cholinergic basal forebrain neurons undergo degenerative 
changes when exposed to amyloid beta (Sotthibundhu et al., 2008). Furthermore through 
in vitro and in vivo experiments, p75NTR has been suggested to mediate this 
degeneration by directly interacting with amyloid beta (Knowles et al., 2009). Additional in 
vitro and in vivo evidence implicates amyloid beta in depression of acetylcholine synthesis 
and release, inhibition of long-term potentiation (LTP) through disturbance of cholinergic 
transmission, and impairment of muscarinic acetylcholine receptor signalling and therefore 
interference with function of at least one of the prominent cell types present in the basal 
forebrain (Auld et al., 2002; Yan and Feng, 2004). However, whether basal forebrain 
pathology is related to amyloid accumulation in humans in vivo, remains unknown. 
Cholinergic neurons have also been shown to exhibit NFT pathology. It is known from 
human post-mortem tissue studies that basal forebrain neurons develop some of the 
earliest pathological tau alterations described in Braak stage I (Braak et al., 2006). Even in 
individuals under 30 years of age, abnormally phosphorylated tau protein was found in 
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basal forebrain neurons (Braak and Del Tredici, 2011b). Recent studies have also 
documented the presence of pretangle tau oligomers in cholinergic basal forebrain 
neurons during the development of Alzheimer’s disease (Mufson et al., 2014; Vana et al., 
2011). Interestingly, an increase in early tau pathological markers coincided with a 
decrease in p75NTR staining and these changes correlated with Alzheimer’s disease 
neuropathology and cognitive decline (Vana et al., 2011). Again, however, the relationship 
between basal forebrain degeneration and aggregation of tau tangles in living subjects has 
not been explored. 
 
1.4.2 GABAergic and calbindin-positive neurons 
 
A study by Geula et al. (2003) demonstrated a significant age-related loss of calbindin-
D(28K) immunoreactivity in cholinergic basal forebrain neurons. Individuals over the age of 
65 showed a 61% reduction of calbindin-D(28K)-positive cholinergic neurons compared to 
those under the age of 65, suggesting a significant age-related loss of expression of 
calbindin-D(28K), whereas no changes in ChAT or p75NTR immunoreactivity were 
observed. This dramatic loss of calbindin-D(28K) from cholinergic neurons presented in 
the same pattern in Alzheimer’s disease patients and was more pronounced in the 
posterior part of the basal forebrain as compared to the anterior part. Cholinergic neurons 
lacking calbindin-D(28K) are not able to buffer high intracellular Ca2+ levels effectively and 
thus are more likely to be vulnerable to pathological processes occurring in Alzheimer’s 
disease such as mitochondrial damage.  
The GABAergic system in the brain was considered to be relatively spared in Alzheimer’s 
disease but this view is currently being challenged. Through immunostaining of the main 
enzymes of the GABAergic system, glutamate decarboxylase 65 (GAD65), GAD67 and 
GABA transferase (GABAT), Schwab and colleagues (2013) demonstrated that these are 
present in the neocortex, hippocampus, basal ganglia and cerebellum in humans. GAD65 
and GAD67 were found in neuropil granules, axons and neurons whereas GABAT was 
found in neurons and glial cells. In Alzheimer’s disease, the authors found a severe 
reduction of GAD65 immunostaining in the middle temporal gyrus, hippocampus and 
putamen accompanied by a similar reduction in GAD65 protein levels as determined by 
western blotting. This GABAergic deficit is likely to contribute to Alzheimer’s disease 
pathogenesis but it remains to be determined whether it occurs in GABAergic basal 
forebrain neurons and therefore possibly contributes to the deterioration of basal forebrain 
function in mild cognitive impairment and Alzheimer’s disease. As well as cholinergic and 
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GABAergic neurons many other cell types exist in the basal forebrain; however changes in 
these populations have not been reported and so whether they also play roles in the 
deterioration of the basal forebrain in Alzheimer’s disease remains poorly understood. 
 
1.5 Anatomy of the basal forebrain 
 
Some of the nuclei of the basal forebrain have already been mentioned in the above 
sections; however this part of the thesis will provide a complete list of all the grey matter 
structures included in the basal forebrain and will further explain how these nuclei are 
situated along the medial and ventral parts of the human forebrain.  
The basal forebrain comprises the medial septum, vertical and horizontal diagonal bands 
of Broca, nucleus basalis of Meynert, magnocellular preoptic nucleus, substantia 
innominata, ventral pallidum, extended amygdala and the interstitial nucleus of the 
posterior limb of the anterior commissure. With regards to the human brain, the 
magnocellular preoptic nucleus is often included as part of the horizontal diagonal band of 
Broca whereas the substantia innominata, ventral pallidum, extended amygdala and 
interstitial nucleus of the posterior limb of the anterior commissure are often included as 
part of the nucleus basalis of Meynert. Different cell types within the basal forebrain are 
mostly dispersed across nuclei and therefore there are no clearly visible anatomical 
boundaries separating these nuclei, and it is viewed overall as a continuum (Schwaber et 
al., 1987; Zaborszky et al., 2005).  
The medial septum is the most rostral nucleus situated between the lateral ventricles 
extending from the level of the genu of the corpus callosum to the level of the fornix. The 
medial septum merges rostroventrally with the vertical diagonal band of Broca. The 
horizontal diagonal band of Broca follows on from the ventral part of the vertical diagonal 
band of Broca and is then rostroventrally connected to the magnocellular preoptic nucleus. 
The Medial septum and diagonal band nucleus are eventually separated by the anterior 
commissure crossing the midline, with the medial septum lying dorsally and the diagonal 
domain located ventral to the anterior commissure. The substantia innominata extends 
ventrolaterally from the magnocellular preoptic nucleus and this structure has often been 
included as part of, or used as a synonym for, the nucleus basalis of Meynert; however 
recently parts of this complex have been attributed to other anatomical systems as a result 
of tracer studies (Zaborszky et al., 2008). The parts often included in the substantia 
innominata/nucleus basalis of Meynert complex are the ventral pallidum, extended 
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amygdala and interstitial nucleus of the posterior limb of the anterior commissure. The 
ventral part of the globus pallidus, or ventral pallidum, is situated rostral to the substantia 
innominata, whereas the caudal part of the substantia innominata is referred to as the 
extended amygdala, which is defined as the cell bridges extending from the centromedial 
amygdala to the bed nucleus of the stria terminalis (Zaborszky et al., 2008).  
Dorsolateral to the ventral pallidum and ventrolateral to the caudate putamen lies the 
interstitial nucleus of the posterior limb of the anterior commissure, which extends dorsally 
to the level of the anterior commissure (Heimer, 2000; Heimer et al., 1991; Riedel et al., 
2002; Zaborszky et al., 2008). The overall anatomy of the basal forebrain is highly 
complex and for the purpose of the magnetic resonance imaging (MRI) investigations of 
the basal forebrain area in this thesis we performed measurements of the whole area, or 
anterior and posterior areas separately. The definitions of the anterior and posterior areas 
(chapter 3, 4, 5) were guided by a recent study showing that degeneration of these areas 
might occur at different stages in Alzheimer’s disease (Grothe et al., 2010). In that study it 
was found that all volumetric changes in mild cognitively impaired patients compared to 
controls were restricted to the posterior part of the basal forebrain, corresponding to the 
nucleus basalis of Meynert. Furthermore these anterior and posterior basal forebrain areas 
also differ in their projection targets. 
 
1.6 Efferents and afferents of basal forebrain neurons 
 
One of the major aims of this thesis was to study basal forebrain degeneration in 
Alzheimer’s disease and how this relates to amyloid and tau accumulation as well as 
cognitive impairment. As the basal forebrain sends projections to many brain areas and 
receives input from many others (see below), it is very likely that toxic protein aggregates 
present in these brain areas come in close contact with basal forebrain neurons and 
therefore possibly exert direct neurodegenerative effects on these neurons. On the other 
hand, degeneration of basal forebrain neurons, and the resulting diminished support of 
neurotransmitters such as acetylcholine to target brain areas, is likely to contribute to the 
cognitive deterioration in Alzheimer’s disease patients. In order to interpret these effects 
on basal forebrain neurons, one has to be aware of the general anatomy of the efferent 
and afferent connections of basal forebrain neurons. A diagram showing the major efferent 
projections of the basal forebrain is given (Fig. 1.1). 
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1.6.1 Efferent projections 
 
Neurons in the medial septum and vertical diagonal band of Broca of the basal forebrain 
project to the hippocampus via the fornix and neurons in the horizontal diagonal band of 
Broca and magnocellular preoptic nucleus project to the olfactory bulb, piriform and 
entorhinal cortices. Furthermore neurons in the nucleus basalis of Meynert, substantia 
innominata, ventral pallidum, extended amygdala and interstitial nucleus of the posterior 
limb of the anterior commissure regions project to the amygdala and the entire neocortex 
(Amaral and Kurz, 1985; Armstrong et al., 1983; Carlsen et al., 1985; Gaykema et al., 
1990; Lamour et al., 1984; Luiten et al., 1987; Mesulam et al., 1983a; Mesulam et al., 
1983b; Nyakas et al., 1987; Rye et al., 1984; Sofroniew et al., 1982; Sofroniew et al., 
1987; Wainer et al., 1985; Woolf et al., 1984; Woolf et al., 1986; Zaborszky et al., 1986). 
The general organization of cortically projecting neurons in the basal forebrain follows a 
rough medio-lateral and antero-posterior topography (Mesulam et al., 1983; Zaborszky et 
al., 2008). In the primate brain, the cortically projecting cholinergic neurons are therefore 
further divided into distinct subnuclei (Mesulam et al., 1983). Accordingly, medial cortical 
areas e.g. cingulate cortex receive projections from the cholinergic anteromedial (Ch4am) 
nucleus, whereas ventral orbital, frontal, and parietal regions and the amygdala receive 
projections from the anterolateral nucleus (Ch4al). The intermediate cholinergic nucleus 
(Ch4i) projects to the lateral frontal, parietal, peristriate and temporal regions and the 
posterior cholinergic nucleus (Ch4p) projects to superior temporal lobe and the temporal 
pole. It was thought that basal forebrain neurons innervate the cortex “diffusely”; however 
recently it was shown that cholinergic and noncholinergic neurons do not project to the 
frontal cortex in a diffuse manner, but are rather organized into groups of neurons 
projecting to the same target region (Zaborszky et al., 2013). Moreover the degree to 
which these “groups” of neurons overlap in the basal forebrain space might depend on the 
extent of the interconnectivity of the target projection areas. The authors propose that this 
organization therefore facilitates modulation of, for example, groups of interconnected but 
nonadjacent cortical regions by the basal forebrain neurons in a parallel manner. Cortical 
cholinergic innervation is present in all cortical layers but it has been shown to be most 
dense in layer V-VI of the motor cortex, layer III-IV in the primary sensory cortices and in 
layer II-III of the association areas (Mesulam et al., 1992; Mrzljak et al., 1995). Even 
though most studies investigating basalocortical innveration were focused on cholinergic 
neurons, it is becoming increasingly evident that basal forebrain efferents to pyramidal 
cells in the cortex and cortical interneurons arise not only from cholinergic but also 
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GABAergic and glutamatergic basal forebrain neurons (Zaborszky et al., 1999; Gritti et al., 
2003; Hur and Zaborszky, 2005; Henny and Jones, 2008), and all neuronal types appear 
to have similar functional roles in regulating cortical activity (Hassani et al., 2009). 
 
Diagonal band
Neocortex
Hippocampus
Nucleus basalis
Medial septum
Amygdala
Efferent projections
 
 
Figure 1.1: Major connections of the basal forebrain efferent neuronal projection 
system in the human brain.  
The main nuclei of the basal forebrain (medial septum, diagonal band, nucleus basalis of 
Meynert) and their respective projections are shown. Cholinergic, GABAergic and 
glutamatergic basal forebrain neurons project along the illustrated pathways. 
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In addition, orexin/hypocretin-expressing neurons in the hypothalamus receive input from 
cholinergic and GABAergic neurons located in the medial septum, vertical diagonal band 
of Broca, horizontal diagonal band of Broca and magnocellular preoptic nucleus areas, 
which might be an important anatomical connection involved in consolidation of 
wakefulness (Sakurai et al., 2005). 
 
1.6.2 Afferent projections 
 
The basal forebrain receives afferent projections from many areas in the brain, including 
the brainstem, amygdala, substantia nigra, ventral tegmental area, striatum, hippocampus 
and prefrontal cortex (Zaborszky et al., 1999). In the brainstem, the locus coeruleus 
(Zaborszky et al., 1993), the medial parabrachial nucleus, the pedunculopontine nucleus, 
the dorsal raphe nucleus, the lateral and ventral tegmental area and the supramammillary 
nucleus project to the substantia innominata and magnocellular preoptic nucleus areas of 
the basal forebrain as revealed by tracer studies; however most of these connections still 
require confirmation at the ultrastructural level (Hallanger and Wainer, 1988; Jones and 
Cuello, 1989; Martinez-Murillo et al., 1989; Semba et al., 1988; Vertes, 1988). Brainstem 
afferents have been shown to be adrenergic and form synapses onto cholinergic neurons 
(Hajszan and Zaborszky, 2002), whereas dopaminergic neurons from the ventral 
tegmental area mainly connect to parvalbumin- and somatostatin- positive cells in the 
basal forebrain (Gaykema and Zaborszky, 1996; Zaborszky and Duque, 2003).  
Neuronal input from the mesopontine tegmentum is cholinergic (Semba, 2000) and a small 
proportion of afferents from the dorsal raphe nucleus are serotonergic and dopaminergic 
neurons (Khateb et al., 1993). Projections from the basolateral amygdala form synapses 
onto either cholinergic or noncholinergic basal forebrain neurons in the ventral pallidum 
and parts of the substantia innominata; however the central amygdala sends efferents only 
to noncholinergic basal forebrain neurons of the substantia innominata (Jolkkonen et al., 
2002; Zaborszky et al., 1984). Hypothalamic orexin/hypocretin-positive afferents onto 
basal forebrain neurons are organized in a topographical manner, whereby lateral 
hypothalamic neurons project to lateral nuclei of the basal forebrain such as the ventral 
pallidum and substantia innominata, and the medial hypothalamic neurons project to 
medial nuclei, including the medial septum, vertical diagonal band of Broca and horizontal 
diagonal band of Broca (Cullinan and Zaborszky, 1991). Cells in the medial septum and 
vertical diagonal band of Broca receive reciprocal projections from the hippocampal 
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formation, and the prefrontal cortex projects to noncholinergic neurons in the basal 
forebrain (Zaborszky et al., 1997). 
 
1.7 Basal forebrain function 
 
The basal forebrain is involved in controlling cerebral blood flow, cortical activity and 
plasticity, and the sleep-wake cycle, as well as the modulation of cognitive functions such 
as attention, learning, spatial and working memory, information encoding, sensory-motor 
gating and memory consolidation (Schliebs and Arendt, 2006). 
 
1.7.1 Cognitive functions 
 
Even though the role of the cholinergic neurons in learning and memory is uncertain 
(McKinney and Jacksonville, 2005), there is no doubt that the basal forebrain as a 
functional unit is crucial for cognitive processes in the brain. Since the initial discovery of 
the loss of cholinergic neurons in Alzheimer’s disease, these cells have been implicated in 
attention, learning and memory (Schliebs and Arendt, 2011). Pharmacological application 
of anticholinergic drugs in young adults cause cognitive disturbances in these subjects, 
whereas administration of enhancers of the cholinergic system have beneficial (albeit 
minor) effects on cognition in patients suffering from Alzheimer’s disease (Schliebs and 
Arendt, 2006). Nonspecific lesions of basal forebrain nuclei have consistently shown 
cognitive impairments in animals using either excitotoxins (Markowska et al., 1990; Page 
et al., 1991; Robbins et al., 1989), which induced nonspecific basal forebrain cell loss, or 
specific toxins at high concentration or damaging injection protocols, which also resulted in 
nonspecific cell death (Baxter and Bucci, 2013; Lehmann et al., 2003).  
However application of immunotoxins, which selectively ablated cholinergic neurons in the 
anterior and/or posterior basal forebrain areas, resulted in almost no effects on learning 
and memory (Berger-Sweeney et al., 1994; Torres et al., 1994; Wenk et al., 1994). Other 
studies that achieved selective lesioning of cholinergic neurons in animal models 
demonstrated that they play a role in attention as well as working memory (Baxter and 
Bucci, 2013; Bucci et al., 1998; Chudasama et al., 2004; Moreau et al., 2008). The 
absence of severe cognitive deficits after selective lesioning of cholinergic neurons also 
initiated studies focused on exploring the functions of noncholinergic neurons such as 
GABAergic neurons and glutamatergic neurons of the basal forebrain. Selective lesioning 
of GABAergic neurons caused a deficit in spatial working memory in animals in one study 
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(Pang et al., 2011) and did not impact spatial reference memory in another study (Radley 
et al., 2009). Simultaneous lesion of cholinergic neurons and application of GABAergic 
compounds caused similar spatial working memory deficits (Pang and Nocera, 1999). 
Furthermore both GABAergic and cholinergic neurons were implicated in regulating 
hippocampal theta rhythm (Yoder and Pang, 2005), as well as regulating proactive 
interference (De Rosa et al., 2004; Pang et al., 2011). Most neurons in the basal forebrain 
(90%), including the cholinergic and GABAergic populations also produce and release 
glutamate (Gritti et al., 2006); therefore investigating the sole role of glutamate in the basal 
forebrain is difficult and this still remains to be determined.  
Interestingly, some studies have explored more specific functions of cholinergic neurons, 
such as the importance of the septohippocampal cholinergic projection neurons for 
plasticity of hippocampal place cells (Ikonen et al., 2002) or the temporal profile of 
prefrontal cortical acetylcholine release upon cue detection (Parikh et al., 2007). It has 
been proposed that acetylcholine released by basal forebrain neurons into the cortex 
increases the amplitude and signal-to-noise ratio of evoked sensory responses, thereby 
selectively amplifying certain inputs while suppressing others (Parikh et al., 2007). 
Acetylcholine has also been shown to trigger different types of hippocampal plasticity 
depending on the spatiotemporal properties of its release (Gu and Yakel, 2011). When 
acetylcholine was released onto Schaffer collateral cells either 100ms or 10ms before 
Schaffer collateral activation, either LTP or short-term depression via alpha7-nictotinic 
acetylcholine receptor activation was induced. When acetylcholine activation followed 
Schaffer collateral cell activation by a 10ms delay, LTP was induced through muscarinic 
acetylcholine receptor activation. Application of amyloid beta abolished these different 
types of acetylcholine-induced hippocampal plasticity (Gu and Yakel, 2011).  
In the prefrontal cortex, tonic acetylcholine release can cause persistent firing of pyramidal 
neurons, a characteristic that has been connected to working memory functions (Dembrow 
et al., 2010). Recent imaging studies indicate that basal forebrain volume, in particular the 
volume of the nucleus basalis of Meynert, is also correlated to general intelligence (Wolf et 
al., 2014), and the medial septum/vertical diagonal band of Broca volumes might be 
associated with human recognition memory accuracy (Butler et al., 2012). 
One aim of the current work was to study the involvement of the basal forebrain in specific 
types of navigation in humans, namely idiothetic – navigation in relation to oneself – and 
allothetic – navigation in relation to external cues – and to determine whether basal 
forebrain degeneration in Alzheimer’s disease affects either navigation type. 
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1.7.2 The sleep-wake cycle 
 
Cholinergic, GABAergic and glutamatergic neurons in the basal forebrain function together 
in order to regulate cortical activity in awake or slow-wave and rapid eye movement (REM) 
sleep states (Hassani et al., 2009) and activation of cholinergic neurons has been shown 
to initiate transitions between these states (Han et al., 2014). In general, the electrical 
discharge profiles of the different neuronal subtypes in the basal forebrain are similar in 
awake and sleep states, but cholinergic neuronal discharge combined with release of 
acetylcholine is maximal only during awake and REM sleep states (Jones, 2004; Marrosu 
et al., 1995) whereas GABAergic and glutamatergic neurons discharge in all states. 
Likewise, antagonists of acetylcholine receptors induce changes in awake and REM sleep 
states, but not slow-wave sleep, whereas non-specific lesions in the basal forebrain have 
effects on all three sleep states (Jones et al., 2004). Cholinergic, GABAergic and 
glutamatergic neurons in the basal forebrain are also associated with gamma, delta and 
theta electroencephalography (EEG) activity in a complex manner, where different 
subgroups of neurons have been shown to be correlated with different types of EEG 
activity (Hassani et al., 2009). 
 
1.7.3 Regulation of blood flow in the brain 
 
Both GABAergic and cholinergic neurons in the basal forebrain have been shown to 
stimulate blood flow and vasodilation in several cortical and subcortical areas (e.g. 
hippocampus, amygdala) in rodents in a complex manner (Barbelivien et al., 1999a; 
Barbelivien et al., 1999b; Sato et al., 2004). Separate injections of carbachol (a cholinergic 
agonist) and GABA into the substantia innominata generated significant increases in brain 
regional blood flow of target projection areas of cholinergic and GABAergic neurons, 
whereas simultaneous injections of carbachol and GABA into the substantia innominata 
resulted in a small increase in blood flow. In contrast, simultaneous injection of picrotoxin 
(a GABA receptor antagonist) and carbachol did not induce any changes in cerebral blood 
flow (Barbelivien et al., 1999b). Acetylcholine esterase inhibitors have shown beneficial 
effects in patients suffering from vascular dementia, the second most common type of 
dementia (Roman, 2005). Furthermore it has been suggested that vascular pathology, 
such as arterial hypertension, sustained hypoperfusion and ischaemic cerebrovascular 
disease, occurring in vascular dementia and partly in Alzheimer’s disease, might play an 
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important role in initiating degeneration of basal forebrain neurons (Nardone et al., 2008; 
Roman, 2005; Roman and Kalaria, 2006). 
 
1.8 Basal forebrain in aging and other neurodegenerative diseases 
 
The basal forebrain has been shown to undergo slow and progressive age-related 
degeneration starting from early adulthood (Grothe et al., 2011; Lowes-Hummel et al., 
1989; Mann et al., 1984; McGeer et al., 1984). In normal aging, beginning around 65-70 
years of age, the rate of basal forebrain degeneration is increased and it has been 
proposed that by the age of 90 approximately 30% of basal forebrain neurons have died. 
In Alzheimer’s disease, these cellular changes are greatly aggravated and a further 60% 
of basal forebrain neurons can be lost (Mann et al., 1984). The age-related atrophy 
appears to occur in all nuclei of the basal forebrain, anterior and posterior, and, equally in 
both brain hemispheres. However tendencies towards increased cell loss in the nucleus 
basalis of Meynert (Grothe et al., 2011) and in the left hemisphere (Lowes-Hummel et al., 
1989) have been reported.  
In healthy aging, the decline of basal forebrain volume over time does not occur in a linear 
fashion, but is stable over the early years before volume loss starts to show in some 
subjects from about 50 years of age (Grothe et al., 2011). It has been further suggested 
that the annual rate of basal forebrain degeneration is greater than that of the 
hippocampus, or grey matter in general (Grothe et al., 2012). However recently, the 
presence of significant age-related cell loss in the brain has been challenged, and early 
histological studies documenting this cell loss have been questioned with respect to 
technical and methodological issues such as tissue processing and sampling design 
(Burke et al., 2006). Functional decline in advanced age, such as a decline in cognitive 
function, is more likely to occur due to axonal and dendritic degeneration of neurons, 
decrements in gene expression, impairments in intracellular signalling and cytoskeletal 
transport rather than frank neuronal cell loss (Burke and Barnes, 2006; Morrison and Hof, 
1997). In disease, however, particularly in those conditions that are accompanied by a 
form of dementia or significant decline in cognitive function, loss of basal forebrain 
neurons is well documented. 
Degeneration of the basal forebrain neurons has been reported in conditions including 
Alzheimer’s disease, Down’s syndrome, Parkinson’s disease (Arendt et al., 1983; 
Jellinger, 2000; Whitehouse et al., 1983), progressive supranuclear palsy, Creutzfeldt-
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Jakob disease (Arendt et al., 1984) and Korsakoff’s syndrome (Arendt et al., 1983; Terry 
and Buccafusco, 2003) as well as being implicated in response to chronic ethanol intake 
(McKinney et al., 2005), traumatic brain injury (Donat et al., 2010; Salmond et al., 2005) 
and other conditions. Cholinergic cells of the basal forebrain might show a particular 
vulnerability to neurodegenerative changes. The reasons for this vulnerability are largely 
unknown but it has been partly attributed to a possible higher energy demand of the 
cholinergic neurons, as these cells require acetyl-CoA for both energy production and 
acetylcholine synthesis (Szutowicz et al., 2006) and are therefore more sensitive to aging-
related energy (glucose) deprivation. In line with this, a recent study has shown age-
related changes in the metabolic activity of cholinergic basal forebrain neurons, such as 
strong upregulation of the transcription factor GA-binding protein alpha, which controls 
expression of nuclear genes encoding mitochondrial proteins (Baskerville et al., 2008). In 
addition cholinergic neurons express the neurotrophin receptors TrkA and p75NTR which 
bind NGF, a neurotrophic substance that has been shown to be important for the survival 
these neurons (Coulson et al., 2009; Mufson, 2003). Imbalances in trophic support can 
affect the function and plasticity of cholinergic basal forebrain neurons and this mechanism 
has been suggested to play an important role in both aging and neurodegenerative 
disease (Mufson et al., 2003). 
  
1.9 Biomarkers of Alzheimer’s disease 
 
Accurately diagnosing people with or at risk of developing Alzheimer's disease, and 
monitoring their progress over time, will be vital to reducing the economic and social 
burden of this condition by enabling existing treatments and care options to be tailored for 
each patient, as well as demonstrating the efficacy of experimental drugs. The current 
method of making a clinical diagnosis of Alzheimer's disease prior to autopsy is by 
neuropsychological testing. An exciting recent development in this field is the 
demonstration that positron emission tomography (PET) imaging of live patients, using 
Pittsburg compound B (PiB), a modified stain that binds to amyloid plaques, can give an 
indication of plaque load prior to autopsy. This raises the possibility of identifying people at 
risk of developing Alzheimer's disease (Villemagne et al., 2011). However whether atrophy 
of the basal forebrain is correlated to amyloid levels measured using PiB imaging has not 
been investigated. However amyloid load, measured either at post-mortem or in vivo with 
PET, does not correlate well with clinical measures of cognitive impairment (Drachman, 
2014). Likewise a recent study found that amyloid deposition and neurodegeneration, such 
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as hippocampal atrophy, are “biologically independent processes”. On the other hand, a 
certain amount of underlying amyloid pathology is associated with increased 
neurodegeneration (Jack et al., 2014). Jack and colleagues recently published a review 
focused on discussing the use of biomarkers including amyloid-PET and MRI in tracking 
the pathophysiological processes in Alzheimer’s disease (Jack et al., 2013). However, in 
this article, the authors identify a clear need for development of new biomarkers and point 
out a lack of studies in the field of PET and structural MRI. 
Unlike amyloid, tau pathology is strongly correlated with cognitive decline and 
neurodegeneration, with an increase in subcortical tau correlating with loss of cholinergic 
basal forebrain neurons as well as Alzheimer’s disease neuropathology and cognitive 
decline (Mufson et al., 2014; Vana et al., 2011). More recently PET tracers capable of 
measuring tau levels in the brain have been developed and verified to show a profile of tau 
in the brain of Alzheimer’s disease patients similar to the distribution found at autopsy 
(Fodero-Tavoletti et al., 2011; Okamura et al., 2014; Villemagne et al., 2014). Whether 
there is an interaction of structural changes of the basal forebrain with tau levels measured 
by these PET tracers in vivo in humans remains to be determined.  
Simultaneous assessment using structural MRI and tau-PET markers of subjects at risk of 
developing Alzheimer’s disease could be of great use in aiding with diagnosis. On the 
other hand, by the time atrophy of a structure can be detected as a volumetric reduction 
with structural MRI, significant cell and tissue loss has already occurred. Furthermore, as 
the diagnosis of mild cognitive impairment or Alzheimer's disease currently occurs at a 
stage at which the cholinergic system has been irreversibly damaged, it is not surprising 
that acetylcholine esterase inhibitors have mild to little effect in prolonging cognitive 
function (Mancuso et al., 2011). Non-invasive early detection of basal forebrain 
neurodegeneration prior to overt tissue loss therefore has the potential to improve the 
window of efficacy of acetylcholine esterase inhibitors for the treatment of Alzheimer's 
disease. 
Diffusion MRI (dMRI) is a technique that can be used to analyse differences in structural 
integrity and brain connectivity, and has been successfully employed to detect differences 
between Alzheimer’s patients and healthy control subjects (Kiuchi et al., 2009; Pievani et 
al., 2010; Teipel et al., 2010). dMRI measures water diffusion within a tissue, and various 
dMRI parameters can be extracted for individual brain regions as well as for streamlines 
generated from dMRI data by tractography, a technique that is used to infer the 
connectivity of the brain, particularly of white-matter tracts (Mori and Zhang, 2006). These 
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methods show promising sensitivity as diagnostic tools for detecting early pathological 
changes in humans, although further validation is still required, and whether these 
methods can be used to assess the integrity of the basal forebrain and its projections is 
not known.  
Levels of amyloid and tau protein (total and phosphorylated tau) can also be determined 
from cerebrospinal fluid (CSF) samples of patients. These CSF biomarkers can be used to 
distinguish Alzheimer’s disease subjects from mild cognitively impaired subjects and 
correlate with the progression of Alzheimer’s disease. However measuring CSF 
concentrations of tau and amyloid is not a feasible way to discriminate Alzheimer’s 
disease from other dementias (Sui et al., 2014). Unfortunately, blood biomarkers used to 
detect tau, phosphorylated tau, amyloid as well as other proteins associated with 
Alzheimer’s disease are also unable to provide valid diagnostic information to date 
(Snyder et al., 2014). Several issues connected to protocols and methods of blood 
biomarker sampling and therefore problems with standardization have so far halted their 
development, but if successful, blood-based biomarkers would certainly provide the most 
cost-efficient way for diagnosis of Alzheimer’s disease.  
Alzheimer’s disease is a complex condition in which only a combination of multiple factors 
yields a successful diagnosis, e.g. amyloid pathology alone is not sufficient, and 
researchers increasingly discern the development of certain Alzheimer’s disease hallmarks 
as independent processes, e.g. rate of amyloid accumulation is independent of 
neurodegeneration, tau and amyloid deposition are independent processes (Jack et al., 
2013), and so on. Therefore a combination of different biomarkers might be required to 
successfully diagnose and monitor this condition. 
 
1.10 Project proposal 
 
Degeneration of basal forebrain neurons is a pathological hallmark of Alzheimer’s disease 
at autopsy, together with the presence of protein aggregates in the brain composed of 
extracellular amyloid and intracelluar tau. Patients also suffer from severe cognitive 
decline in late stage Alzheimer’s disease; however whether this cognitive decline relates to 
basal forebrain atrophy has not been extensively investigated. In addition, how amyloid 
and tau accumulation in the brain influences degeneration of the basal forebrain neurons 
in vivo is completely unknown. 
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1.10.1 Aim 
 
The overall aim of this proposal is to generate and validate structural and dMRI methods 
to quantify basal forebrain neurons and their projections in mouse models and humans. 
Once developed, the MRI methods will be used to test the hypotheses that quantification 
of the basal forebrain cholinergic neurons can be used as a method of diagnosing and/or 
monitoring progression of Alzheimer’s disease. Furthermore the methods will be used to 
investigate the relationship of basal forebrain degeneration and amyloid as well as tau 
accumulation in live Alzheimer’s disease patients. Finally, this work will explore whether 
the basal forebrain is associated with spatial navigation and working memory and whether 
the dysfunction of these cognitive processes in Alzheimer’s disease are correlated to basal 
forebrain degeneration. 
 
1.10.2 Hypothesis 
 
The basal forebrain degenerates during the development of Alzheimer’s disease and 
changes will be detectable in amnestic mild cognitively impaired patients. This 
degeneration will correlate with cognitive decline and will be related to the level of amyloid 
as well as tau pathology. The basal forebrain will further be associated with navigation 
performance and its atrophy will be paralleled by a decline in navigational ability. 
 
1.10.3 Specific research questions 
 
1. Does the basal forebrain selectively degenerate in Alzheimer’s disease, and its 
prodromal stage, amnestic mild cognitive impairment? 
2. Is basal forebrain degeneration correlated to the cognitive decline observed in 
Alzheimer’s disease? 
3. Is basal forebrain atrophy linked to amyloid and tau accumulation during the 
development of Alzheimer’s disease? 
4. Can degeneration of cholinergic basal forebrain neurons be measured using diffusion 
MRI and tractography? 
5. Is basal forebrain degeneration involved in spatial navigation impairments observed in 
Alzheimer’s disease patients? 
 
The following chapters describe the results of the hypothesis and are formatted as per 
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submitted to journals including separate introduction and discussion for further 
commentary for each study. 
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Chapter 2: Basal forebrain degeneration is associated with amyloid 
accumulation in Alzheimer’s disease 
 
2.1 Introduction 
 
Two critical events in the aetiology of Alzheimer’s disease are accumulation of amyloid-
beta and degeneration of basal forebrain neurons. At the time the work reported in the 
following chapter was performed, nothing was known about the in vivo relationship 
between these two features either in Alzheimer’s disease, or its prodromal stage, mild 
cognitive impairment. However in vitro (Coulson, 2006) and in vivo (Sotthibundhu et al., 
2008) studies performed in the Coulson laboratory were pointing towards a potential 
mechanism whereby amyloid-beta could induce death of basal forebrain neurons through 
activating cascades mediated by the p75NTR neuronal death receptor, which is expressed 
almost exclusively in the adult brain by cholinergic basal forebrain neurons. 
Advances in PET imaging had made it possible to use compounds such as PiB to assess 
amyloid burden in living subjects (Villemagne et al., 2011). PiB-PET imaging in 
combination with structural MRI scans had been performed in a large number of subjects 
of the longitudinal Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing 
(AIBL) study, which enabled the evaluation of the effects of amyloid on brain structural 
changes. Therefore we decided to investigate whether basal forebrain volumes were 
correlated to amyloid burden in subjects of the AIBL study. 
One particular finding from amyloid imaging was that a significant portion (~30%) of 
normal control subjects/healthy elderly people had an amyloid burden comparable with 
that of Alzheimer’s disease subjects. Likewise, many mild cognitively impaired subjects, in 
particular amnestic mild cognitively impaired subjects, also displayed a considerable 
amyloid load by this method. Thus it was hypothesized that subjects with high amyloid 
burden in clinical groups were at higher risk of developing cognitive impairment (normal 
controls showing high amyloid load), or progression to Alzheimer’s disease (mild 
cognitively impaired subjects with high amyloid load) status. Hence we were particularly 
interested in investigating the relationship between basal forebrain volume and amyloid 
load in these amyloid-defined subgroups. 
However, in order to perform these correlations it was first imperative to develop masks 
that could be used for structural MRI measures of the basal forebrain. The masks were 
developed using data from the AIBL study and then validated in an independent data set 
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from the Alzheimer’s disease Neuroimaging Initiative (ADNI) study. Details about the 
creation of these maps and illustrations of each map can be seen in the following chapter. 
This study has been published in the journal Neuroimage Clinical. 
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2.2 Basal forebrain atrophy correlates with amyloid β burden in Alzheimer’s disease 
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Australia 
4The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, 
Melbourne, 3084 Vic. Australia 
42
    
Abstract 
 
The brains of patients suffering from Alzheimer's disease (AD) have three classical 
pathological hallmarks: amyloid-beta (Aβ) plaques, tau tangles, and neurodegeneration, 
including that of cholinergic neurons of the basal forebrain. However the relationship 
between Aβ burden and basal forebrain degeneration has not been extensively studied. 
To investigate this association, basal forebrain volumes were determined from magnetic 
resonance images of controls, subjects with amnestic mild cognitive impairment (aMCI) 
and AD patients enrolled in the longitudinal Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) and Australian Imaging, Biomarkers and Lifestyle (AIBL) studies. In the AIBL 
cohort, these volumes were correlated within groups to neocortical gray matter retention of 
Pittsburgh compound B (PiB) from positron emission tomography images as a measure of 
Aβ load. The basal forebrain volumes of AD and aMCI subjects were significantly reduced 
compared to those of control subjects. Anterior basal forebrain volume was significantly 
correlated to neocortical PiB retention in AD subjects and aMCI subjects with high Aβ 
burden, whereas posterior basal forebrain volume was significantly correlated to 
neocortical PiB retention in control subjects with high Aβ burden. Therefore this study 
provides new evidence for a correlation between neocortical Aβ accumulation and basal 
forebrain degeneration. In addition, cluster analysis showed that subjects with a whole 
basal forebrain volume below a determined cut-off value had a 7 times higher risk of 
having a worse diagnosis within ~18 months. 
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Abbreviations 
 
3D: 3-dimensional 
Aβ: amyloid-beta  
AD: Alzheimer’s disease 
ADNI: Alzheimer’s Disease Neuroimaging Initiative 
AIBL: Australian Imaging, Biomarkers and Lifestyle Flagship Study of Aging 
aMCI: amnestic mild cognitive impairment 
CSF: cerebrospinal fluid 
GM: gray matter 
HC: healthy control 
MCI: mild cognitive impairment 
MNI: Montreal Neurological Institute 
MPM: maximum probability maps 
MPRAGE: magnetization prepared rapid gradient echo 
MRI: magnetic resonance imaging 
OR: odds ratio 
PET: positron emission tomography 
PiB: Pittsburgh compound B 
SPSS: Statistics Software Package for the Social Sciences 
SUVR: standard uptake value ratio 
SyN: symmetric normalization 
T1W: T1-weighted 
TG-ROC: two-graph receiver operating characteristic 
WM: white matter   
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1. Introduction 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that results in 
widespread brain atrophy of both gray and white matter brain regions. Other hallmarks of 
the disease include the extracellular deposition of amyloid-β (Aβ) and intracellular 
accumulation of hyper-phosphorylated tau. An emerging method of early diagnosis of AD 
is to assess brain Aβ burden through Pittsburgh compound B (PiB)-positron emission 
tomography (PET) imaging. This measure has shown promise in identifying people at risk 
of developing AD (Villemagne et al., 2011); however, reports of correlations between PiB 
retention and hippocampal atrophy, the magnetic resonance imaging (MRI) measure most 
widely used together with traditional cognitive assessment for the diagnosis of AD (Frisoni 
et al., 2010), have been inconsistent. Therefore it remains unclear what additional factors 
control the progression to dementia of healthy subjects with high Aβ load. 
Cholinergic neurons in the basal forebrain, a gray matter region located in the medial and 
ventral aspects of the brain, provide the neurotransmitter acetylcholine to a variety of 
different brain regions. Anterior basal forebrain nuclei, including the medial septum and 
diagonal band send projections to the hippocampus, olfactory bulb, and piriform and 
entorhinal cortices. Posterior basal forebrain nuclei, including the nucleus basalis of 
Meynert project to the amygdala and frontal, cingulate and parietal cortices, as well as to 
the orbital and peristrate cortices and the temporal lobe (Mesulam et al., 1983; Zaborszky 
et al., 2008). Regulation of acetylcholine supply to these brain regions is involved in local 
activation and modulation of plasticity, and cholinergic basal forebrain neurons can 
therefore influence critical behaviors such as attention, learning and memory (Mufson, 
2003; Schliebs and Arendt, 2011). Post-mortem assessment has revealed significant 
degeneration of these neurons as an early pathological feature of AD patients, and their 
degeneration, which is likely to underpin aspects of cognitive decline associated with the 
disease (Contestabile, 2011; Mesulam, 2004; Schliebs and Arendt, 2011), drove the 
development of the now widely prescribed acetyl cholinesterase inhibitor class of drugs.  
Consistent with this, recent studies have demonstrated that AD patients, as well as 
patients with mild cognitive impairment (MCI), a prodromal stage to AD, show significant 
basal forebrain volume loss compared to age-matched controls (Grothe et al., 2011; Hall 
et al., 2008; Muth et al., 2010), with atrophy of discrete regions within the basal forebrain 
being significantly associated with global cognitive decline as well as delayed recall scores 
in AD subjects (Grothe et al., 2010). Although the basal forebrain has been shown to 
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degenerate in normal aging, the rate of atrophy is significantly higher in subjects suffering 
from dementia (Grothe et al., 2012), and specific areas within the basal forebrain appear 
to be particularly vulnerable to AD-associated degeneration (Grothe et al., 2011).  
An association between basal forebrain atrophy and Aβ burden in AD has recently been 
reported using MRI and AV45-PET data (Grothe et al., 2014; Teipel et al., 2013) acquired 
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. In this study we also 
found a significant association between basal forebrain atrophy, based on a histological 
mask restricted to AD-specific degeneration, and Aβ load using PiB-PET, including a 
correlation between these hallmarks that extends to healthy control subjects of the 
Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort (Ellis et al., 2009). 
Furthermore, we determined that degeneration of the basal forebrain is a significant risk 
factor for further cognitive decline in control and MCI cohorts, irrespective of Aβ burden. 
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2. Materials and Methods 
 
2.1 Subjects 
 
Data analyzed for this report were obtained from the AIBL study (Ellis et al., 2009) 
(http://www.aibl.csiro.au/) and the ADNI study (adni.loni.ucla.edu). From the AIBL study, 
longitudinal PiB and 3T T1-weighted (T1W) MRI images of AD, amnestic MCI (aMCI) and 
healthy control (HC) subjects at two time-points (Table 1) were used. The HC and aMCI 
groups were further subdivided into subjects with high (PiB+) and low (PiB-) PiB retention 
levels, as previously reported (Villain et al., 2012). The methodology for cohort recruitment 
and evaluation has been reported elsewhere (Ellis et al., 2009). From the ADNI-2/GO 
study, 3T T1W MRI images of HC, aMCI and AD subjects (Table 2) were examined.  
 
2.2 Imaging protocol 
 
From the ADNI cohort, 3T MR images were acquired using the magnetization prepared 
rapid gradient echo (MPRAGE) imaging protocol in accordance with ADNI’s guidelines for 
these scans (http://adni.loni.ucla.edu/research/protocols/mri-protocols). For the AIBL 
cohort, 3T MR structural images were acquired on a Siemens 3T Trio. Participants 
received a MRI scan using the ADNI 3D MPRAGE sequence, with 1x1mm in-plane 
resolution and 1.2mm slice thickness, TR/TE/T1=2300/2.98/900, flip angle 9° and field of 
view 240x256 and 160 slices. In addition, each AIBL subject received ~370MBq PiB 
intravenously over 1 minute. A 30-minute acquisition in 3-dimensional (3D) mode starting 
40 minutes after injection of PiB was performed with a Philips Allegro PET camera. A 
transmission scan was performed for attenuation correction. PET images were 
reconstructed using a 3D RAMLA algorithm. 
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2.3 MRI processing 
 
The hippocampus, pons and gray matter (GM), white matter (WM) and cerebrospinal fluid 
(CSF) were segmented from the MPRAGE images using the method outlined in (Bourgeat 
et al., 2010). A skull strip mask was generated from the GM, WM and CSF segmentation. 
All volume calculations reported are normalized by intracranial volume. 
Using the AIBL study data, the skull-stripped MPRAGE images of all subjects were 
normalized to create an average elderly template brain using the open-source deformable 
registration tool ANTS. ANTS provides functionality for generating optimal templates, given 
a collection of images, which offers advantages over a priori templates for image 
normalization (for instance in the hippocampus; Avants et al., 2010). The population-
specific template was generated by iteratively registering images to the current template 
estimate. A new shape and intensity average were then computed from the results of the 
registrations and the current template estimate was set as the average. This template 
generation procedure was repeated iteratively (I=5). Each registration in this procedure 
used the greedy symmetric normalization algorithm (SyN, parameters outlined below) and 
the cross-correlation after subtracting the local mean from the image match metric. A z-
score map of the deformation field of the AD subjects with HC subjects from the AIBL 
cohort was generated. 
The registration between each subject’s MPRAGE image (AIBL and ADNI) and the 
population-specific template was performed using the SyN algorithm (GradStep = 0.5, 
regularization sigma = 2.0). The image match metric was the cross-correlation between 
the images. Cross-correlation after subtracting the local mean from the image at each 
voxel was computed using a 5×5×5 voxel window. Registration was performed in a multi-
resolution scheme, with a maximum of 30 iterations at 4× subsampling, 90 iterations at 2× 
subsampling, and 50 iterations at full resolution. 
To establish basal forebrain masks encompassing only those areas that undergo atrophy 
in AD patients (Fig. 1), we compared all control and AD subjects from the AIBL cohort and 
overlaid the resultant z-score map (set to -0.5 and -1 standard deviations) on a standard 
Montreal Neurological Institute (MNI) brain (z-score map, Fig. 1A, B). Using published 
probabilistic basal forebrain maps derived from histological data as a guide for the limits of 
the structure (Zaborszky et al., 2008), we then manually segmented the regions of atrophy 
within the standard space corresponding to the basal forebrain area. Using this method we 
created two types of basal forebrain masks.  
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First, we used published raw probabilistic maps (Zaborszky et al., 2008) from at least one 
post-mortem brain as a guide, resulting in a basal forebrain mask covering a large number 
of basal forebrain voxels (BF raw; size: 3193 voxels; Fig. 1A, B) and a final delineated 
area of intermediate anatomical specificity. Second, we used maximum probability maps 
(MPMs; Zaborszky et al., 2008) as guidance, resulting in a basal forebrain mask covering 
voxels that were identified as lying in the basal forebrain in ten post-mortem brains (BF 
MPM; size: 1160 voxels; Fig. 1A, B) and a final delineated area of high anatomical 
specificity. One aim of this study was to assess and compare the sensitivity of both BF raw 
and MPM masks in detecting volumetric changes as well as identifying associations with 
global Aβ burden. To study anterior and posterior basal forebrain compartments 
separately, we further divided the BF MPM map into an anterior BF MPM volume (size: 
595 voxels; Fig. 1A), covering Ch1-3 as well as Ch4 anterior cell groups, and a posterior 
BF MPM volume (size: 565 voxels; Fig. 1B), covering Ch4 intermediate and posterior cell 
groups (nomenclature according to Mesulam et al., 1983). 
The final BF raw and BF MPM masks comprised areas throughout the entire extent of the 
basal forebrain area (Ch1-4 cell groups) and were validated by overlaying the masks onto 
newly developed raw probabilistic and MPM basal forebrain post-mortem maps (Eickhoff 
et al., 2006; Eickhoff et al., 2007; Eickhoff et al., 2005), respectively. This showed an 
overlap of 50% for the BF raw mask with the raw probabilistic post-mortem map, an 
overlap of 85% for the BF MPM map with the raw probabilistic post-mortem map and an 
overlap of 46% for the BF MPM map with the MPM post-mortem map. Neither the BF raw 
nor the BF MPM map was specific for cholinergic cells of the basal forebrain, but rather 
represented the general basal forebrain area. Using the aforementioned registration 
between the subject and atlas, the basal forebrain masks were propagated into the 
subjects’ space and any voxels labeled as CSF (from CSF segmentation) were removed. 
The resulting mask was then used to extract the GM volume. 
Because the basal forebrain masks were created based on atrophy maps derived from 
comparing AD and control subjects from the AIBL cohort, we tested whether the BF raw 
mask was able to detect changes in the AIBL cohort as well as in an independent cohort, 
namely the ADNI cohort (Fig. 2). This analysis revealed similar changes between AD and 
control subjects as well as AD and aMCI subjects in both cohorts. 
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2.4 PET image processing 
 
The PET images were processed as described by Bourgeat et al. (2010). In summary, 
PET and MR images were co-registered. The PiB images were standard uptake value 
ratio (SUVR) normalized (pons WM) with PiB+ defined as SUVR>0.71 (Villain et al., 2012) 
and neocortical PiB retention calculated within the GM segmentation.  
 
2.5 Statistical analysis 
 
The Statistics Software Package for the Social Sciences (SPSS, v20.0) was used to 
determine significant differences and correlations. Group comparisons were performed 
using ANOVA followed by the Bonferroni post-hoc test. The parameters compared 
between groups were corrected for age. Partial correlations controlling for age were used 
to determine significant associations between parameters. There was no significant 
difference for sex or years of education between groups. Basal forebrain volume, 
hippocampal volume and neocortical PiB retention values were significantly correlated to 
age but not sex or years of education. 
Hierarchical cluster analysis was used to determine the basal forebrain volumes that 
distinguished discrete clusters. Two-step cluster analysis automatically identified three 
existing clusters in the basal forebrain volume data, and both non-hierarchical (K-means) 
cluster analysis and two-step cluster analysis provided highly similar cluster groups. The 
two-graph receiver operating characteristic (TG-ROC) was used to determine cut-off 
values between clusters (Greiner, 1995). The odds ratio (OR) was calculated to determine 
the probability of subjects being within the in high/medium vs. low-risk basal forebrain 
volume group at baseline if their diagnosis worsened at follow-up. A chi-square test was 
used to determine the significance of this ratio.  
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3. Results 
 
3.1 Differences in basal forebrain volume between HC, aMCI and AD subjects 
 
To measure basal forebrain atrophy in this study, four different masks were used (Fig. 1). 
These masks were based on raw probabilistic (BF raw) and MPM maps (BF MPM, BF 
MPM anterior and BF MPM posterior) of post-mortem delineations of the basal forebrain, 
and further restricted to represent basal forebrain areas found to undergo atrophy in AD 
subjects versus age-matched controls. The results of group comparisons of BF raw 
volumes in the AIBL and ADNI cohorts (Fig. 2) and group comparisons of BF MPM 
volumes in the AIBL cohort (Table 3) are shown. All basal forebrain volumes of the AD 
group were significantly less than those of HC subjects. In addition AD subjects had 
significantly smaller basal forebrain volumes than aMCI subjects. The BF raw volumes 
between the HC and aMCI groups in the ADNI cohort were not significantly different. 
Furthermore all basal forebrain volumes of aMCI subjects were significantly smaller than 
those of HC PiB- subjects (control subjects showing low PiB retention values), but only the 
BF raw volume of aMCI subjects was significantly different from that of HC PiB+ subjects 
(control subjects showing high PiB retention values). To test whether controls at risk of 
developing AD, according to PiB retention status, namely HC PiB+ subjects, had smaller 
basal forebrain volumes than HC PiB- subjects, we compared the two groups. No 
significant difference in the mean basal forebrain volume between the HC PiB+ and HC 
PiB- groups was detected. 
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Figure 1: Basal forebrain masks of AD-specific changes in template space. Coronal slices 
illustrating the z-score map on a whole template brain (blue; top row A, B) calculated by 
comparing the HC and AD groups in the AIBL study. In the lower rows (A, B), a magnified 
view of the basal forebrain area is shown to better illustrate the z-score map (blue) as well 
as individual basal forebrain volumes. The BF raw mask (red; A, B) was used as a 
combination of the anterior and posterior parts for analysis of the whole basal forebrain 
area. The BF MPM mask (green; A, B) was used both as a combination of the anterior and 
posterior regions, and the anterior and posterior regions individually, to analyze the basal 
forebrain area. The same slices at different levels from rostral to caudal are shown in A 
and B, on a T1-weighted image. BF = basal forebrain, MPM = maximum probability map.  
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Figure 2: Group comparisons of basal forebrain volume in the AIBL and ADNI study 
cohorts. In the AIBL (A) study, the basal forebrain volume was significantly decreased in 
the AD and aMCI groups compared to controls. In the ADNI study (B), the basal forebrain 
volume of the AD subject group was significantly smaller than that of the HC and aMCI 
subject groups. Basal forebrain volumes of the aMCI groups display high variability in both 
study cohorts. *** p<0.001. Whiskers represent min/max values except data points 
(circles) more than 1.5 interquartile ranges away from the 75th percentile. 
 
 
Volume AD vs 
HC PiB+ 
AD vs 
HC PiB- 
AD vs 
aMCI 
aMCI vs 
HC PiB+ 
aMCI vs 
HC PiB- 
HC PiB+ vs 
HC PiB- 
BF raw <0.001 <0.001 0.002 0.02 <0.001 1.0 
BF MPM <0.001 <0.001 0.001 0.151 0.002 1.0 
BF MPM 
anterior 
<0.001 <0.001 0.026 0.066 0.001 1.0 
BF MPM 
posterior 
<0.001 <0.001 0.021 0.393 0.001 0.385 
Table 3: P-values of group comparisons of basal forebrain volumes in the AIBL cohort. All 
volumes were significantly different between the AD and control, AD and aMCI as well as 
aMCI and HC PiB- groups, whereas only the BF raw volume was significantly different 
between the aMCI and HC PiB+ subjects. BF = basal forebrain, MPM = maximum 
probability map.  
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3.2 Correlation between whole basal forebrain volumes and neocortical amyloid burden 
 
To determine whether the volume of the whole basal forebrain area was correlated to the 
neocortical amyloid level measured by PiB-PET we performed partial age-controlled 
correlations between the two measures in the AIBL cohort. Scatter plots of BF raw volume 
correlations are shown in Fig. 3 and r- and p-values of BF raw as well as BF MPM 
volumes are listed in Table 4. We found that, on average, subjects with high Aβ burden, 
regardless of clinical diagnosis, had smaller BF raw and BF MPM volumes, whereas 
subjects with low Aβ burden had basal forebrain volumes in the normal range. Correlations 
in individual groups, namely in the HC (PiB+ and PiB-), aMCI (PiB+ and PiB-) and AD 
groups revealed that the BF raw volume was correlated to the neocortical PiB retention 
value in the AD (r=0.39; p<0.05) and HC PiB+ (r=0.31; p<0.05) groups, but not in the aMCI 
PiB+ (r=0.33; p=0.12), aMCI PiB- (r=0.17; p=0.55) and HC PiB- (r=0.09; p=0.36) groups. 
In contrast, neither BF MPM volume, nor hippocampal volume (data not shown), was 
correlated to the neocortical PiB retention in any of the abovementioned groups. 
 
3.3 Correlation between anterior/posterior basal forebrain volumes and neocortical 
amyloid burden 
 
Anterior basal forebrain volume (BF MPM anterior), representing the medial septum (Ch1 
nucleus) and the vertical (Ch2 nucleus) and horizontal diagonal band of Broca (Ch3 
nucleus), as well as anterior parts of the nucleus basalis of Maynert (Ch4 nucleus), was 
significantly correlated to neocortical PiB retention (Fig. 4, Table 4) when pooling all 
subjects together (r=0.43; p<0.001), as well as in the AD (r=0.42; p<0.05) and aMCI PiB+ 
(r=0.43; p<0.05) groups but not the HC PiB+ (r=0.06; p=0.71) group alone. Notably the 
posterior basal forebrain volume (BF MPM posterior), corresponding to intermediate and 
posterior parts of the NbM (Ch4 nucleus), was correlated to neocortical PiB retention (Fig. 
4, Table 4) in all subjects (r=0.44; p<0.001) and HC PiB+ subjects (0.33; p<0.05) alone, 
but not in the aMCI PiB+ (r=0.29; p=0.19) and AD (r=0.22; p=0.19) subject groups. There 
was no correlation of either BF MPM anterior or BF MPM posterior volume to neocortical 
Aβ burden in the HC PiB- and aMCI PiB- groups. 
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Figure 3: Correlation of BF raw volume (x-axis) to neocortical PiB retention (y-axis) in the 
AIBL study. The interaction between the two measures is shown for all subjects pooled 
together (A) as well for individual subject groups (B-E). The cut-off value used to 
determine high and low PiB status (0.71) at the baseline time point is indicated in (A) by 
the horizontal dashed line. Significant interactions were observed in the HC PiB+ (C) and 
AD (D) subject groups. Even though the correlation coefficient was high in the aMCI PiB+ 
group, the interaction was not significant. A linear fit line with 95% confidence interval is 
shown. 
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Volume All 
subjects 
HC PiB- HC PiB+ aMCI aMCI 
PiB+ 
AD 
BF raw r 0.47 0.09 0.32 0.18 0.33 0.39 
p-value <0.001 0.36 <0.05 0.27 0.12 <0.05 
BF MPM r 0.46 0.17 0.24 0.26 0.39 0.32 
p-value <0.001 0.1 0.12 0.11 0.066 0.053 
BF MPM 
anterior 
r 0.43 0.17 0.06 0.23 0.43 0.42 
p-value <0.001 0.1 0.71 0.16 <0.05 <0.05 
BF MPM 
posterior 
r 0.44 0.13 0.33 0.25 0.29 0.22 
p-value <0.001 0.19 <0.05 0.12 0.19 0.19 
Table 4: Correlations of basal forebrain volumes to the neocortical PiB retention values in 
groups of the AIBL cohort. Significant interactions were found for BF raw and BF MPM 
posterior volumes in the HC PiB+ group, whereas BF raw and BF MPM anterior volumes 
showed significant interactions in the AD group. Only the BF MPM anterior volume was 
significantly correlated to neocortical PiB retention in aMCI PiB+ subjects. BF = basal 
forebrain, MPM = maximum probability map. 
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Figure 4: Significant correlations of anterior and posterior BF MPM posterior volumes (x-
axis) to neocortical PiB retention (y-axis) in the AIBL study. Whereas BF MPM anterior 
volume showed significant correlations in aMCI PiB+ (A) and AD (B) subjects, BF MPM 
posterior volume was significantly correlated to neocortical PiB retention in HC PiB+ (C) 
subjects. A linear fit line with 95% confidence interval is shown. 
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3.4 Basal forebrain cluster analysis for diagnosis of converters 
 
To test the diagnostic potential of basal forebrain volume in identifying subjects at risk of 
converting from either HC to aMCI, or aMCI to AD clinical status, we performed cluster 
analysis of basal forebrain volume (BF raw) in the AIBL (Figure 5) and ADNI (data not 
shown) cohorts using all subjects, irrespective of diagnostic status. Three clusters of 
normal, reduced and low basal forebrain volume were revealed, and similar cut-off values 
were found to separate the clusters in both study cohorts. The mean basal forebrain 
volume of the AD and the aMCI groups fell into the low and reduced basal forebrain 
volume clusters, respectively. In addition, the mean basal forebrain volume of the HC 
subjects who were PiB+ fell within the reduced basal forebrain cluster. Moreover, in both 
the AIBL and ADNI cohorts, the basal forebrain volumes of subjects whose diagnosis 
changed from either HC to aMCI (AIBL, n=3), HC to AD (AIBL, n=1) or aMCI to AD (AIBL, 
n=5; ADNI, n=3) were found in either the low or reduced basal forebrain volume group 
(with the exception of one PIB+ aMCI subject). Cluster analysis of hippocampal volume 
(data not shown) revealed that all but one PiB- subject, whose diagnosis worsened, fell in 
either the low or reduced hippocampal volume cluster. Finally, we found that the risk of 
having a worse diagnosis within ~18 months (based on calculations using AIBL data) was 
significantly greater (OR=7.2; chi-squared=4.53, p<0.05) for subjects falling into either the 
low or reduced basal forebrain volume category, as compared to subjects with a basal 
forebrain volume in the normal range.  
 
3.5 Neocortical and cerebellar volume group comparisons and correlations with basal 
forebrain volume 
 
The AD group was found to have a significantly reduced mean neocortical volume as 
compared to the HC PiB+ group (Table 5). There were no other neocortical volume 
differences between groups, and cerebellar volumes were not significantly reduced in any 
of the subject groups (Table 5). To assess whether basal forebrain atrophy was associated 
with neocortical atrophy or cerebellar volume, correlations of basal forebrain volumes with 
neocortical and cerebellar volumes were performed. No significant correlation of basal 
forebrain volume to either neocortical or cerebellar volume was found. 
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Figure 5: Delineations based on basal forebrain cluster analysis using the BF raw volume, 
highlighting the subjects in the AIBL study whose diagnosis worsened (‘converters’). In the 
AIBL study. Basal forebrain cut-off values of 0.00145 and 0.00163 were determined by 
hierarchical cluster analysis to distinguish three clusters (delineated by vertical dashed 
lines); the PiB cut-off value of 0.71 is indicated by the horizontal dashed line. Subjects are 
colored according to their group status at baseline. The mean basal forebrain volume for 
each group is as follows (given in mean ± SD): AD: 0.001414 ± 0.000138; aMCI: 0.001525 
± 0.000184; HC PiB+: 0.001612 ± 0.000089; HC PiB-: 0.001629 ± 0.000123. The 
converters are indicated by the diamond-shaped (conversion to AD), triangular 
(conversion to aMCI) and circular (reversion to HC) data points, with the fill showing the 
group status at baseline. All but one HC PiB+ to aMCI converting subject fall into the high 
or medium risk clusters. The subject reverting from aMCI to HC PiB+ group status is 
shown as a circular data point with a black border. aMCI to AD = aMCI diagnosis at 
baseline, AD diagnosis at follow up; aMCI to HC PiB+ = aMCI diagnosis at baseline, HC 
PiB+ diagnosis at follow up; HC PiB+ to AD = HC PiB+ diagnosis at baseline, AD 
diagnosis at follow up; HC (PiB+ or PiB-) to aMCI = HC diagnosis at baseline, aMCI 
diagnosis at follow up.
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4. Discussion 
 
Despite AD being characterized by both accumulation of Aβ and atrophy of the basal 
forebrain, the relationship between these two pathological features has not been widely 
investigated within independent patient cohorts. We confirm the findings recently 
published using data from the ADNI cohort (Grothe et al., 2014; Teipel et al., 2013) and 
demonstrate here that whole basal forebrain volume significantly correlates with 
neocortical Aβ burden, measured through PiB retention, in AD and HC PiB+ groups. In the 
HC PiB+ group, neocortical Aβ burden correlates with posterior basal forebrain volume, 
whereas in aMCI PiB+ and AD groups, neocortical Aβ burden correlates with anterior 
basal forebrain volume. Furthermore, subjects who retrospectively converted from a 
diagnosis of either HC to aMCI or aMCI to AD were found to have reduced basal forebrain 
volumes prior to conversion. These findings provide validity to emerging human and 
animal studies demonstrating a link between cholinergic basal forebrain neuron 
degeneration and Aβ production and/or deposition (Gil-Bea et al., 2012; Grothe et al., 
2014; Ramos-Rodriguez et al., 2013; Teipel et al., 2013).  
The interaction between basal forebrain volume and neocortical Aβ burden was studied 
using whole, anterior or posterior basal forebrain masks created by delimiting those areas 
found to undergo atrophy in AD subjects (versus age-matched controls) within the basal 
forebrain area. However the final masks showed only partial overlap with not yet publicly 
available post-mortem maps, developed by Eickhoff (Heinrich-Heine University 
Düsseldorf) and colleagues, being significantly larger; We acknowledge that this may 
represent areas of atrophy in anatomically close brain regions in some subjects, but 
nonetheless, we reasoned that this method of estimating basal forebrain volume may 
provide increased sensitivity to detect change in AD over the purely post-mortem -based 
segmentations previously used by others. Indeed, the results of our volumetric analysis 
using the atrophy-based whole basal forebrain mask are consistent with the findings of 
previous studies in which subnuclei of the basal forebrain or closely located brain regions 
were analyzed (Grothe et al., 2012; Grothe et al., 2011; Grothe et al., 2010), with 
differences in average basal forebrain volume being detected when comparing healthy 
controls to AD, very mild AD, and MCI groups. The analysis of the ADNI cohort shown 
here (Fig. 2) further supports data presented previously (George et al., 2011). 
Interestingly, there was a significant difference between aMCI and HC PiB+ groups for BF 
raw but not BF MPM volumes in the AIBL cohort. This might be explained by the fact that 
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the BF raw volume is almost three times the size of the BF MPM volume and may 
therefore be more sensitive to overall changes. The absence of a significant correlation 
between basal forebrain volume and either neocortical volume or cerebellar volume (Table 
5) further strengthens the specificity of basal forebrain degeneration assessed by our 
measurements as a feature of AD pathology. 
In order to investigate whether the correlations between whole basal forebrain volume with 
neocortical PiB retention observed in this study were driven by interactions with sub-areas 
of the basal forebrain, we performed correlations of the anterior (Ch1, Ch2, Ch3 and Ch4 
anterior nuclei) and posterior (Ch4 intermediate and posterior nuclei) basal forebrain 
volumes with neocortical PiB retention. In the earliest stages of AD the posterior and 
intermediate parts of the Ch4 cell group, which are represented by the BF MPM posterior 
volume in this paper, are the regions predominantly affected by pathological changes 
(Grothe et al., 2011). The posterior basal forebrain nuclei send projections to the temporal 
lobe, amygdala and peristrate and orbital cortices, as well as to brain regions subject to 
heavy Aβ deposition, such as the frontal, cingulate and parietal cortices (Klunk et al., 
2004). Furthermore, loss of cholinergic innvervation to the aforementioned regions was 
recently found in vivo in MCI patients (Haense et al., 2012). Thus it is significant that we 
found a correlation between posterior basal forebrain volume and neocortical PiB retention 
in the HC PiB+ group, a cohort which represents a control subgroup that might be at high 
risk of developing AD. 
We also observed significant correlations of neocortical PiB retention with BF MPM 
anterior volume in the aMCI PiB+ and AD groups. In this study, even though the BF raw 
mask was more sensitive than the BF MPM maps in identifying volumetric differences 
between groups, BF MPM volumes showed higher correlation coefficients and identified 
additional significant interactions with neocortical PiB retention as compared to the 
associations with BF raw volume. In addition, raw probabilistic maps have been shown to 
be at risk of misclassifying voxels, whereas MPM maps should not suffer from this 
limitation despite showing similar sensitivity (Eickhoff et al., 2006). Therefore we 
recommend the use of BF MPM maps, particularly subregional anterior/posterior volumes, 
for the future study of associations between global Aβ burden and basal forebrain 
volumes. 
The associations between basal forebrain volumes and amyloid burden presented in this 
work are consistent with previous reports of a correlation between AV45 retention and 
basal forebrain volume (Grothe et al., 2014),  and the finding that, as subjects progress to 
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aMCI and AD clinical status, changes in anterior basal forebrain areas, containing nuclei 
that project to the hippocampus, olfactory bulb and piriform and entorhinal cortices, 
become much more pronounced (Grothe et al., 2011). In line with this are also recent 
studies demonstrating cholinergic neuronal dysfunction in the cerebral cortex in MCI and 
AD based on the use of PET to assess the activity of the key cholinergic enzyme 
acetylcholine esterase. Acetylcholine esterase is primarily membrane-bound and located 
on presynaptic cholinergic neurons, and its activity is known to reflect the integrity of the 
ascending cholinergic system (Garibotto et al., 2013). Degeneration of the cortical 
cholinergic projection system arising from posterior basal forebrain nuclei, represented by 
the posterior mask in this paper, was found to occur at early stages of dementia (Haense 
et al., 2012; Herholz et al., 2008). This is consistent with early dysfunction of posterior 
nucleus basalis of Meynert neurons, and acetylcholine esterase activity in temporal lobe 
regions has also been correlated to memory impairment in MCI and AD patients (Haense 
et al., 2012; Marcone et al., 2012). 
While the correlations between basal forebrain volume and neocortical PiB retention 
reported here may merely reflect the progressive nature of basal forebrain atrophy 
occurring independently of increasing Aβ load, we hypothesize that this is not the case. 
Firstly, Aβ burden does not correlate with atrophy of other brain areas, including the 
hippocampus. Previous work using data from the AIBL study has reported a correlation 
between hippocampal volume and temporal neocortical PiB retention in the HC PiB+ 
group (Bourgeat et al., 2010) and subjective cognitively impaired subjects (Chetelat et al., 
2010). However, no correlations were found for the AD or the MCI groups, and atrophy of 
the hippocampus did not correlate with hippocampal PiB retention in another AIBL study 
(Rowe et al., 2010). Furthermore, similar analyses of AIBL subjects, performed in the 
present study, failed to reveal any correlation between hippocampal volume and 
neocortical PiB retention in any subject group (data not shown). Moreover, the correlation 
in the AD group between BF raw volume and PiB retention increased from r = 0.39 to r = 
0.42 when controlling for hippocampal volume. This indicates that the relationship between 
basal forebrain volume and Aβ deposition is not driven purely by reduced hippocampal 
volume, even though these volumes are strongly correlated (data not shown). 
Furthermore, in agreement with our findings, a recent study suggested that basal forebrain 
atrophy can predict cortical amyloid burden, and is more closely associated with cortical 
amyloid burden than hippocampal atrophy (Teipel et al., 2013). Secondly, a causal 
relationship is supported by emerging studies in animal models of AD in which cholinergic 
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basal forebrain neuron shrinkage, synaptic loss and axonal degeneration partly caused by, 
or causing, Aβ deposition in the brain, have been reported (Gil-Bea et al., 2012; Knowles 
et al., 2009; Ramos-Rodriguez et al., 2013; Sotthibundhu et al., 2008). Although our basal 
forebrain measurments encompasse a structure which is heterogenous in nature, the 
cholinergic neurons of the basal forebrain are preferentially lost in AD (Mufson, 2003) and 
their degeneration could, at least partly, account for the observed reduction in basal 
forebrain volume. It also remains to be determined what other factors might correlate with 
or drive basal forebrain volume loss and/or Aβ burden. Of particular relevance is the 
development of tau pathology that occurs in basal forebrain neurons (Braak et al., 2006; 
Braak and Del Tredici, 2004, 2011). Tau pathology is more strongly associated with 
cognitive decline (Braak and Braak, 1991) and is likely to have pronounced effects on 
basal forebrain volumetric measures. 
Regardless of the cause of the observed basal forebrain volume loss, in support of the 
assertion that early basal forebrain atrophy is a key disease hallmark, cluster analysis of 
raw BF volume, including analysis of subjects whose diagnosis converted to more 
cognitively impaired, revealed that most subjects converting from HC to aMCI or from 
aMCI to AD had a low basal forebrain volume prior to conversion. All converters in both 
the AIBL and ADNI studies (with the exception of one aMCI PiB+ subject) fell into the low 
or reduced basal forebrain volume clusters prior to conversion, which could be considered 
to be the high/medium risk categories. In the AIBL study the mean basal forebrain 
volumes of AD subjects fell into the low volume cluster whereas mean basal forebrain 
volumes of the aMCI, HC PiB+ and HC PiB+ groups fell into the reduced volume cluster. 
Subjects in the latter groups were found in all three volume clusters indicating that the 
range of basal forebrain volumes is large even in non-demented elderly subjects, which is 
a limitation of using only basal forebrain volumetric measures for diagnostic purposes. 
Nevertheless we found that subjects belonging to the high/medium risk categories in the 
AIBL study were 7.2 times more likely to convert to more cognitively impaired than 
subjects in the low risk category. Interestingly, 3 of the normal controls in the medium risk 
category who were cognitively impaired at follow up were PiB- at the time of baseline 
diagnosis, again indicating that basal forebrain atrophy might be a preclinical marker of 
dementia, albeit that these people may not progress to AD. Although the sample size used 
to assess basal forebrain volumes for risk of conversion was small, and additional 
longitudinal data are required to verify our findings, the significant cumulative evidence for 
basal forebrain atrophy being observed in life in AD clinical cohorts provides increasing 
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impetus for including basal forebrain volume in the general “atrophy signature” for the 
diagnosis of patients at risk of, or with, AD.  Furthermore, basal forebrain measures used 
in conjunction with other disease markers, such as Aβ load (Kim et al., 2012; Villemagne 
et al., 2011), may further delineate subjects at risk of progressing to AD or those for whom 
other interventions, including anti-Aβ treatments, may be of most benefit. 
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2.3 Discussion and implication of findings 
 
Overall, the work presented in this chapter demonstrated for the first time that global 
amyloid load in all evaluated groups, namely Alzheimer’s disease and mild cognitively 
impaired subjects as well as healthy controls, is correlated to basal forebrain volume. In 
addition subjects with a basal forebrain volume below a certain cut-off value at the 
baseline time point of the study were at increased risk to show cognitive deterioration at 
the follow-up time point. 
Through showing that the basal forebrain volume is significantly reduced in Alzheimer’s 
disease and amnestic mild cognitive impairment we demonstrate that basal forebrain 
volumetrics might have significant diagnostic utility in the future. Furthermore, associations 
of basal forebrain volume with Aβ load and the potential predictive power of conversion of 
subjects strengthen this argument. Therefore the methods developed in this chapter 
represent the ground-work for future imaging studies aimed at examining basal forebrain 
degeneration in humans. Our findings of an amyloid-basal forebrain interaction were also 
recently confirmed by others in the field (Grothe et al., 2014). 
Having observed a significant correlation between amyloid beta and basal forebrain 
degeneration the next question is whether this is due to a direct interaction and whether 
one phenomenon drives the other. Additional mechanistic investigations aiming to 
characterise an interaction between amyloid accumulation and basal forebrain neuronal 
degeneration in more detail will be required to answer this question. In particular, one 
model that could be tested based on the results of this study is that the neurons located in 
the nucleus basalis of Meynert, which were associated with amyloid in the healthy control 
group, could be particularly vulnerable to degeneration early on in the disease process. 
Later in disease, atrophy of anterior basal forebrain areas, at least partly driven by amyloid 
accumulation, might become more pronounced. Another question is whether other 
features of Alzheimer’s disease, such as the accumulation of tau, might have an additional 
effect on basal forebrain neuronal integrity, and this is the focus of the next chapter.  
In summary, we developed new ways of imaging basal forebrain degeneration and 
demonstrated that these methods can be used to separate clinical groups. By showing 
that basal forebrain degeneration correlates with amyloid accumulation we have also 
further established basal forebrain degeneration as a hallmark of early Alzheimer’s 
disease aetiology, and revealed that this process might commence in subjects with no 
apparent signs of cognitive impairment.  
72
  
Chapter 3: Basal forebrain degeneration is associated with tau 
accumulation in Alzheimer’s disease 
 
3.1 Introduction 
 
In addition to amyloid accumulation, aggregation of tau neurofibrillary tangles in 
Alzheimer’s disease represents a key pathological hallmark of this condition. Unlike 
amyloid, tau has been shown to be associated with measures of cognitive decline such as 
MMSE and CDR in this condition (Okamura et al., 2014; Villemagne et al., 2014). It has 
been known for a while that the basal forebrain is one of the first places where tau 
accumulates in the brain. Subsequently temporal lobe areas and then other cortical areas 
are affected which are also brain regions receiving basal forebrain neuronal connections 
(Braak et al., 2006). However, like the interaction with amyloid accumulation, the 
relationship of tau aggregation with basal forebrain degeneration in vivo in humans 
remained unknown until the study in the following chapter was conducted. 
Unlike amyloid imaging, a technology which has been available for ten years (Klunk et al., 
2004), in vivo imaging of tau using PET compounds in humans was not possible until very 
recently. In collaboration with researchers from the AIBL study and the Tohuku University, 
who pioneered the initial development and first application of PET compounds capable of 
imaging tau NFTs in the human and animal brain (Fodero-Tavoletti et al., 2011; Okamura 
et al., 2014; Villemagne et al., 2014), we were able to investigate the relationship of basal 
forebrain volume with tau burden in two cohorts of normal controls and Alzheimer’s 
disease patients using two different tracers to measure tau burden. 
As imaging of both amyloid beta and tau was performed in the same subjects, another 
aim of the study was to compare the interaction of basal forebrain volume with tau 
aggregation, and amyloid aggregation.  
This work is in preparation for submission to the journal Nature Neuroscience as a brief 
communication. 
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3.2 Cortical tau pathology is linked to basal forebrain degeneration in Alzheimer’s 
disease 
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Abstract  
 
Due to advances in clinical imaging, the preclinical relationships between the key 
pathological Alzheimer’s disease (AD) hallmarks of amyloid-beta (Aβ) plaques, tau 
neurofibrillary tangles (NFTs) and neurodegeneration, can now be investigated. Here we 
show that basal forebrain atrophy correlates with cognitive performance, amyloid burden 
and tau aggregate levels in two independent cohorts of AD patients and controls, 
suggesting a close etiological relationship between these disease features. 
 
Main text 
 
The formation of Aβ plaques and NFTs are key hallmarks of AD that underpin synaptic 
and neuronal dysfunction and ultimately lead to gray matter atrophy and cognitive decline. 
Whereas Aβ is mostly deposited in allocortical structures such as the frontal, cingulate and 
parietal cortices 1, tau deposits are initially found in the locus coeruleus, basal forebrain 
(BF) and temporal lobe 2, before spreading to neocortical areas 3. Another hallmark of the 
disease, loss of BF cholinergic neurons 4, may play a role in the cognitive dysfunction 
observed in AD patients 5 and these neurons are the target of the widely prescribed 
choline esterase inhibitors 6. In particular the intermediate and posterior part of the nucleus 
basalis of Meynert of the BF, that projects to regions including the neocortex and the 
temporal lobe, is one of the areas that undergoes atrophy early in AD, whereas the 
anterior medial septal and diagonal band BF areas, which project to the orbitofrontal 
cortex and hippocampus, are affected later in the course of the disease 7. 
Atrophy of the BF as measured by MRI has been shown to correlate with neocortical Aβ 
level in elderly cohorts 8, 9 However, Aβ load does not correlate well with clinical measures 
of cognitive impairment 10. In contrast, at autopsy the level of subcortical tau correlates 
with loss of cholinergic BF neurons as well as AD neuropathology and preclinical cognitive 
decline 11, 12. However a link between BF degeneration and tau pathology has not been 
established in vivo.  
Recently PET tracers have been developed to image NFTs in living subjects 13, 14. 18F-
THK523 and the second generation tracer 18F-THK5105 bind to recombinant tau and 
NFTs in transgenic mice and human post-mortem tissue, but not to Aβ 13, 14. Moreover, 
although the diagnostic use of tau tracers is still in the developmental phase, in vivo 
cortical retention of these tracers in AD patients reflects the histopathological distribution of 
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tau, and correlates with hippocampal atrophy and cognitive impairment 15, 16.  
To determine the relationship between tau burden and BF volume in vivo, we assessed 
two cohorts of AD patients and controls (Supplementary Tables 1 and 2). Subjects in the 
first cohort underwent 18F-THK523 and PiB PET scans (Figure 1) as well as a structural 
3D T1-weighted MRI scan to allow BF volumes, restricted to areas of AD-specific 
degeneration, to be extracted for each patient (Supplementary Figure 1; see MRI 
processing). The volumes for Ch4 intermediate and posterior areas, and the anterior 
volume covering the Ch1-3 and Ch4 anterior cell groups, were analysed separately. The 
second cohort of subjects underwent 18F-THK5105 and PiB PET scans as well as a 
structural 3D T1-weighted MRI scan. 
As previously been reported 17, we found that the combined AD subject group (n=18) had 
a significantly reduced average BF volume in comparison to that of the combined HC 
subjects (n=17; BF anterior, p=0.045; BF posterior, p=0.001). Furthermore, correlational 
analysis revealed that both the anterior and posterior BF volumes correlated with 
measures of cognitive function (Supplementary Table 3). 
Correlations were then performed in cohort 1 between anterior/posterior BF volumes and 
18F-THK523 standardized uptake value ratios (SUVRs) for regions anatomically connected 
to either anterior or posterior basal forebrain areas 18. When the HC and AD subject 
groups were combined, we found significant negative correlations were found between the 
anterior BF volume and the hippocampal, orbitofrontal and gyrus rectus 18F-THK523 
SUVR (Table 1). In addition, the posterior BF volume was significantly correlated to the 
parietal, inferior temporal and neocortical 18F-THK523 SUVR (Table 1, Figure 2). When 
the AD group was considered alone, significant correlations were found between the 
anterior BF volume and hippocampal and orbitofrontal 18F-THK523 SUVR, as well as 
between the posterior BF volume and the inferior temporal 18F-THK523 SUVR. No 
significant correlations were identified when the HC group was analyzed separately.  
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Figure 1: Representative surface projection maps for (a) aggregated tau (18F-THK523) and 
(b) amyloid plaques (11C-PiB) in an AD patient (82 yo male, MMSE 11) showing the 
different brain regional distribution of each pathology. For comparison purposes, the scale 
is set at the maximal (100%) SUVR for each tracer, but 11C-PiB SUVR was three times 
higher than that of 18F-THK523. 
 
 
 
To validate these findings, correlations between BF volume and regional tau SUVR found 
to be significant in cohort 1 were tested in the second cohort. The posterior BF volume 
was again significantly correlated to parietal and neocortical, but not inferior temporal, 18F-
THK5105 SUVR (Table 2, Figure 2). Anterior BF volume did not correlate with either 
hippocampal or orbitofrontal 18F-THK5105 SUVR (Table 2). However, as the most 
clinically accurate tau tracer is yet to be confirmed, we suggest that these findings should 
not yet be dismissed as irrelevant. 
In assessing Aβ burden, when all subjects were analyzed together, we found a significant 
correlation between retention of neocortical PiB with the combined BF volume (r2adj=0.11; 
p=0.031). However, when we undertook correlations between PiB and individual BF 
regions or the independent cohorts no significant interactions were found. This suggests 
that a weaker correlation exists between BF atrophy and Aβ load.  
a b
77
  
Our results indicate that a strong correlation exists between BF atrophy, particularly of the 
posterior BF, and tau burden in brain regions that are typically affected by NFT pathology 
and which are also anatomically connected to the posterior BF, namely the parietal lobe 
and neocortex. Tau and basal forebrain atrophy are associated with degree of cognitive 
decline 11,12 whereas Aβ burden is not 10. Our findings therefore support the idea that Aβ 
accumulation is a necessary but insufficient cause for progression to AD, with secondary, 
downstream or parallel events being required to trigger tau aggregation and BF 
degeneration, which then directly underpin cognitive decline. 
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 HC/AD AD 
 (n= 19) (n=10) 
 r2adj p r2adj p 
BF anterior     
Hippocampus 0.34     0.005 *# 0.44   0.021 * 
Orbitofrontal 0.27     0.014 *# 0.33   0.047 * 
Gyrus rectus 0.17   0.047 * -0.10 0.675 
Posterior 
cingulate 
-0.06 0.825 0.25 0.079 
Parietal -0.01 0.380 -0.07 0.557 
Amygdala -0.06 0.970 -0.12 0.917 
BF posterior     
Ventrolateral 
prefrontal 
-0.06 0.848 -0.05 0.470 
Parietal 0.17   0.047 * -0.06 0.514 
Superior 
temporal 
-0.01 0.360 -0.10 0.682 
Inferior 
temporal 
0.51 < 0.001 * # 0.35    0.041 * 
Neocortical 0.17 0.046 * -0.12 0.937 
Table 1: Linear regression analysis between basal forebrain (BF) volumes and THK523 
retention in the whole sample, healthy control (HC)/Alzheimer’s disease (AD), and the AD 
group alone. (* Significant correlation, # Significant correlation after correction for multiple 
comparisons.) 
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Figure 2: Tau burden correlates with posterior basal forebrain atrophy. Regression 
analysis between age-corrected posterior BF volumes (x-axes) and (a,b) 18F-THK523 or 
(c,d) 18F-THK5105 retention (y-axes) in neocortex (a,c) and parietal lobe (b,d). 
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 HC/AD 
 (n=16) 
 r2adj P 
BF anterior   
Hippocampus -0.06 0.688 
Orbitofrontal -0.06 0.666 
Gyrus rectus 0.04 0.222 
BF posterior   
Parietal 0.39      0.006 * # 
Inferior temporal 0.05 0.211 
Neocortical 0.36      0.008 * # 
Table 2: Linear regression analysis between basal forebrain (BF) volumes and THK5105 
retention in the whole sample, healthy control (HC)/Alzheimer’s disease (AD). (* Significant 
correlation, # Significant correlation after correction for multiple comparisons.) 
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Methods 
 
Subjects. 
Written informed consent was obtained from all participants. Approval for the study was 
obtained from the Austin Health Human Research Ethics Committee. The methodology for 
cohort recruitment and evaluation has been reported elsewhere 15. Briefly, healthy elderly 
controls (HC) were recruited by advertisement in the community and dementia patients 
were recruited from tertiary Memory Disorders Clinics or from physicians who specialize in 
dementia care. All participants were classified on the basis of their clinical and 
neuropsychological performance by consensus of a neurologist and a neuropsychologist.  
Individuals classified as HC performed within normal limits on cognitive tests. AD patients 
met NINCDS-ADRDA criteria for probable AD 19. None of the AD patients had a family 
history of dementia. Subject details are provides in Supplementary Tables 1 and 2. 
 
MRI processing. 
The pons and gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF) were 
segmented from the MPRAGE images using the method outlined in 20. A skull strip mask 
was generated from the GM, WM and CSF segmentation. All volume calculations reported 
are normalized by intracranial volume. 
The skull stripped MPRAGE images of 80 healthy elderly subjects from the Australian 
Imaging Biomarkers and Lifestyle study (AIBL; http://www.aibl.csiro.au/) were normalized 
to create an average elderly template brain using the open-source deformable registration 
tool ANTS. The population-specific template was generated by iteratively registering 
images to the current template estimate. A new shape and intensity average were then 
computed from the results of the registrations and the current template estimate was set 
as the average. This template generation procedure was repeated iteratively (I=5). Each 
registration in this procedure used the greedy Symmetric Normalization algorithm (SyN, 
parameters outlined below) and the cross-correlation after subtracting the local mean from 
the image match metric.  
The registration between each subject’s MPRAGE image and the population-specific 
template was performed using the SyN algorithm (GradStep = 0.5, regularization sigma = 
2.0). The image match metric was the cross-correlation between the images. Cross-
correlation after subtracting the local mean from the image at each voxel was computed 
using a 5×5×5 voxel window. Registration was performed in a multi-resolution scheme, 
with a maximum of 30 iterations at 4× subsampling, 90 iterations at 2× subsampling, and 
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50 iterations at full resolution.  
To establish BF masks encompassing only those areas that undergo atrophy in AD 
patients, we previously compared control (n=80) and AD (n=38) subjects from the AIBL 
cohort 9 and overlaid the resultant z-score map (set to -0.5 and -1 standard deviations) on 
a standard Montreal Neurological Institute (MNI) brain. Using published probabilistic BF 
maps derived from histological data as a guide for the limits of the structure 18, regions of 
atrophy within the standard space corresponding to the BF area were then segmented. 
We used maximum probability maps 18 as guidance, resulting in a BF mask covering 
voxels that were identified as lying in the BF in ten post-mortem brains and a final 
delineated area of high anatomical specificity. To study anterior and posterior BF 
compartments separately, we further divided the BF map into an anterior volume (size: 
595 voxels; top row, Supplementary Figure 1), covering Ch1-3 as well as Ch4 anterior cell 
groups, and a posterior volume (size: 565 voxels; bottom row, Supplementary Figure 1), 
covering Ch4 intermediate and posterior cell groups (nomenclature according to 18). Note 
that BF MRI maps used by us and other researchers are not specific for cholinergic cells of 
the BF, but rather represent the general BF area. The BF masks were propagated to the 
subjects’ space to extract the BF volume, and GM and WM masks were used to remove 
any falsely included CSF voxels. 
 
Positron emission tomography. 
Productions of 11C-PIB, 18F-THK523 and 18F-THK5105 were performed in the Centre for 
PET, Austin Hospital. 11C-PIB was synthesized using the one step 11C-methyl triflate 
approach as previously described 21. The decay corrected average radiochemical yield for 
11C-PIB was 30% with a radiochemical purity of > 98% and a specific activity of 30 ± 7. 5 
GBq/µmol. 18F-THK523 and 18F-THK5105 were synthesized by nucleophilic substitution of 
their respective tosylate precursors as previously described 15, 16. Briefly, the decay-
corrected average radiochemical yield of the production of 18F-THK523 was 22.5%, with a 
radiochemical purity of >95% and a specific activity of 225.6±134.8 GBq/µmol (6.2±3.3 
Ci/µmol). The decay-corrected average radiochemical yield of the production of 18F-
THK5105 was 45%, with a radiochemical purity of >95% and a specific activity of 229.6 
GBq/µmol (6.2±3.3 Ci/µmol). 
A 30-min acquisition (6 x 5-min frames) on an Allegro™ PET camera started 40 min after 
intravenous injection of 300 MBq 11C-PiB. A 90-min and a 120-min list-mode emission 
acquisition was performed in 3D mode after injection of 200 MBq 18F-THK523 and 18F-
THK5105, respectively. List-mode raw data were sorted off-line into 6 x 30 sec, 7 x 1-min, 
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4 x 2.5-min, 2 x 5-min and 6 x 10-min frames. The sorted sinograms were reconstructed 
using a 3D RAMLA algorithm. The interval between the 18F-THK523 and PiB PET studies 
was 0.3±3.8 months. The interval between the 18F-THK5105 and PiB PET studies was 
0.9±2.4 months. 
PET images were processed using a semi-automatic region of interest (ROI) method as 
previously described 22. Briefly, PET images were co-registered to each individual’s MRI 
using SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK), and the same ROI 
template was applied. SUVR for PiB and THK523 were generated using the cerebellar 
cortex as reference region 21. Neocortical tau and Aβ burden were expressed as the 
average SUVR for the following ROIs: frontal (dorsolateral prefrontal, ventrolateral 
prefrontal and orbitofrontal regions), superior parietal, lateral temporal, lateral occipital and 
anterior and posterior cingulate regions.  
Partial volume correction, accounting for both gray matter atrophy and white matter spill-
over was performed applying a 3-compartment approach using PMOD 3.1 (PMOD 
Technologies Ltd.).  
 
Statistical analysis.  
Normality of distribution was tested using the Shapiro-Wilk test and visual inspection of 
variable histograms. Linear regression analyses were conducted between imaging and 
clinical variables. One-way analysis of variance was used for group comparisons of 
variables. Data are presented as mean ± standard deviation unless otherwise stated. Tau 
values were not adjusted for age as we observed no significant interaction between age 
and global 18F-THK523 (p = 0.726) and 18F-THK5105 (p = 0.078) SUVR. Before 
conducting statistical analyses of BF volumes the effect of age was removed, as 
significant interactions between age and BF volume have been reported. Correction for 
multiple comparisons was performed using false discovery rate. The p-values given are 
uncorrected values. 
 
  
84
  
Acknowledgements 
 
G.M.K. was funded by an ANZ Trustees PhD scholarship for medical research and a 
University of Queensland International Scholarship. E.J.C. was supported by a National 
Health and Medical Research Council of Australia Career Development Fellowship 
(569601). V.L.V. was supported by a National Health and Medical Research Council of 
Australia Research Fellowship (1046471). The study was partially supported by an 
Alzheimer Drug Discovery Foundation Research Grant (20101208 AFTD) and by a 
National Health and Medical Research Council of Australia Project Grant 1044361. 
 
Contributions 
 
G.M.K. and V.L.V designed the study. J.F., M.F.-T., S.F. and N.O. conducted the 
experiments. J.F., M.F.-T., S.F., N.O., V.L.V. and G.M.K. analyzed the data. G.M.K and 
E.J.C. wrote the manuscript with input from all authors. The study was managed by S.R., 
C.C.R. and V.L.V. 
 
Competing financial interests 
 
The authors declare no competing financial interests.  
85
  
References 
 
1. Klunk, W.E., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh 
Compound-B. Ann Neurol 55, 306-319 (2004). 
2. Braak, H. & Del Tredici, K. The pathological process underlying Alzheimer's disease 
in individuals under thirty. Acta Neuropathol 121, 171-181 (2011). 
3. Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H. & Del Tredici, K. Staging of 
Alzheimer disease-associated neurofibrillary pathology using paraffin sections and 
immunocytochemistry. Acta Neuropathol 112, 389-404 (2006). 
4. Mufson, E.J., et al. Loss of basal forebrain p75NTR immunoreactivity in subjects with 
mild cognitive impairment and Alzheimer's disease. J Comp Neurol 443, 136-153 (2002). 
5. Schliebs, R. & Arendt, T. The significance of the cholinergic system in the brain 
during aging and in Alzheimer's disease. J Neural Transm 113, 1625-1644 (2006). 
6. Schneider, L.S., et al. Clinical trials and late-stage drug development for 
Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 275, 251-283 (2014). 
7. Grothe, M., Heinsen, H. & Teipel, S.J. Atrophy of the cholinergic basal forebrain 
over the adult age range and in early stages of Alzheimer's disease. Biol Psychiatry 71, 
805-813 (2011). 
8. Teipel, S., et al. Cholinergic basal forebrain atrophy predicts amyloid burden in 
Alzheimer's disease. Neurobiol Aging 35, 482-491 (2013). 
9. Kerbler, G.M., et al. Basal forebrain atrophy correlates with amyoid β burden in 
Alzheimer's disease. Neuroimage Clin  (2014). 
10. Drachman, D.A. The amyloid hypothesis, time to move on: Amyloid is the 
downstream result, not cause, of Alzheimer's disease. Alzheimers Dement  (2014). 
11. Mufson, E.J., Ward, S. & Binder, L. Prefibrillar tau oligomers in mild cognitive 
impairment and Alzheimer's disease. Neurodegener Dis 13, 151-153 (2014). 
12. Vana, L., et al. Progression of tau pathology in cholinergic Basal forebrain neurons 
in mild cognitive impairment and Alzheimer's disease. Am J Pathol 179, 2533-2550 (2011). 
13. Fodero-Tavoletti, M.T., et al. 18F-THK523: a novel in vivo tau imaging ligand for 
Alzheimer's disease. Brain 134, 1089-1100 (2011). 
14. Okamura, N., et al. Novel 18F-labeled arylquinoline derivatives for noninvasive 
imaging of tau pathology in Alzheimer disease. J Nucl Med 54, 1420-1427 (2013). 
15. Villemagne, V.L., et al. In vivo evaluation of a novel tau imaging tracer for 
Alzheimer's disease. Eur J Nucl Med Mol Imaging  (2014). 
16. Okamura, N., et al. Non-invasive assessment of Alzheimer's disease neurofibrillary 
86
  
pathology using 18F-THK5105 PET. Brain 137, 1762-1771 (2014). 
17. George, S., et al. MRI-based volumetric measurement of the substantia innominata 
in amnestic MCI and mild AD. Neurobiol Aging 32, 1756-1764 (2011). 
18. Zaborszky, L., et al. Stereotaxic probabilistic maps of the magnocellular cell groups 
in human basal forebrain. Neuroimage 42, 1127-1141 (2008). 
19. McKhann, G., et al. Clinical diagnosis of Alzheimer's disease: report of the 
NINCDS-ADRDA Work Group under the auspices of Department of Health and Human 
Services Task Force on Alzheimer's Disease. Neurology 34, 939-944 (1984). 
20. Bourgeat, P., et al. b-amyloid burden in the temporal neocortex is related to 
hippocampal atrophy in elderly subjects without dementia. Neurology 74, 121-127 (2010). 
21. Rowe, C.C., et al. Imaging b-amyloid burden in aging and dementia. Neurology 68, 
1718-1725 (2007). 
22. Villemagne, V.L., et al. Longitudinal assessment of Ab and cognition in aging and 
Alzheimer disease. Ann Neurol 69, 181-192 (2011). 
 
  
87
  
3.3 Supplementary data 
 
Supplementary Table 1: Demographics of healthy control (HC) and Alzheimer’s disease 
(AD) patients of the THK523 sample.  
 
 HC AD 
 (n=9) (n=10) 
Age 76.3 ± 10.0 75.6 ± 9.5 
Gender (M/F) 2/7 4/6 
MMSE 29.4 ± 1.0 16.7 ± 6.6* 
CDR 0.0 1.3 ± 0.6* 
CDR SOB 0.1 ± 0.2 7.3 ± 4.5* 
Years of education 15.0 ± 2.7 11.5 ± 3.6* 
Episodic memory scores -0.4 ± 0.6 -3.8 ± 0.5* 
Non-memory scores -0.1 ± 0.4 -3.4 ± 1.6* 
Aβ burden (PiB SUVR) 1.45 ± 0.6 2.87 ± 0.5* 
* Significantly different from HC (p < 0·05) Abbreviations: MMSE: Mini mental state 
examination; CDR: Clinical dementia rating; CDR-SOB: Clinical dementia rating sum of 
boxes; PiB: Pittsburgh compound B; SUVR: Standardized uptake value ratio. 
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Supplementary Table 2: Demographics of healthy control (HC) and Alzheimer’s disease 
(AD) patients of the THK5105 sample.  
 
 HC AD 
 (n=8) (n=8) 
Age 70.5 ± 4.4 74.1± 6.9 
Gender (M/F) 3/5 3/5 
MMSE 28.8 ± 1.5 17.3 ± 6.6* 
CDR 0.0 0.9 ± 0.5* 
CDR SOB 0.0 6.1 ± 4.9* 
Years of education 15.4 ± 2.4 11.3 ± 3.2* 
Episodic memory 
scores 
-0.06 ± 0.8 -3.8 ± 0.3* 
Non-memory scores -0.06 ± 0.5 -3.0 ± 1.9* 
Aβ burden (PiB 
SUVR) 
1.2 ± 0.1 2.0 ± 0.2* 
* Significantly different from HC (p < 0·05) Abbreviations: MMSE: Mini mental state 
examination; CDR: Clinical dementia rating; CDR-SOB: Clinical dementia rating sum of 
boxes; PiB: Pittsburgh compound B; SUVR: Standardized uptake value ratio. 
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Supplementary Table 3: Linear regression analysis between basal forebrain (BF) volumes 
and cognitive scores in the whole sample.  
 
 BF anterior BF posterior 
 r
2
adj p r2adj p 
MMSE 0.246 0.001 * # 0.282 < 0.001 * # 
CDR 0.233 0.002 * # 0.288 < 0.001 * # 
CDR-SOB 0.250 0.001 * # 0.253    0.001 * # 
Episodic 
memory 
0.147 0.013 * # 0.347 < 0.001 * # 
Episodic non-
memory 
0.160  0.010 * # 0.271 < 0.001 * # 
* Significant correlation, # Significant correlation after correction for multiple comparisons 
(n = 35). Abbreviations: MMSE: Mini mental state examination; CDR: Clinical dementia 
rating; CDR-SOB: Clinical dementia rating sum of boxes; PiB: Pittsburgh compound B; 
SUVR: Standardized uptake value ratio.  
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Supplementary Figure 1: BF masks of the anterior and posterior areas in template space. 
Coronal slices from rostral (left) to caudal (right) showing (top row, red) the anterior and 
(bottom row, blue) the posterior BF mask used to calculate volumes for each patient. Both 
masks were restricted to encompass only those areas within the boundaries of the BF that 
undergo atrophy in AD patients in order to investigate the interaction of these areas with 
NFT burden in an AD cohort. Coronal slices at different levels from rostral to caudal are 
shown on a T1-weighted image. 
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3.4 Discussion and implication of findings 
 
Strikingly, the results of this chapter show for the first time that there is a strong correlation 
of basal forebrain volume with tau burden in vivo in a human Alzheimer’s disease cohort. 
The fact that the interaction with amyloid accumulation was found to be not as strong in 
this study possibly indicates that tau aggregation is more closely related to basal forebrain 
degeneration. 
Here we demonstrated a potential mechanistic link between basal forebrain integrity and 
NFT burden in regions closely associated with basal forebrain neurons through their 
projections. Taken together with the previous finding that basal forebrain degeneration 
correlates with amyloid burden, which was also replicated in the current study, we have 
now demonstrated that basal forebrain degeneration in Alzheimer’s disease also 
correlates with other features of disease progression in humans in vivo. This further shows 
the potential of basal forebrain measures as biomarkers of Alzheimer’s disease. However, 
we are also starting to discern potential differences in the interaction of basal forebrain 
degeneration with amyloid and tau accumulation. Future studies aimed at investigating the 
potential underlying biological mechanisms will be required to understand the causal 
relationship between these features. 
The fact that we were able to show similar interactions between basal forebrain atrophy 
and tau burden employing two different PET tracers in two independent subject cohorts 
particularly strengthens the findings of this study. It was recently demonstrated, that 
THK5105 has higher binding affinity to synthetic tau fibrils, human Alzheimer’s disease 
post-mortem brain homogenates as well as human post-mortem brain sections, as 
compared to THK523. Therefore, THK5105 might be a more promising candidate as PET 
tracer for the future. 
Here, we also replicated our previous results (section 2.2) of significant basal forebrain 
volumetric differences between Alzheimer’s and control subjects. In addition the 
correlations of basal forebrain volume with cognitive scores were confirmed in this new 
study. 
Interestingly, tau also seems to be a significantly better predictor and correlate of cognitive 
status in human subjects (Fodero-Tavoletti et al., 2011) when compared to amyloid 
burden. Given basal forebrain volume is also associated with cognition, this warrants 
further investigation into the specific involvement of the basal forebrain in general cognitive 
status, as well as more explicit cognitive functions such as navigation, which has been 
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shown to be impaired in Alzheimer’s subjects (Hort et al., 2014) and this will be the focus 
of the next chapter.
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Chapter 4: Basal forebrain degeneration is associated with spatial 
navigation deficits in Alzheimer’s disease 
 
4.1 Introduction 
 
As demonstrated in the previous chapter and by others in the field, basal forebrain volume 
is correlated with memory scores such as episodic memory (chapter 3) and MMSE (e.g. 
Grothe et al., 2011), especially in Alzheimer’s disease subjects; however not many studies 
in humans have explored the involvement of the basal forebrain in more specific cognitive 
functions. Work carried out in mice by members of the Coulson laboratory has revealed an 
effect of cholinergic basal forebrain degeneration on spatial navigation performance 
(Hamlin et al., 2013). In this study, loss of cholinergic neurons was shown to impair 
idiothetic navigation of mice, whereas the animals did not display any changes in cued 
navigation or generalized learning or memory, fear-related tasks and sleep-wake cycle 
characteristics. 
This animal study prompted us to investigate whether the basal forebrain plays a similar 
role in humans, such that Alzheimer’s disease subjects with basal forebrain atrophy 
display impaired uncued navigation. With the structural MRI methods developed in this 
thesis, we were able to study the association of basal forebrain volume with performance 
of normal controls, amnestic mild cognitively impaired subjects and Alzheimer’s disease 
patients, on spatial navigation tasks. Furthermore different subtypes of tasks allowed us to 
specifically look into the association of basal forebrain volume with either egocentric 
(uncued) or allocentric (cued) navigation. This work was conducted in collaboration with 
researchers from the Charles University in Prague, who collected MRI data as well as 
performing cognitive testing on site. 
This work has been submitted to the journal Brain Structure and Function.  
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4.2 The basal forebrain contributes to cue-based spatial navigation performance in 
Alzheimer’s disease 
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Abstract 
 
The basal forebrain degenerates in Alzheimer’s disease (AD) and this process is believed 
to contribute to the cognitive decline observed in AD patients. Impairment in spatial 
navigation is an early feature of the disease but whether basal forebrain dysfunction is 
responsible for the impaired navigation skills of AD patients is not known. Our objective 
was to investigate the relationship between the basal forebrain volume and performance in 
real space as well as computer-based navigation paradigms in an elderly cohort 
comprising cognitively normal controls, subjects with amnestic mild cognitive impairment 
and those with AD. We also tested whether basal forebrain volume could predict the 
participants’ ability to perform allocentric- vs. egocentric-based navigation tasks. The basal 
forebrain volume was calculated from 1.5 T MRI scans and navigation skills were 
assessed using the human analog of the Morris water maze employing allocentric, 
egocentric and mixed allo/egocentric real space as well as computerized tests. We found 
that basal forebrain volume was correlated with spatial accuracy in allocentric (cued) and 
mixed allo/egocentric navigation tasks but not the egocentric (uncued) task in the entire 
sample, demonstrating an important role of the basal forebrain in mediating cue-based 
spatial navigation capacity. Regression analysis revealed that although hippocampal 
volume reflected navigation performance across the entire sample, basal forebrain volume 
contributed to mixed allo/egocentric navigation in the AD group, whereas hippocampal 
volume did not. This suggests that atrophy of the basal forebrain contributes to aspects of 
navigation impairment in AD that are independent of hippocampal changes.  
 
 
Keywords 
 
Basal forebrain, navigation, Alzheimer’s disease, cholinergic dysfunction, cognitive 
impairment
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Introduction 
 
The basal forebrain, encompassing the septum, vertical and horizontal diagonal bands of 
Broca and the nucleus basalis of Meynert, degenerates in Alzheimer’s disease (AD) and 
this process plays a role in the general cognitive decline observed in AD patients (Mufson, 
2003; Schliebs and Arendt, 2006). Using magnetic resonance imaging (MRI), smaller 
basal forebrain volumes have been shown to be associated with poorer performance in a 
multitude of cognitive tests used to measure memory dysfunction in AD, such as the 
clinical dementia rating (George et al., 2011; Grothe et al., 2012) and the California verbal 
learning test (Butler et al., 2012), as well as the mini mental state examination (MMSE; 
Grothe et al., 2011).  
Moreover, basal forebrain neurons (e.g. cholinergic neurons), which project to the 
hippocampus, amygdala and almost the entire neocortex, have been shown to play a role 
in attention in humans (Hasselmo and McGaughy, 2004; Sarter et al., 2006). 
Lesion studies in rodents have also demonstrated that selective loss of basal forebrain 
cholinergic neurons causes impairment in both egocentric (uncued) and allocentric (cued) 
spatial navigation (Berger-Sweeney et al., 2001; Hamlin et al., 2013). The basal forebrain 
cholinergic system has also been shown to be involved in feature binding – the ability to 
process different features of objects and combine these into a complete picture (Botly and 
De Rosa, 2009) – and visuospatial attention (Botly and De Rosa, 2012), which together 
are crucial for correct allocentric navigation. More specifically, acetylcholine is released 
from basal forebrain neurons when spatial cues are detected, but not when cues are 
missed (Parikh et al., 2007).  
Likewise, the administration of donepezil, an acetylcholine esterase inhibitor that is used to 
treat cognitive dysfunction in patients diagnosed with mild AD, by prolonging synaptic 
acetylcholine availability, has been shown to improve the allocentric navigation 
performance of patients in a human analog of the Morris water maze (hMWM; Hort et al., 
2014), a commonly used spatial working memory task. Taken together, these studies 
suggest a role for basal forebrain function in allocentric navigation; however the role of the 
basal forebrain in allocentric versus egocentric spatial navigation has never been studied 
in vivo in humans. 
Here we investigated the relationship between basal forebrain volume (measured by MRI) 
and performance in cued (allocentric), uncued (egocentric) and mixed allo/egocentric 
spatial navigation in the real space and computerized versions of the hMWM task. We also 
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assessed differences in basal forebrain volume between groups and determined whether 
impaired performance in hMWM tasks in amnestic mild cognitive impaired (aMCI) and AD 
patients was associated with basal forebrain volume.   
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Subjects and Methods 
 
Subjects 
 
Between October 2010 and October 2012, eligible subjects (Supplementary Table 1) with 
probable AD (n=22) or aMCI (n=27) were consecutively recruited and followed up at the 
Memory Disorders Clinic, Department of Neurology, Charles University and Motol 
University Hospital in Prague, the Czech Republic (a longitudinal memory clinic-based 
cohort). Cognitively normal elderly subjects, who we refer to as normal controls (NC; 
n=17), were recruited from the University of the Third Age, Charles University in Prague, 
or patients’ family members. Eligibility was defined as 1) absence of primary neurological 
disease other than aMCI and AD that could interfere with cognitive functioning, and  2) 
sufficient brain scan quality free of structural abnormalities such as tumors, cortical 
infarcts, subdural hematoma or hydrocephalus, although lacunar infarcts and white matter 
hyperintensities were not excluded. The study was approved by the institutional review 
board, and informed consent was obtained from subjects or their proxies. 
 
Clinical evaluations and diagnosis 
 
Subjects received annual clinical, neurological and laboratory evaluations, 
neuropsychology tests, brain MRI, and spatial navigation testing using the hMWM. Based 
on a panel consensus conference of 3 neurologists, and 3 neuropsychologists, subjects 
were diagnosed as probable AD (McKhann et al., 1984) or aMCI (Petersen, 2004). 
Memory impairment was established when the patient scored more than 1.5 SD below the 
mean of age- and education-adjusted norms on any memory test (Laczo et al., 2011). 
Details of neuropsychological testing are described elsewhere (Vyhnalek et al., 2014). 
 
Spatial navigation testing using the human analogue of the Morris water maze 
 
Spatial navigation was tested using in-house developed real space and computerized 
versions of the hMWM (Hort et al., 2014) based in the Laboratory of Spatial Cognition, a 
joint workplace of the Department of Neurology, 2nd Faculty of Medicine, Charles 
University in Prague, Czech Republic and Institute of Physiology, Academy of Sciences of 
the Czech Republic v.v.i., Prague, Czech Republic. The hMWM has been designed to 
examine separately the two basic types of navigation: 1) allocentric (cued) which is 
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hippocampus-driven, self-position independent, and uses salient distal cues to find the 
goal (Astur et al., 2002, and 2) egocentric (uncued), which is predominantly parietal cortex- 
and caudate nucleus-driven, and is self and start position dependent (Weniger et al., 
2009). The real space and computer-based versions are described in detail elsewhere 
(Hort et al., 2007; Laczo et al., 2011).  
Briefly, the real space task was conducted within a fully enclosed arena surrounded by a 
dark blue velvet curtain and operated by a computer program. The computer-based 2D 
task was conducted using the map-view of the velvet arena represented by a circle on a 
computer touch screen. The purpose of the tasks regardless of the version used was to 
locate the invisible goal on the arena floor or within the circle on the computer screen 
using either the start position (uncued, egocentric), two distal orientation cues (cued, 
allocentric), or both the start position and distal cues (mixed allo/egocentric). The 
(invisible) goal was initially shown to subjects for approximately 10-15 seconds 
immediately prior to the first trial. In the computer-based version, subjects were asked to 
use a mouse and screen to draw the way from the start to the goal. In the real space 
version, they were asked to walk directly from the start, and to indicate where they thought 
the goal was by pointing a long stick with a light-emitting diode to the floor once they 
walked into goal’s presumed position.  
Navigation performance was recorded automatically based on the position of either the 
point drawn by patient on the computer screen or the diode on the stick location. The 
navigation accuracy was measured as the distance error (in pixels in the computerized 
version and in centimetres in the real space version) between the goal position determined 
by the subject, and the correct goal position. Each of allocentric, egocenric or mixed tasks 
consisted of eight trials in both versions. Each computerized task preceded the respective 
real space task. The order of the tasks was as follows: 1) mixed allo/egocentric, 2) 
egocentric and 3) allocentric. Trials had no time limit, mainly to reduce bias caused by 
differences in cognitive, sensory, and physical functioning. Examiners were blinded to the 
diagnosis and supervised the task without interference beyond standard instructions. 
 
MRI acquisition 
 
Images were acquired at 1.5T (Siemens AG, Erlangen, Germany) using T1-weighted 3-
dimensional high resolution magnetization-prepared rapid acquisition with a gradient echo 
(MPRAGE) sequence with the following parameters: TR/TE/TI = 2000/3.08/1100 ms, flip 
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angle 15°, 192 continuous partitions, slice thickness 1.0 mm, and in-plane resolution 1 
mm. Scans were visually examined by a single neuroradiologist (J.Li.), blinded to the 
diagnosis, for appropriate quality and structural findings contradicting eligibility. 
 
MRI processing 
 
The hippocampus, pons and gray matter (GM), white matter (WM) and cerebrospinal fluid 
(CSF) were segmented from the MPRAGE images using the method outlined in Bourgeat 
et al. (2010). A skull strip mask was generated from the GM, WM and CSF segmentation. 
All volume calculations reported are normalized by intracranial volume. 
The skull stripped MPRAGE images of 80 healthy elderly subjects from the Australian 
Imaging Biomarkers and Lifestyle study (AIBL; http://www.aibl.csiro.au/) were normalized 
to create an average elderly template brain using the open-source deformable registration 
tool ANTS (Avants et al., 2010). The population-specific template was generated by 
iteratively registering images to the current template estimate. A new shape and intensity 
average were then computed from the results of the registrations and the current template 
estimate was set as the average. This template generation procedure was repeated 
iteratively (I=5). Each registration in this procedure used the greedy symmetric 
normalization algorithm (SyN, parameters outlined below; Avants et al., 2008) and the 
cross-correlation after subtracting the local mean from the image match metric.  
The registration between each subject’s MPRAGE image and the population-specific 
template was performed using the SyN algorithm (GradStep = 0.5, regularization sigma = 
2.0). The image match metric was the cross-correlation between the images. Cross-
correlation after subtracting the local mean from the image at each voxel was computed 
using a 5×5×5 voxel window. Registration was performed in a multi-resolution scheme, 
with a maximum of 30 iterations at 4× subsampling, 90 iterations at 2× subsampling, and 
50 iterations at full resolution.  
We have previously established a mask of the entire basal forebrain, encompassing only 
those areas that undergo atrophy in AD patients, by comparing control (n=80) and AD 
(n=38) subjects from the AIBL cohort (Kerbler et al., submitted) and overlaid the resultant 
z-score map (set to -0.5 and -1 standard deviations) on a standard Montreal Neurological 
Institute (MNI) brain. Using published probabilistic basal forebrain maps derived from 
histological data as a guide for the limits of the structure (Zaborszky et al., 2008), regions 
of atrophy within the standard space corresponding to the basal forebrain were then 
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segmented. 
We used maximum probability maps (MPMs; Zaborszky et al., 2008) as guidance, 
resulting in a mask covering voxels that were identified as lying in the basal forebrain in 
ten post-mortem brains and a final delineated area of high anatomical specificity. To study 
anterior and posterior basal forebrain compartments separately, we further divided the 
basal forebrain map into an anterior volume (size: 595 voxels), covering the medial 
septum and diagonal bands of Broca (Ch1-3) as well as anterior regions of the nucleus 
basalis of Meynert (Ch4), and a posterior volume (size: 565 voxels), covering the 
intermediate and posterior nucleus basalis of Meynert (nomenclature according to 
Zaborszky et al., 2008). Note, that basal forebrain MRI maps used by us and other 
researchers are not specific for cholinergic cells of the basal forebrain, as basal forebrain 
nuclei also contain other neuronal subtypes (e.g GABAergic projection neurons). The 
masks were propagated to the subjects’ space to extract the basal forebrain volume, and 
GM and WM masks were used to remove any falsely included CSF voxels. 
 
Statistics 
 
Basal forebrain and hippocampal volumes as well as navigation scores were corrected for 
age, education and gender. Analysis of variance (ANOVA) in conjunction with Bonferroni 
post-hoc testing was used to calculate group differences. A two-tailed Pearson’s product 
moment correlation between age-, education- and gender-corrected variables was used. 
Multiple linear regressions were performed to assess the relationships between modalities 
in predicting distance error in navigation tests.  
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Results 
 
Basal forebrain volumes are significantly reduced in AD 
 
In order to compare the basal forebrain integrity between clinical groups, we first 
calculated the basal forebrain volume of the whole structure, as well as its anterior and the 
posterior regions. These volumes were then corrected for age, education and gender and 
subsequently compared between the NC, aMCI and AD groups as well as correlated to 
hippocampal volumes. Group comparisons revealed that the mean whole (Supplementary 
Fig. 1A; p=0.032), as well as the anterior (Supplementary Fig. 1B; p=0.044), but not the 
posterior (Supplementary Fig. 1C) basal forebrain volumes, were significantly reduced in 
aMCI subjects compared to NC subjects. No other significant differences in mean basal 
forebrain volume were found between diagnostic groups, perhaps due to the small group 
sizes. Furthermore, whole (p<0.001), anterior (p<0.001) and posterior (p<0.001) basal 
forebrain volumes were all highly correlated to hippocampal volume. 
 
Basal forebrain correlates with navigation scores in the whole cohort 
 
To investigate the relationship between allocentric, egocentric as well as mixed 
allo/egocentric spatial navigation performance and the basal forebrain we correlated the 
navigation scores of both the real space and computer-based versions of the navigation 
tasks with the basal forebrain volumes of NC, aMCI and AD subjects. In the whole cohort 
(Fig. 1), the distance error in the allocentric real space task was correlated to the anterior 
(Fig. 1A; R=0.32, p=0.041), posterior (Fig. 1B; R=0.34, p=0.028) and whole (R=0.35, 
p=0.022) basal forebrain volume. Furthermore, the distance error in the mixed 
allo/egocentric real space test was significantly associated with the anterior (Fig. 1C; 
R=0.38, p=0.009) and whole (R=0.34, p=0.019) but not the posterior basal forebrain 
volume. Associations between computer-based navigation test scores with basal forebrain 
volumes revealed that only the mixed allo/egocentric computer-based navigation task was 
significantly correlated to the posterior (Fig. 1D; R=0.31, p=0.027) and whole basal 
forebrain (R=0.29, p=0.037) volumes. This was in spite of the performances of subjects in 
the real space and computer-based versions of the navigation tasks being significantly 
correlated: allocentric, R=0.78, p<0.001; egocentric, R=0.79, p<0.001; allo/egocentric, 
R=0.84, p<0.001. 
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Figure 1: Significant correlations of anterior and posterior basal forebrain volumes (x-axis) 
to distance error (y-axis) in allocentric (A, B) and mixed allo/egocentric (C, D) real space 
tests. Both anterior (A) and posterior (B) basal forebrain volumes were significantly 
correlated to distance error in the allocentric real space test. Furthermore distance error in 
the mixed allo/egocentric real space test was also correlated to anterior (C) and posterior 
(D) basal forebrain volume. Data points are colored according to clinical diagnosis. A linear 
fit line with 95% confidence interval is shown.  
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Basal forebrain volume correlates with navigation scores in AD patients 
 
To test whether basal forebrain volumes were correlated to navigation dysfunction in 
clinical groups, we performed correlations of basal forebrain volumes and navigation task 
scores in individual groups. This analysis revealed no significant interactions of any basal 
forebrain volumetric measure with distance error in any of the real space or computer-
based navigation tasks in the aMCI and NC groups. However in the AD group, the anterior 
(Fig. 2; R=0.82, p=0.003) and whole (R=0.68, p=0.029) basal forebrain volumes were 
significantly correlated to distance error in the allo/egocentric real space task.  
 
Regression analysis in the whole cohort and in the AD group 
 
Basal forebrain measures (anterior and posterior) which showed significant correlations 
with real space navigation scores were entered into regression models with and without 
hippocampal volume to determine their relative contributions in predicting performance in 
the allocentric and mixed allo/egocentric navigation tasks for the whole cohort, and mixed 
allo/egocentric navigation performance for AD patients. 
When mixed allo/egocentric navigation performance for the whole cohort was considered 
as the dependent variable and each modality (anterior basal forebrain volume and 
hippocampal volume) was entered separately into the model, the relationship was 
significant for each modality (Table 1, Model 1). Both modalities were then entered 
together into the model to determine whether each modality independently contributed to 
mixed allo/egocentric navigation deficits when taking into account the effect of another 
modality (Table 1, Model 2). This model was still found to be predictive of mixed 
allo/egocentric navigation scores; however only hippocampal volume remained 
significantly associated with navigation performance. 
When allocentric navigation performance in the whole cohort was considered as the 
dependant variable and each modality (anterior, posterior basal forebrain volume and 
hippocampal volume) was entered separately into the model, relationships were significant 
for all modalities (Table 2, Model 1). However when entering combinations of two 
modalities into the model (Table 2, Model 2), only those combinations including 
hippocampal volume showed significant association with allocentric test scores. When 
entering hippocampal volume and basal forebrain volume together into the model, only 
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hippocampal volume remained significantly associated with allocentric navigation 
performance.  
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Figure 2: Anterior basal forebrain volume is significantly correlated to distance error in the 
mixed allo/egocentric real space test. A linear fit line with 95% confidence interval is 
shown. 
 
 
 
By contrast, when mixed allo/egocentric navigation performance in the AD group was 
considered as the dependent variable and each modality (anterior basal forebrain volume 
and hippocampal volume) was entered separately into the model, the relationship was 
only significant for anterior basal forebrain volume (Table 3, Model 1). Therefore, when 
entering both modalities together into the model, only anterior basal forebrain volume, and 
not hippocampal volume, remained significantly associated with mixed allo/egocentric 
navigation performance in the AD group. 
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Table 1: Results of the regression models with distance error in the allo/egocentric real 
space test as the dependent variable and anterior basal forebrain volume and 
hippocampal volume separately (Model 1) or simultaneously (Model 2) entered as 
predictive variables, while controlling for age, gender and years of education, within the 
whole cohort. BF: basal forebrain 
 
Model Volume R2 Beta t-value P-value 
1  
 BF Anterior 0.14** -0.378 -2.738 0.009 
Hippocampus 0.17** -0.414 -3.047 0.004 
2  
BF Anterior 0.20** -0.210 -1.272 0.21 
+ Hippocampus -0.293 -1.780 0.082 
R2 = R2 value of the overall model significant at ** p<0.01. Beta = standardized regression 
coefficient. P-value = association of each modality with the dependent variable. 
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Table 2: Results of the regression models with distance error in the allocentric real space 
test as the dependent variable and anterior basal forebrain volume, posterior basal 
forebrain volume and hippocampal volume separately (Model 1) or simultaneously (Model 
2 and Model 3) entered as predictive variables, while controlling for age, gender and years 
of education, within the whole cohort. BF: basal forebrain 
 
Model Volume R2 Beta t-value P-value 
1  
 BF Anterior 0.10* -0.316 -2.107 0.041 
BF Posterior 0.12* -0.339 -2.279 0.028 
Hippocampus 0.26** -0.512 -3.772 0.001 
2  
BF Anterior 0.13 -0.232 -1.056 0.297 
+ BF Posterior -0.147 -0.668 0.508 
BF Anterior 0.26**  0.011  0.060 0.952 
+ Hippocampus -0.519 -2.931 0.006 
BF Posterior 0.27** -0.064 -0.383 0.704 
+ Hippocampus -0.475 -2.823 0.007 
3  
BF Anterior 0.27**  0.075  0.342 0.734 
+ BF Posterior -0.106 -0.507 0.615 
+ Hippocampus -0.498 -2.718 0.01 
R2 = R2 value of the overall model significant at * p<0.05, ** p<0.01. Beta = standardized 
regression coefficient. P-value = association of each modality with the dependent variable. 
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Table 3: Results of the regression models with distance error in the allo/egocentric real 
space test as the dependent variable and anterior basal forebrain volume and 
hippocampal volume separately (Model 1) or simultaneously (Model 2) entered as 
predictive variables, while controlling for age, gender and years of education, within the 
AD group. BF: basal forebrain 
 
Model Volume R2 Beta t-value P-value 
1  
 BF Anterior 0.68** -0.824 -4.107 0.003 
Hippocampus 0.18 -0.428 -1.339 0.217 
2  
BF Anterior 0.68* -0.829 -3.284 0.013 
+ Hippocampus  0.010  0.041 0.969 
R2 = R2 value of the overall model significant at * p<0.05, ** p<0.01. Beta = standardized 
regression coefficient. P-value = association of each modality with the dependent variable. 
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Discussion 
 
Here we show, that the basal forebrain, particularly the anterior area, undergoes 
significant atrophy in AD. In all groups, basal forebrain volumes were significantly 
correlated to real space allocentric, as well as to mixed allo/egocentric navigation in real 
space and computer-based tasks, whereas no interactions with purely egocentric-based 
navigation performances were found. Furthermore, individual group correlations revealed 
a significant association of mixed allo/egocentric navigation performance with anterior 
basal forebrain volume in the AD group, an association that was independent of 
hippocampal change. This suggests that anterior basal forebrain degeneration is most 
closely associated with the navigation impairment observed in AD subjects. As we 
consistently found that significant interactions of navigation scores with whole basal 
forebrain could be explained by an interaction of navigation scores with a specific sub-
region (anterior or posterior) of the basal forebrain, only results for anterior and posterior 
basal forebrain volumes are discussed below.  
In particular, we demonstrated that the interaction between anterior basal forebrain volume 
and performance in the allocentric and mixed allo/egocentric navigation task of AD 
patients was strong. By contrast, we did not find significant associations of basal forebrain 
volume with purely egocentric-type navigation. In the AD group, the significant correlations 
observed herein suggest that anterior basal forebrain degeneration contributes to the 
observed functional decline in allocentric navigation performance in AD subjects. 
Regression analysis further revealed that the association of anterior basal forebrain 
volume with the AD-related decline in mixed allo/egocentric navigation ability was 
independent of hippocampal volume, as the regression model including both anterior basal 
forebrain volume and hippocampal volume as predictors did not show an improvement of 
fit (or increase in R2) over using only anterior basal forebrain as a modality. However, our 
findings are consistent with those of previous studies in rodents that have demonstrated 
that basal forebrain-derived acetylcholine is important for tasks involving cues and cue 
detection, including feature binding (Botly and De Rosa, 2009; Parikh et al., 2007), as well 
as a report that enhancement of cholinergic neuromodulation using physostigmine, an 
acetylcholine esterase inhibitor, increases the selectivity of neural responses during visual 
working memory tasks in humans (Furey et al., 2000).  
Furthermore, supply of acetylcholine to the hippocampus via the anterior Ch1-2 basal 
forebrain neurons is important for the plasticity of hippocampal place cells (Ikonen et al., 
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2002), and we have shown that the acetyl cholinesterase inhibitor donepezil improves 
navigation performance in the allocentric but not egocentric hMWM tasks (Hort et al., 
2014). Therefore, our work provides additional evidence for the role of basal forebrain-
supplied acetylcholine, particularly from the anterior nuceli, in allocentric spatial memory 
performance in humans. 
Although basal forebrain volume and navigation performance were correlated in the AD 
group, and significant interactions were identified in the entire sample between basal 
forebrain volumes and allocentric as well as mixed allo/egocentric test scores, no 
significant interactions were found between basal forebrain and navigation test scores in 
the other subgroups (NC, aMCI) when considered independently. A similar interaction has 
been reported for hippocampal volume (Nedelska et al., 2012). When considering the 
effect of hippocampal as well as basal forebrain volume in the navigation performance of 
the entire cohort, the relationship of basal forebrain subregion (anterior, posterior) with 
navigation in either task (allocentric, mixed allo/egocentric) became non-significant, 
suggesting that atrophy of the basal forebrain in cognitively normal and mildly impaired 
subjects might be a secondary effect to that of hippocampal dysfunction. In addition 
cholinergic activity has been shown to be increased in the hippocampus of MCI subjects 
(DeKosky et al., 2002), suggesting a compensatory increased activity of basal forebrain 
neurons. Indeed, a deterioration of the entorhinal-hippocampal pathway, which eventuates 
in MCI (DeKosky et al., 2002; Ikonomovic et al., 2003) might cause increased sprouting of 
the basal forebrain-hippocampal connection (Stanfield and Cowan, 1982), which in turn 
could lead to a temporary increase in acetylcholine in the hippocampus (Contestabile, 
2011). 
By contrast, anterior basal forebrain volume predicted performance independently of 
hippocampal volume in the AD group. One possibility is that allocentric and mixed 
allo/egocentric navigation impairment manifests only when both hippocampal and basal 
forebrain function are compromised, with anterior basal forebrain degeneration occurring 
predominantly in the transition between mild AD and late-stage AD (Grothe et al., 2011).  
Therefore in the regression analysis, anterior basal forebrain degeneration would be the 
most predictive element of early cognitive dysfunction, measured herein as allocentric 
navigation performance. However given many aMCI subjects respond to cholinergic 
treatments and already have cholinergic dysfunction that may not fully be reflected by 
measures of basal forebrain volume loss, functional assessment of basal forebrain activity 
(e.g. cholinergic activity; Petrou et al., 2014; Kim et al., 2012) may provide increased 
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sensitivity as a predictor of navigation performance of normal and aMCI subjects, 
compared to mere volumetric assessment.  
Surprisingly, the basal forebrain volume was more strongly associated with real space 
navigation than navigation performance in the computerized task. Even though real space 
and computer-based navigation scores were highly correlated for each test (allocentric, 
egocentric, mixed allo/egocentric) for the whole cohort, only posterior basal forebrain 
volume was correlated to the computer-based mixed allo/egocentric navigation 
performance. In rats, the posterior basal forebrain – the nucleus basalis of Meynert, which 
projects cortically – is implicated in visual search (Botly and De Rosa, 2012), whereas 
cholinergic cells located in the anterior medial septum release acetylcholine in the 
hippocampus after stimulation of the vestibular (motion detection) system (Tai and Leung, 
2012). Therefore our finding that performance in the mixed allo/egocentric computer-
based navigation task was significantly correlated to posterior basal forebrain atrophy 
would be consistent with the idea that a purely visual task, such as the computer-based 
version of the hMWM is more dependent on the function of the nucleus basalis of Meynert, 
whereas the real space hMWM, which involves integration of vestibular as well as visual 
information, requires functional septal and nucleus basalis basal forebrain neurons. 
In conclusion, this study establishes that the basal forebrain is involved in regulating mixed 
allo/egocentric and allocentric, but not pure egocentric navigation in humans. In addition, 
atrophy of the basal forebrain contributes to allocentric navigation impairments in subjects 
with severe dementia, and this is independent of hippocampal changes. Our work also 
provides added justification for the use of the hMWM as a diagnostic tool for AD and/or 
aMCI subjects who may be of particular benefit from drugs targeting the cholinergic 
system. 
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4.3 Supplementary data 
 
Supplementary Table 1: Demographics of NC, aMCI and AD groups. Age and years of 
education are expressed as mean ± standard deviation. 
 NC aMCI AD 
 (n=17) (n=27) (n=22) 
Age 70.1 ± 4.8 71.4 ± 8.1 74.7 ± 8.1 
Gender M/F 7/10 17/10 10/12 
Years of education 15.6 ± 2.3 15.1 ± 3.2 12.1 ± 2.3 
MMSE 28.5 ± 1.7 25.3 ± 3.8 19.5 ± 2.9 
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Supplementary Figure 1: Group comparisons of whole, anterior and posterior basal 
forebrain volumes between NC, aMCI and AD groups. There was a significant reduction in 
whole (A) and anterior (B) but not posterior (C) basal forebrain volume between the NC 
and aMCI groups. The AD group was not significantly different from either the NC or aMCI 
group for any of the basal forebrain volumes. * p<0.05. Whiskers represent min/max 
values except data points (circles) more than 1.5 interquartile ranges away from the 75th 
percentile. 
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4.4 Discussion and implication of findings 
 
Two main findings of this study were that (1) basal forebrain volume is indirectly 
associated with navigation performance in healthy/mild cognitively impaired subjects, 
possibly through modulation of activity of hippocampal and cortical areas and (2) 
degeneration of the anterior basal forebrain volume is a strong correlate of navigation 
impairment in Alzheimer’s disease subjects, independent of hippocampal volume. This is 
the first study to our knowledge that demonstrates involvement of the basal forebrain with 
a specific type of navigation in a dementia cohort. 
Contrary to the hypothesis based on the results of the animal study conducted in the 
Coulson laboratory, which demonstrated an effect of basal forebrain degeneration on 
egocentric navigation (Hamlin et al., 2013), we found correlations of basal forebrain 
volume with allocentric or mixed allo/egocentric navigation, but no interaction with purely 
egocentric navigation. However, this finding is consistent with a human study showing that 
an acetylcholine esterase inhibitor aimed at improving basal forebrain neuronal function 
also improved allocentric but not egocentric navigation (Hort et al., 2014). It must also be 
remembered that a selective and mild lesion of cholinergic neurons in mice is also not 
necessarily comparable to severely cognitively impaired human subjects displaying the full 
spectrum of Alzheimer’s dementia symptoms. Indeed the lesion of cholinergic neurons in 
these mice did not result in basal forebrain atrophy (see next chapter), which has been 
demonstrated to be a consistent feature of Alzheimer’s disease patients (chapters 3, 4). 
Therefore a more sensitive measure of basal forebrain dysfunction may reveal interactions 
with other features of Alzheimer’s disease (behavioural or pathological) earlier in the 
disease aetiology.  
Indeed MRI imaging methods are also capable of measuring integrity of brain connections, 
which might have additional diagnostic value, as network disconnection possibly occurs 
before actual volume change of a brain area, such as the basal forebrain, in Alzheimer’s 
disease. This is the focus of the next chapter. 
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Chapter 5: Imaging degeneration of basal forebrain cholinergic neuronal 
connections in a mouse model 
 
5.1 Introduction 
 
The cholinergic lesion mouse model used in the Coulson laboratory displays loss of 
cholinergic neurons as well as denervation of basal forebrain efferents to the 
hippocampus, as demonstrated in this chapter. This robust phenotype of degeneration of 
basal forebrain neuronal connections in a mouse model enabled a proof-of-principle study 
to test if it was possible to detect corresponding changes through imaging measures and 
correlate these changes back to histological measures of the lesion. In humans, 
tractography has previously been used to assess white matter integrity in Alzheimer’s 
disease patients and amnestic mild cognitively impaired subjects compared to controls 
(e.g. Agosta et al., 2011); however it was not possible to attribute the observed changes to 
an underlying biological mechanism. 
Here, we asked whether dMRI could be used to assess changes in local diffusion in the 
basal forebrain area as well as changes in diffusion parameters of the basal forebrain-
hippocampal pathway as a measure of early basal forebrain degeneration prior to atrophy, 
using a technique called tractography (Mori and Zhang, 2006). 
This study has been published in the journal Neuroimage. 
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5.2 Diffusion-weighted magnetic resonance imaging detection of basal forebrain 
cholinergic degeneration in a mouse model 
 
1GM Kerbler, 1AS Hamlin, 2,3K Pannek, 3ND Kurniawan, 3MD Keller, 2,3SE Rose, 1EJ 
Coulson. (2013) Diffusion-weighted magnetic resonance imaging detection of basal 
forebrain cholinergic degeneration in a mouse model. Neuroimage, 66C: 133-141 
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NeurodegenerationLoss of basal forebrain cholinergic neurons is an early and key feature of Alzheimer's disease, and magnetic
resonance imaging (MRI) volumetric measurement of the basal forebrain has recently gained attention as a
potential diagnostic tool for this condition. The aim of this study was to determine whether loss of basal fore-
brain cholinergic neurons underpins changes which can be detected through diffusion MRI using diffusion
tensor imaging (DTI) and probabilistic tractography in a mouse model. To cause selective basal forebrain cho-
linergic degeneration, the toxin saporin conjugated to a p75 neurotrophin receptor antibody (mu-p75-SAP)
was used. This resulted in ~25% loss of the basal forebrain cholinergic neurons and signiﬁcant loss of terminal
cholinergic projections in the hippocampus, as determined by histology. To test whether lesion of cholinergic
neurons caused basal forebrain, hippocampal, or whole brain atrophy, we performed manual segmentation
analysis, which revealed no signiﬁcant atrophy in lesioned animals compared to controls (Rb-IgG-SAP). How-
ever, analysis by DTI of the basal forebrain area revealed a signiﬁcant increase in fractional anisotropy (FA;
+7.7%), mean diffusivity (MD; +6.1%), axial diffusivity (AD; +8.5%) and radial diffusivity (RD; +4.0%) in
lesioned mice compared to control animals. These parameters strongly inversely correlated with the number
of choline acetyl transferase-positive neurons, with FA showing the greatest association (r2=0.72), followed
by MD (r2=0.64), AD (r2=0.64) and RD (r2=0.61). Moreover, probabilistic tractography analysis of the
septo-hippocampal tracts originating from the basal forebrain revealed an increase in streamline MD
(+5.1%) and RD (+4.3%) in lesioned mice. This study illustrates that moderate loss of basal forebrain
cholinergic neurons (representing only a minor proportion of all septo-hippocampal axons) can be detected
by measuring either DTI parameters of the basal forebrain nuclei or tractography parameters of the basal
forebrain tracts. These ﬁndings provide increased support for using DTI and probabilistic tractography as
non-invasive tools for diagnosing and/or monitoring the progression of conditions affecting the integrity of
the basal forebrain cholinergic system in humans, including Alzheimer's disease.
Crown Copyright © 2012 Published by Elsevier Inc. All rights reserved.Introduction
The cholinergic basal forebrain is a key modulator of neurotrans-
mission, function and plasticity of the hippocampus and amygdala,
as well as the entire cortical mantle (Mesulam et al., 1983), and is
strongly implicated in regulating attention, learning and memory
(Mufson, 2003). Pathologically, loss of basal forebrain cholinergice acetyl transferase; DePeX,
TI, diffusion tensor imaging;
n diffusivity; MCI, mild cogni-
NHS, normal horse serum;
r; PBS, phosphate buffered sa-
iffusivity; ROI, region of inter-
d spatial statistics.
12 Published by Elsevier Inc. All righ
122neurons is a pathological hallmark of Alzheimer's disease at autopsy
(Mufson et al., 2002; Whitehouse et al., 1982). Furthermore, numer-
ous studies have shown that degeneration of the basal forebrain is
linked, albeit indirectly, to early signs of cognitive decline in
Alzheimer's disease patients, including deﬁcits in spatial navigation
and memory (George et al., 2009; Grothe et al., 2010, 2011; Muth
et al., 2010). In these studies, magnetic resonance imaging (MRI)
methods were used to detect structural changes associated with at-
rophy of the basal forebrain (Grothe et al., 2011), which has been
correlated with cognitive decline in cohorts of patients diagnosed
with Alzheimer's disease or its prodromal stage, mild cognitive im-
pairment (MCI) (Grothe et al., 2011). In some cases, basal forebrain
atrophy was observed as early as 4.5 years before the onset of
overt clinical symptoms (Hall et al., 2008).
By the time atrophy of a structure can be detected as a volumetric
reduction with structural MRI, signiﬁcant cell and tissue loss hasts reserved.
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Alzheimer's disease, inhibitors of acetyl cholinesterase, enhance basal
forebrain cholinergic function by inhibiting the degradation of acetyl-
choline produced by the surviving neurons. However, as the diagnosis
of MCI or Alzheimer's disease currently occurs at a stage at which the
cholinergic system has been irreversibly damaged, it is not surprising
that these drugs have mild to little effect in prolonging cognitive
function (Mancuso et al., 2011). Non-invasive early detection of
basal forebrain neurodegeneration prior to overt tissue loss therefore
has the potential to improve the window of therapeutic efﬁcacy.
Diffusion MRI (dMRI), a technique used to analyze structural integ-
rity and brain connectivity, has been successfully employed to detect
differences between Alzheimer's patients and healthy control subjects
(Kiuchi et al., 2009; Pievani et al., 2010; Teipel et al., 2010). In particu-
lar, tractography analysis of axonal regions known to degenerate in
Alzheimer's disease, such as the fornix and the cingulum, have
shown signiﬁcant changes in diffusion parameters in humans with
the condition (Oishi et al., 2011; Pievani et al., 2010). However the
pathophysiological reason for these changes is not known. The aim
of the current study was to determine, using a mouse model, wheth-
er mild to moderate loss of basal forebrain cholinergic nuclei and
axons could underpin changes to dMRI measures and tractography
prior to the point at which changes correlate with overt atrophy.
The most commonly used transgenic mouse models of Alzheimer's
disease show only certain pathological features of the human condi-
tion (Kokjohn and Roher, 2009), failing to reproduce the loss of basal
forebrain cholinergic neurons characteristic of Alzheimer's disease.
Consequently, both diffusion and structural imaging studies of trans-
genic Alzheimer's disease mice have focused on brain regions other
than the basal forebrain (Harms et al., 2006; Lau et al., 2008;
Maheswaran et al., 2009; Mueggler et al., 2004; Sun et al., 2005;
Thiessen et al., 2010). However, one study of a transgenic mouse
model using structural MRI has reported a signiﬁcant interaction be-
tween age and genotype in a variety of brain regions including the
medial septum, a sub-nucleus of the basal forebrain (Badea et al.,
2010). In the current study, we investigated a robust model of selec-
tive basal forebrain cholinergic neuron loss, which results in a similar
spatial navigation and memory deﬁcit in mice (Berger-Sweeney et
al., 2001; Moreau et al., 2008; Perry et al., 2001) to that seen in
Alzheimer's disease patients (Hort et al., 2007). In this model, the
toxin saporin, conjugated to an antibody to a receptor almost exclusive-
ly expressed by basal forebrain cholinergic neurons (p75 neurotrophin
receptor; p75NTR) is injected into the ventricles (Berger-Sweeney et al.,
2001). Therefore, unlike in transgenic mouse models of Alzheimer's
disease, the changes in dMRI induced by cholinergic degeneration can
be studied with little inﬂuence from other pathological features.
Materials and methods
Animals
Experimentally naive male C57Bl/6 J mice were housed in groups
of four and maintained on a 12 h light/dark cycle, with food and
water provided ad libitum. All procedures were approved by the Uni-
versity of Queensland Animal Ethics Committee.
Surgery
Twelve 8- to 10-week-old male C57Bl/6J mice (22–24 g) were
anesthetized by intraperitoneal (i.p.) injection with a mixture of
ketamine (130 mg/kg) and the muscle relaxant xylazine (6 mg/kg).
Each mouse was then placed in a stereotaxic frame (with the incisor
bar maintained at −3.3 mm below horizontal to achieve a ﬂat skull
position). Bilateral infusions of mu-p75-saporin (Advanced Targeting
Systems, San Diego, CA; 5 mice) or control rabbit-IgG-saporin
(Advanced Targeting Systems; 7 mice) dissolved in phosphate buffered12saline (PBS; 0.2 μg/ventricle) were performed using a 30 G needle at-
tached to a 5 μl Hamilton syringe. The needle was lowered into the lat-
eral ventricle using the following co-ordinates: A–P,−0.3 mm;M-L, ±
1.0 mm; D-V,−2.0 mm from Bregma (Franklin and Paxinos, 2007). In-
fusions were conducted over 5 min, after which the needle was left
in place for 10 min to allow for diffusion. Immediately after surgery,
mice were injected subcutaneously (s.c.) with the analgesic
torbogesic (1.3 mg/kg), and the antibiotic Baytril® (0.43 mg/kg).
Fourteen days post-surgery mice were deeply anesthetized with
sodium pentobarbital (100 mg/kg i.p.) and perfused transcardially
with 20 ml of 0.9% saline, containing 1% sodium nitrite and heparin
(5000 I.U./ml), followed by 100 ml of 4% paraformaldehyde in
0.1 M phosphate buffer (PB), pH 7.4. Brains were removed from
the skulls and post-ﬁxed overnight in the same ﬁxative, followed
by repeated washing in PBS (pH 7.4) for 4 days prior to MRI
acquisition.
After close examination of whole brain MR scans and histological
sections in each animal, two mice (one control and one lesioned ani-
mal) were excluded from the study prior to analysis due to injuries to
the ﬁmbria/fornix caused by the injections.MRI acquisition
Mouse brainswere immersed in Fomblin oil (Y06/6 grade, Solvay, NY)
and diffusion weighted magnetic resonance images were acquired
according to the protocol of Moldrich et al. (2010). Brieﬂy, a small animal
MRI system (16.4 T vertical bore; Bruker Biospin, Rheinstetten, Germany;
ParaVision v5.0) with a 15 mm linear SAW coil (M2MImaging, Brisbane,
Australia) was used. A 3D diffusion-weighted spin-echo sequence was
acquired with TR/TE=400 ms/22.3 ms, signal average of 1, and 1.4
phase encoding accelerations using partial Fourier acquisition. High angu-
lar resolution diffusion images were acquired with two minimally
diffusion-weighted (b=0 s/mm2), and 30 high diffusion-weighted im-
ages (δ/Δ=2.5/14 ms, b=5000 s/mm2) with the encoding gradient
vectors uniformly distributed using the electrostatic approach
(Jones et al., 1999). The image data resolution was 100 μm isotropic
(uninterpolated) and total acquisition time was 16 h.Segmentation and DTI analysis
DTI reconstruction of the diffusion datawas performed usingMRtrix
(v0.2.9, www.nitrc.org/projects/mrtrix). The basal forebrainwas drawn
manually on 12 consecutive coronal slices using color-coded fractional
anisotropy (FA) maps and using the mouse brain atlas of Franklin and
Paxinos (2007) as a guide. Volumes of the basal forebrain were created,
starting at approximately 1.34 mm anterior to Bregma and ﬁnishing at
approximately 0.26 mm anterior to Bregma, thereby assuring that the
mask predominately encompassed the medial septum and the vertical
and horizontal diagonal bands of Broca. The anterior-posterior distance
covered was 1200 μm (12 slices of 100 μm). However, given the lack of
speciﬁc anatomical boundaries observable by MRI contrast, the masks
were also likely to contain minor parts of the lateral diagonal band of
Broca (also called the magnocellular preoptic nucleus), as well as the
basal part of the substantia innominata in the posterior section of the
mask (ventral part of the mask in Fig. 2E).
The hippocampal volume, starting at approximately −0.88 mm
posterior to Bregma and ﬁnishing at approximately −4.04 mm pos-
terior to Bregma, and the whole brain volume, were manually seg-
mented on gray-scale FA maps. The basal forebrain volume and
hippocampal volume were normalized to the whole brain volume.
The whole brain, hippocampal and basal forebrain volumes were
measured by a researcher blind to group status. The basal forebrain
mask was used to extract FA, mean diffusivity, axial diffusivity and ra-
dial diffusivity values.3
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MRtrix (v0.2.9, www.nitrc.org/projects/mrtrix) was used to per-
form constrained spherical deconvolution and to generate the ﬁber
orientation distribution. Probabilistic tractography was performed
withMRtrix (Tournier et al., 2012), creating whole brain tractograms
by seeding every voxel ﬁve times and using tracking parameters
optimized for themouse brain (step size=0.01 mm, radius of curva-
ture=0.07 mm; see Moldrich et al., 2010).
Basal forebrain streamlines were then extracted by applying the
basal forebrain volume as a waypoint mask to the whole brain
tractograms. To extract streamlines that project from the basal fore-
brain through the ﬁmbria/fornix to the hippocampus, but not including
cortical areas, a hippocampalwaypoint region of interest (ROI)was cre-
ated at approximately−2.60 mmposterior to Bregma. This hippocam-
pal waypoint ROI, together with additional exclusion ROIs used in
conjunction with the basal forebrain mask, eliminated false positive
streamlines such as the stria terminalis and the optic tract.
To test whether the streamline changes were selective for the
basal forebrain tracts, we performed tractography on a control tract,
namely the inferior cerebellar peduncle. Bilateral ROIs were drawn
on color-coded FA maps on three consecutive slices from approxi-
mately −6.00 to −6.24 mm posterior to Bregma, using the mouse
brain atlas of Franklin and Paxinos (2007) as guidance. Inferior cere-
bellar peduncle streamlines were obtained by applying the ROI to
whole brain tractograms.
Streamline number was normalized to the voxel number of the cor-
responding ROI. For every tract, the number of streamlines traversing
each voxel was counted, and a threshold of 15 streamlines per voxel
(determined empirically) was used to measure track volume. In addi-
tion, FA, mean diffusivity, axial diffusivity and radial diffusivity were
extracted using the individual tracks for sampling.
MRI data analysis
An unpaired two-tailed Mann–Whitney test (CI=95%) was used to
determine signiﬁcant differences between groups of the basal forebrain,
hippocampus and whole brain volumes, as well as the basal forebrain
DTI parametric and tractography measures. Spearman's rho was used
to assess correlations between DTI parametric and cholinergic neuron
number. A false discovery rate (α=0.1)was used to correct formultiple
comparisons.
Immunohistochemistry
Immediately following scanning (see Surgery section) brains were
placed in 20% sucrose solution overnight. Brains were blocked using a
matrix (Stoelting Co., Wood Dale, IL), aligned to the atlas of Franklin
and Paxinos (2007), and 40 μm coronal sections were cut in three seri-
ally adjacent sets through the basal forebrain and hippocampus using a
sliding microtome (SM2000r, Leica, Sydney, Australia). Sections were
stored in 0.1% sodium azide in 0.1 M PBS.
One series of sections was used to reveal choline acetyltransferase
(ChAT) using peroxidase immunohistochemistry. Free-ﬂoating sections
were washed repeatedly in 0.1 M PB, followed by two 30 min washes
in 50% ethanol, the second of which contained 3% H2O2. Sections were
then incubated in 5% normal horse serum (NHS) in PB for 30 min,
followed by incubation with goat anti-ChAT antibody (1:3000;
Millipore, Billerica, MA), diluted in 0.1 M PB containing 0.1% sodium
azide, 2% NHS and 0.2% Triton X-100 (PBT-X), for 48 h at 4 °C with
gentle agitation. After washing, sections were incubated overnight
at room temperature in biotinylated donkey anti-goat IgG (1:1000;
Jackson Immunoresearch Laboratories, West Grove, PA) diluted in
2% NHS PBT-X. Sections were then incubated for 2 h at room temper-
ature in ABC reagent (Vector Elite kit: 6 μl/ml avidin and 6 μl/ml bi-
otin; Vector Laboratories, Burlingame, CA). Black immunoreactive124cytoplasm labeled for ChAT was revealed by a nickel-intensiﬁed
diaminobenzidine reaction, with peroxide being generated by glu-
cose oxidase. First, sections were washed in PB, followed by 0.1 M
acetate buffer, and then incubated for 15 min in 0.1 M acetate buffer
(pH 6.0) containing 2% nickel sulfate, 0.025% 3,3-diaminobenzidine,
0.04% ammonium chloride, and 0.02% D-glucose. The peroxidase re-
action was started by adding glucose oxidase (0.2 μl/ml) and
stopped using acetate buffer (pH 6.0). Brain sections were then
washed in PB. Sections were mounted onto chrome-alum/gelatin-
treated slides, dehydrated, cleared in histolene, and coverslipped
with DePeX (Distrene-80/plasticizer/xylene; Crown Scientiﬁc,
Sydney, Australia).
A second series of sections through the basal forebrain of lesioned and
control mice was used to immunohistochemically label parvalbumin.
Free-ﬂoating sections were washed repeatedly in PBS, followed by a 2 h
incubation in PBS containing 10% NHS and 0.5% Triton X-100. Mouse
anti-parvalbumin (1:1000; Millipore), diluted in 0.1 M PBS containing
0.1% sodium azide, 2% NHS and 0.2% Triton X-100, was then added to
the sections, which were incubated for 48 h at room temperature,
with gentle agitation. After washing, sections were incubated for 4 h
at room temperature in donkey anti-mouse FITC (1:200; Jackson
Immunoresearch Laboratories), diluted in 2% NHS PBT-X. After wash-
ing, sections were mounted onto chrome alum/gelatin-treated slides
and coverslipped with buffered glycerol (pH 8.6).
Neuronal counting
Bilateral counts of neurons immunoreactive for ChAT were
conducted through the rostro-caudal extent of the basal forebrain
from 1.32 mm anterior to Bregma to 0.24 mm anterior to Bregma
(Franklin and Paxinos, 2007) on sections that were 120 μm apart, to
exactly match the basal forebrain mask created by MRI. Images of
the sections were taken a Zeiss Axio Imager Z1 and were counted
using Imaris software (v7.5, Bitplane) by a researcher blind to the ex-
perimental conditions.
Counts of parvalbumin-positive (p75NTR-negative) neurons were
analyzed as above using images of sections of mu-p75-saporin and
Rb-IgG-saporin injected brains. Eight-bit monochrome images were
taken of the basal forebrain sections from 1.32 mm anterior to Bregma
to 0.98 mm anterior to Bregma. Images were captured using a Zeiss
Axio Imager Z1 and AxioVision v4.8 software, before being exported
into ImageJ software (NIH) where bilateral counts of parvalbumin-
positive nuclei were conducted by a researcher blind to the conditions.
Differences in the mean number of ChAT-immunoreactive and
parvalbumin-immunoreactive cells counted for each region of the
basal forebrain per animal per group were analyzed using ANOVA.
Results
Mu-p75-SAP induced speciﬁc lesion of the cholinergic basal forebrain
To selectively ablate basal forebrain cholinergic neurons, mice
were injected with saporin conjugated to either a p75NTR antibody
(mu-p75-SAP) or to a rabbit IgG (Rb-IgG-SAP) as a control. Following
MRI scans, the extent and speciﬁcity of the lesion was determined by
immunohistological analysis of the medial septum and the vertical
and horizontal diagonal bands of Broca (Fig. 1). These regions contain
approximately equal numbers of cholinergic neurons, which express
p75NTR (Mufson et al., 1989), and GABAergic neurons, which do not
express p75NTR (Wainer et al., 1985). Both neuronal populations pro-
vide input to the hippocampus through the ﬁmbria/fornix.
A signiﬁcant loss of approximately 25% of ChAT-positive (cholin-
ergic) cells in the medial septum, and the vertical and horizontal
diagonal bands of Broca was observed in the lesioned animals com-
pared to the controls (Figs. 1A, C).We also observed a clear reduction
in ChAT-positive terminal labeling in the hippocampus of the
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Fig. 1. Intracerebroventricular application of mu-p75-saporin produced a speciﬁc lesion of
basal forebrain cholinergic neurons. A. Mean (± SEM) total number of ChAT-positive neu-
rons in the basal forebrain following application of mu-p75-SAP (Lesion, n=4) or
Rb-IgG-SAP (Control, n=6). A signiﬁcant decrease in the number of ChAT-positive neurons
was found following application ofmu-p75-SAP. B. Mean (± SEM) number of parvalbumin-
positive neurons in the basal forebrain following application of mu-p75-SAP (n=4) or
Rb-IgG-SAP (n=3). Application of mu-p75-SAP had no effect on the number of
parvalbumin-positive neurons. C. Photomicrographs of ChAT-immunopositive neuronal cell
bodies in the basal forebrain and ChAT-immunoreactive terminal ﬁelds in the hippocampus
following application of Rb-IgG-SAP (left) and mu-p75-SAP (right). D. Photomicrographs of
parvalbumin-immunopositive neuronal cell bodies in themedial septum and vertical diago-
nal band of Broca following application of Rb-IgG-SAP (left) and mu-p75-SAP (right). Scale
bar=400 μm. *pb0.05.
136 G.M. Kerbler et al. / NeuroImage 66 (2013) 133–141lesioned mice compared to control mice (Fig. 1C), indicating that the
septo-hippocampal cholinergic system was functionally impaired in
these animals.
To determine if the treatment caused a speciﬁc loss of the cholin-
ergic cells in the basal forebrain we also quantiﬁed the number of
GABAergic neurons, visualized by parvalbumin staining, in the medial
septum and the vertical diagonal band of Broca (Figs. 1B, D). This
analysis revealed no signiﬁcant effect of mu-p75-SAP injections12compared to Rb-IgG-SAP treatment on parvalbumin-positive neuron
number (Figs. 1B, D), demonstrating that we had achieved a speciﬁc
lesion of basal forebrain cholinergic neurons. Furthermore, no overt
atrophy of the basal forebrain was appreciable on parvalbumin-
immunolabeled histological sections (Fig. 1D).
Manual segmentation analysis showed no volumetric differences
between control and lesioned groups
To test if the observed loss of basal forebrain cholinergic neurons in-
duced atrophy of the basal forebrain, the hippocampus or the whole
brain, we conducted manual segmentation analysis (see Segmentation
and DTI analysis section). Firstly, individual whole brain, hippocampal
and basal forebrain masks were created. The latter encompassed the
medial septum and the vertical and horizontal diagonal bands of
Broca (Fig. 2). We then compared the volumes of these masks between
groups. There was no signiﬁcant reduction in the average whole brain
volume of the lesioned group compared to the control group
(Table 1), and no signiﬁcant difference in normalized basal forebrain
or hippocampal volume between lesioned and control groups.
Increased diffusion in the basal forebrain was inversely correlated to
cholinergic neurodegeneration
To determinewhether the lesion could be detected by diffusionMRI
measures, the basal forebrain DTI parameters for each of the brains
were analyzed. The mean FA (Fig. 2D), mean diffusivity (Fig. 2F), axial
diffusivity (Fig. 2G) and radial diffusivity (Fig. 2H) within the basal
forebrain volume were then extracted for each mouse and compared
between groups. Representative images of the various DTI maps used
for the analysis within the basal forebrain area can be seen in Figs. 2D,
F–H. Interestingly, this analysis revealed that all diffusion metrics
were signiﬁcantly increased for the basal forebrain area in the lesioned
group compared to the control group. Speciﬁcally, the mean values for
FA (Fig. 3A), mean diffusivity (Fig. 3B), axial diffusivity (Fig. 3C) and ra-
dial diffusivity (Fig. 3D) were all signiﬁcantly higher in the lesioned
animals.
To determine the correlation between histological measures and
DTI-associated changes in response to basal forebrain cholinergic
neuron loss, we performed nonparametric bivariate correlation anal-
ysis of the ChAT-positive neuron numbers and DTI parameters. This
revealed that all DTI measures except for radial diffusivity were sig-
niﬁcantly inversely correlated to ChAT-positive neuron number
(Figs. 3E–H). This indicates that DTI parameters such as FA, mean dif-
fusivity and axial diffusivity are sensitive measures of neuronal le-
sions and can reﬂect the degree of neurodegeneration in this model.
Tractography streamlines showed decreased integrity
We next investigated whether a signiﬁcant reduction in septo-
hippocampal connectivity could be detected in the lesioned group of an-
imals. In order to analyze the streamlines connecting the basal forebrain
and hippocampus, whole brain tractograms of mice were created using
MRtrix. The basal forebrain mask was used together with a hippocampal
waypoint ROI (Fig. 4A; see Tractography section), and applied to the
tractograms to delineate the streamlines between these two structures
via the ﬁmbria/fornix. The resulting streamlines (Figs. 4A–C) were ana-
tomically veriﬁed (Fig. 4D) as innervating the alveus and the oriens
layer of the hippocampus and, to a lesser degree, other regions of the hip-
pocampus such as the CA3 region and the dentate gyrus, replicating the
innervation of cholinergic axons measured eletrophysiologically (Cole
and Nicoll, 1984).
Having established a septo-hippocampal connection, we analyzed
the septo-hippocampal streamlines (Fig. 4) in each mouse by com-
paring FA, mean diffusivity, axial diffusivity, and radial diffusivity, as
well as tract volume, streamline length and streamline number5
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Fig. 2. Basal forebrain mask encompassing the medial septum, and the vertical and horizontal diagonal bands of Broca overlaid on A–E. FA, F. mean diffusivity (MD), G. axial dif-
fusivity (AD) and H. radial diffusivity (RD) maps. The position of the basal forebrain mask (red) in MRI space is shown in three planes: A. sagittal (midline), B. horizontal (level
of anterior commissure crossing the midline), and C-H. coronal sections through the extent of the basal forebrain depicting the mask at approximately 1.10 mm (C), 0.86 mm
(D, F-H) and 0.50 mm (E) anterior to Bregma. To illustrate the contrast within the basal forebrain area the mask was outlined on the same slice on D. FA, F. mean diffusivity, G.
axial diffusivity and H. radial diffusivity maps (the outline itself is not part of the mask but depicts the ﬁrst row of voxels outside of the mask). The mask was used for volumetric
analysis of the basal forebrain and to extract DTI parameters for the basal forebrain and as a waypoint region for tractography streamlines.
137G.M. Kerbler et al. / NeuroImage 66 (2013) 133–141between the control and lesioned groups. This revealed statistically
signiﬁcant increases in mean diffusivity (Fig. 5B) and radial diffusivity
(Fig. 5D) in the lesioned group. No signiﬁcant differences were ob-
served in FA (Fig. 5A) and axial diffusivity (Fig. 5C), or in tract volume,
streamline length or normalized streamline number (Table 2).
Finally, to determinewhether the diffusion changes observed for the
basal forebrain tracts occurred elsewhere, we performed tractography
analysis on a cerebellar tract (see Tractography section), namely the
inferior cerebellar peduncle (Figs. 6A, B). We reasoned that this tract
should not be affected by the application of mu-p75-SAP, based on pre-
vious reports that cerebellar Purkinje neurons are unaffected by this
toxin (Berger-Sweeney et al., 2001; Moreau et al., 2008). Our compari-
son revealed no differences in measures of streamline FA, mean diffu-
sivity, axial diffusivity, or radial diffusivity (Figs. 6C–F), or in tract
volume, streamline length or streamline number (Table 3) in the inferi-
or cerebellar peduncle between test and control mice. This indicated
that the changes in diffusion measures of the septo-hippocampal
streamlines were unlikely to be due to nonspeciﬁc effects of the toxin.
Discussion
In this study we used a robust animal model of speciﬁc cholinergic
lesion of the septo-hippocampal system, generating animals with aTable 1
MRI volumes of the whole brain and normalized MRI volumes of basal forebrain and
hippocampus (normalized to the whole brain volume) of lesioned and control animals.
No signiﬁcant differences were found between groups. n=6 for control group, n=4
for lesioned group, mean±SEM.
Structure Control Lesion Signiﬁcance (p value)
Whole brain (mm3) 510.333±5.800 509.960±7.364 1.00
Basal forebrain
(*10−3 mm3)
0.173±0.006 0.177±0.006 0.61
Hippocampus
(*10−3 mm)
4.827±0.062 4.913±0.097 0.61
126~25% reduction in cholinergic neurons with no effect on the GABAergic
neurons of the region. The cholinergic loss therefore replicates the cell
loss and denervation of basal forebrain cholinergic neurons observed
in Alzheimer's disease (Rossner, 1997). Through manual segmentation
analysis we showed that the lesion did not cause atrophy of the basal
forebrain. Therefore, the degeneration mimics the mild pathology of
MCI or the prodromal stage of Alzheimer's disease rather than severe
loss of basal forebrain cholinergic neurons seen in late-stage disease
(Hall et al., 2008; Mufson et al., 2002).
In most studies to date, DTI has been used to assess white mater
integrity; however, DTI-derived parameters can also be used to reli-
ably quantify ﬁber-rich gray matter regions such as the thalamus
(Unrath et al., 2008). We demonstrate here that DTI is able to distin-
guish differences between basal forebrain neurodegeneration and the
unlesioned state. A total of four diffusion parameters, FA, mean diffu-
sivity, axial diffusivity and radial diffusivity, showed a signiﬁcant in-
crease within the basal forebrain area and all of these measures
signiﬁcantly inversely correlated with the basal forebrain cholinergic
neuron count. We observed an average 6.5% increase in the diffusion
parameters (FA: +7.7%; mean diffusivity: +6.1%; axial diffusivity:
+8.5%; radial diffusivity: +4.0%) of the basal forebrain in comparison
to an average 25% loss of cholinergic neurons. However, this repre-
sents a minor loss of septo-hippocampal projection neurons and an
even lesser percentage change relative to the entire tissue, in which
the volume includes glial cells, axons and dendrites within the ROI.
The ~6.5% change may therefore be proportional to the change in tis-
sue density of the basal forebrain. As the FA parameter showed the
greatest effect, we propose that this could provide a sensitive mea-
sure to determine the extent of tissue damage.
In general, increases in mean, axial and radial diffusivity are
well-established features of white matter degeneration (Filippi and
Agosta, 2011). However it has been shown that degeneration usually
results in a decrease of FA in the affected regions (i.e. a less preferred
direction of diffusion; Filippi and Agosta, 2011). In contrast we ob-
served an increase in FA in the lesioned group compared to the
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Fig. 3. The mean FA, mean diffusivity, axial diffusivity and radial diffusivity values of lesioned animals in the area of the basal forebrain mask inversely correlated to the cholinergic
neuron number in the basal forebrain. A comparison of DTI parameters for lesioned and control animals revealed that A. FA (mean±SEM), B. mean diffusivity (mean±SEM), C.
axial diffusivity (mean±SEM) and D. radial diffusivity (mean±SEM) values were signiﬁcantly increased for the basal forebrain of lesioned compared to control animals. Correla-
tion analysis of ChAT-positive neuron number (x-axis) to the previously mentioned DTI parameters (y-axis) of individual animals of mu-p75-SAP (lesion) and Rb-IgG-SAP (control)
groups revealed a signiﬁcant inverse correlation of E. FA, F. mean diffusivity and G. axial diffusivity parameters with ChAT-positive neuron number. n=6 for control group, n=4 for
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Fig. 4. Tractography streamlines connecting the basal forebrain and hippocampus. The basal forebrain mask shown in Fig. 3 was used as a waypoint region to generate a streamline
proﬁle of the basal forebrain and further delineated to only measure septo-hippocampal connections (yellow), shown in sagittal (A), coronal (B) and horizontal (C) planes. To
achieve this, a hippocampus waypoint ROI at the level of (a) as indicated by the dashed line, was applied. D. A slice through the streamline proﬁle is shown to validate the regions
of the highest ﬁber density. Most streamlines were found to pass through the alveus (alv) and the oriens layer of the hippocampus (or) which are known to contain ﬁmbria/fornix
output from pyramidal neurons and the septal/diagonal band of Broca input to basal dendrites of pyramidal neurons, respectively. A very small proportion of streamlines were
found to project to areas such as the cingulum, CA1–3 and other regions of the hippocampus. Additional abbreviations: cg, cingulum; cp, cerebellar peduncle; DG, dentate
gyrus; fmj, forceps major of the corpus callosum; MoDG, molecular layer of the dentate gyrus.
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Fig. 5. Increased mean diffusivity and radial diffusivity of septo-hippocampal stream-
lines after lesion of the cholinergic basal forebrain. Diffusion parameters for the
streamlines shown in Fig. 4 were analyzed, revealing that FA (A) and axial diffusivity
(C) parameters were not signiﬁcantly different between control and lesioned animals
(p=0.17 and p=0.07, respectively), whereas mean diffusivity (B) and radial diffusiv-
ity (D) values showed signiﬁcant increases in the lesioned animals. n=6 for control
group, n=4 for lesioned group; unit for mean diffusivity, axial diffusivity and radial
diffusivity is [10−3 mm2/s]. *pb0.05.
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axial diffusivity (+8.5%) was larger than the change in radial diffusiv-
ity (+4.0%). These changes are likely to be due to a loss of isotropic
(cholinergic) cells, which then leads to a greater contribution from
residual anisotropic cells/axons in the basal forebrain. In addition,
the observed changes are unlikely to occur as a result of a loss of
crossing ﬁbers in the basal forebrain, as comparison of principal ei-
genvector orientations for the basal forebrain area between control
and lesioned animals revealed no difference (data not shown). The
phenomenon of increased FA in pathological conditions has been pre-
viously documented (Jones, 2010; Tuch et al., 2005) and highlights
the fact that interpretation of diffusion parameters must be carried
out with reference to the nature of the pathology and the composition
of the tissue being examined. Our study provides insight into how
MRI parameters could change due to selective loss of a single neuron
population, namely the basal forebrain cholinergic neurons, both in
gray (basal forebrain) and white matter (septo-hippocampal tracts)
areas.
The present study demonstrates that diffusion MR tractography
has the potential to be a sensitive measure of cholinergic degenera-
tion. Probabilistic tractography measures of projections between theTable 2
Septo-hippocampal connections remained unchanged for track volume, streamline
length and normalized streamline number in lesioned animals. n=6 for control
group, n=4 for lesioned group, mean±SEM.
Parameter Control Lesion Signiﬁcance (p value)
Track volume (mm3) 10.152±0.677 11.115±0.373 0.35
Streamline length (mm) 10.21±0.07 10.12±0.02 0.48
Normalized streamline
number
1.22±0.08 1.27±0.06 1.00
128basal forebrain nuclei and the hippocampus via the ﬁmbria/fornix
successfully detected changes in streamline characteristics induced
by loss of cholinergic axons, revealing signiﬁcant increases in stream-
line mean diffusivity and streamline radial diffusivity, as well as a
trend toward signiﬁcantly increased axial diffusivity (p=0.07). A sig-
niﬁcant number of axonal tracts project from the basal forebrain
through the fornix, of which the cholinergic axons that were affected
by the lesion make up only a minor proportion. The actual volume
occupied by cholinergic axons in the ﬁmbria/fornix is even less, as cho-
linergic axons (a) are unmyelinated, and (b) have a signiﬁcantly smaller
axon diameter compared to, for example, myelinated GABAergic axons
(Gartner et al., 2001) projecting via the same pathway. To confound the
detection of cholinergic axons further, cholinergic axons are closely as-
sociated with myelinated axons in the ﬁmbria/fornix, making it techni-
cally impossible for tractography to separate them. We were not
surprised, therefore, to observe no changes inmeasures such as number
of streamlines, tract volume or streamline length.
Of the factors that can inﬂuence diffusion anisotropy, intra-axonal
organization appears to have the greatest inﬂuence (Pierpaoli et al.,
1996). However, other features, such as the density of ﬁber and glial
cell packing, degree of myelination, and individual ﬁber diameter may
also play a role (Melhem et al., 2002).We observed signiﬁcant increases
in mean diffusivity and radial diffusivity, which suggest that subtle mi-
croscopic changes to aminor proportion of ﬁber tracts are detectable by
tractography. Although the molecular changes remain undeﬁned, axo-
nal degeneration resulting in debris and/or changes to axonal organiza-
tion and packing, may underpin the observed changes. In addition, a
decrease in the proportion of unmyelinated cholinergic ﬁbers relative
to myelinated ﬁbers (which are unaffected by the lesion) within the
measured region may also contribute to the signiﬁcant increases in
mean diffusivity and radial diffusivity. Consistent with this idea, demy-
elination of the optic tract has been shown to result in decreased axial
diffusivity with no change in radial diffusivity (Wu et al., 2007).
Although FA has been widely used as a measure to assess the in-
tegrity of brain connections (Kiuchi et al., 2009; Pievani et al., 2010;
Teipel et al., 2010), we did not observe any trend towards signiﬁcance
in this parameter in our study. We observed signiﬁcant increases in
mean diffusivity and radial diffusivity, replicating signiﬁcant in-
creases in mean diffusivity and radial diffusivity in the fornix of
Alzheimer's disease patients found by Oishi et al. (2011), as well as
the increase in radial diffusivity in the fornix in MCI and Alzheimer's
disease patients compared to healthy controls found by Pievani et
al. (2010). Indeed, based on ourwork, the changes reported for the for-
nix may have been caused by degeneration of the cholinergic axons. In
addition, signiﬁcant changes in the integrity of tracts originating in the
basal forebrain have been observed in Alzheimer's disease patients
using tract-based spatial statistics (TBSS, Smith et al., 2006), where
measures of tract integrity were determined based on FA (Teipel et al.,
2010). TBSS (part of FSL; Smith et al., 2004) and the method
employed by Oishi et al. (2011) utilize voxelwise cross-subject
statistics to analyze local diffusion information, whereas we used a
probabilistic tractography method to assess three-dimensional
tract information, which might explain the difference in the ob-
served parameter changes. However, we suggest that mean and
radial diffusivities rather than FA (using either tractography or
voxelwise analyses) may be the most sensitive parameters to reveal
cholinergic axonal degeneration in the fornix.
In neurodegenerative conditions such as Alzheimer's disease, axonal
dystrophy and retraction occur early and may be reversible (Burek and
Oppenheim, 1996; Ypsilanti et al., 2008). In the current study, the death
of cholinergic neurons was mediated through administration of the
toxinmu-p75-SAP such that axonal degeneration occurred coincidental
or subsequent to cell body loss. Nonetheless, our ﬁndings of signiﬁcant
changes to diffusion parameters in the septo-hippocampal streamlines
serve as proof of principle that a moderate loss of cholinergic ﬁbers
within the fornix can result in changes to mean and radial diffusivity
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Fig. 6. Tractography of the inferior cerebellar peduncle, a white matter tract that should not be affected by the toxin-induced lesion or the surgery itself, shown in MRI space in
coronal (A) and horizontal (B) planes. No changes in control vs. lesioned animals were observed for FA (C), mean diffusivity (D), axial diffusivity (E) or radial diffusivity (F).
n=6 for control group, n=4 for lesioned group; unit for mean diffusivity, axial diffusivity and radial diffusivity is [10−3 mm2/s].
140 G.M. Kerbler et al. / NeuroImage 66 (2013) 133–141parameters, and thus early changes associated with neurodegeneration
may be observable even if the cell bodies are not yet lost. We therefore
conclude that tractography shows promising sensitivity as a diag-
nostic tool for detecting pathological changes in the neuronal integ-
rity of this ﬁber tract in humans, although further validation is still
required.
Conclusions
Our study demonstrates that loss of basal forebrain cholinergic
neurons is highly correlated to changes in water diffusion in the
basal forebrain area. In addition, cholinergic neurodegeneration can
be detected by analyzing diffusion parameters of the streamlines of
the septo-hippocampal tracts in a mouse model. This study provides
an important step forward in validating DTI and tractography as diag-
nostic imaging tools for the detection of subtle neurodegenerative
events. Given that cholinergic basal forebrain degeneration is an
early feature of Alzheimer's disease, our ﬁndings demonstrate the po-
tential feasibility of combining conventional DTI with tractography as
a non-invasive diagnostic tool to analyze both regional brain changes
and variations in connectivity.
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5.3 Discussion and implication of findings 
 
The observed dMRI measures presented in this chapter were found to be correlated to an 
underlying, quantifiable biological event in the investigated animals. To our knowledge this 
is one of the first studies to successfully associate imaging measures with histological 
measures. By showing this relationship we provide further validity for using a technique 
such as dMRI for the assessment of neurodegenerative events in mice. In addition we give 
evidence for the way in which cholinergic neuronal degeneration could induce dMRI 
parameter changes, which could also be present in aging or in neurodegenerative disease 
in humans; however this requires further validation. 
We also offer a novel imaging method for the assessment of neurodegenerative disease, 
which might be more sensitive than conventional structural MRI in detecting early 
structural damage. This study also forms the basis for follow-up investigations, which 
should be aimed at determining how additional pathological features such as amyloid 
plaques and NFT pathology as well as astrogliosis, in addition to cholinergic degeneration, 
influence dMRI parameters, in order to give a better estimate of the parameter changes to 
be expected when comparing human Alzheimer’s disease subjects with controls. 
In the current chapter we focussed on studying the septohippocampal connection 
originating from anterior basal forebrain areas; however as the results from our human 
studies suggest, the posterior basal forebrain connections might be affected even earlier in 
Alzheimer’s disease. Therefore the next step would be to assess whether diffusion MRI 
can successfully measure changes in the connections between the basal forebrain and 
cortical regions. 
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Chapter 6: Development of a cytoarchitectonic map of the mouse 
cholinergic basal forebrain 
 
6.1 Introduction 
 
In the previous study it was highlighted that delineation of the mouse basal forebrain on 
structural MR images is difficult as there are no clearly visible anatomical boundaries.  
dMRI on the other hand, in particular fractional anisotropy images of mouse brains, reveal 
the basal forebrain as an area of high fibre bundle density (chapter 5), resulting from its 
efferent and afferent projections as well as fibres passing through this region. Fractional 
anisotropy values within the basal forebrain are therefore higher in comparison with other 
grey matter structures, and in some parts of the basal forebrain reach values comparable 
to those of white matter. Fractional anisotropy or colour-coded fractional anisotropy 
diffusion MR images, used in conjunction with the mouse brain atlas (Franklin and 
Paxinos, 2007), were therefore used to segment the basal forebrain in the previous 
chapter. 
However the resulting segmentation is not ideal and starting/end-points of 
anterior/posterior boundaries are still difficult to delineate, as related fibre bundles extend 
beyond the cell body-defined boundaries of basal forebrain nuclei. Hence the aim of this 
study was to generate a map of the basal forebrain, which can be reliably used as a tool 
for imaging modalities such as MRI and PET, particularly in large animal cohorts, when 
manual structural segmentation is tedious.  
In order to create a basal forebrain map in the greatest possible detail we used histological 
images to segment the basal forebrain into its traditionally demarcated nuclei (medial 
septum, vertical/horizontal/lateral diagonal band of Broca, nucleus basalis of Meynert). As 
cholinergic cells are located in all nuclei we decided to use ChAT as a marker to guide the 
segmentation process. To eliminate the need for immunohistochemistry and the inherent 
variation in staining intensity between sections/animals, we chose to use a transgenic 
mouse line expressing enhanced green fluorescent protein (eGFP) driven by the ChAT 
promoter: ChAT-eGFP (The Jackson Laboratory). Three adult male ChAT-eGFP mice at 
postnatal day 90 were used to generate the basal forebrain map. 
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6.2 Materials and Methods 
 
Animals 
 
Experimentally naïve male ChAT-eGFP mice were housed in groups of four and 
maintained on a 12 h light/dark cycle, with food and water provided ad libitum. All 
procedures were approved by the University of Queensland Animal Ethics Committee. 
 
MRI acquisition and histological processing 
 
Three twelve-week old male ChAT-eGFP mice were anaesthetized with sodium 
pentobarbital (100 mg/kg i.p.) and perfused transcardially with 4% paraformaldehyde in 
phosphate buffered saline (PBS). Brains were removed from the skulls and post-fixed 
overnight in the same fixative and then washed in PBS at 4°C for one day. Then brains 
were transferred into PBS 0.2% Magnevist and incubated for 4 days at 4°C. Next, the 
mouse brains were immersed in Fomblin oil (Y06/6 grade, Solvay) and images using a 3D 
gradient echo sequence according to the protocol of Ullmann et al. (2012) were acquired. 
In addition diffusion weighted MR images were acquired according to the protocol of 
Kerbler et al. (2012).  
After MRI acquisition, brains were transferred into 20% sucrose solution and incubated 
overnight, after which 30 µm sections were cut through the extent of the basal forebrain 
using a sliding microtome (SM2000r, Leica). Sections were collected into PBS containing 
0.1% sodium azide and stored at 4°C. Next, sections were transferred to 0.9% saline and 
mounted on Superfrost™ Plus glass slides, allowed to dry for 4 hours and then 
coverslipped with Dako® Fluorescence Mounting Medium and stored at 4°C. Images of 
sections were taken with a Zeiss Axio Imager Z2 and the basal forebrain was delineated 
using ITK-SNAP software (www.itksnap.org). 
 
Segmentation of basal forebrain areas in histological sections 
 
Compartments of the basal forebrain were traced on 2D images of sections (30 µm 
thickness) of each mouse using ITK-Snap (www.itksnap.org). There were no gaps 
between sections so the basal forebrain could be delineated with best possible detail. A 
contour line of each individual basal forebrain nucleus was drawn on each slice. We 
employed the nomenclature of the mouse brain atlas (Franklin and Paxinos, 2007) to 
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demarcate individual basal forebrain nuclei, with the exception that we employed the term 
lateral diagonal band of Broca (formerly called the magnocellular preoptic nucleus). The 
cholinergic neurons were easily identifiable on histological sections of mice and often 
arranged in cell aggregates. The borders of individual nuclei were drawn where the 
number of cells diminished toward surrounding regions. 
 
Registration, stacking and generation of 3D basal forebrain maps 
 
A MRI-guided histology reconstruction method (Yang et al., 2012) was adapted to stack 
the digitized sections into a histological volume and to register it to the MRI data (Figure 
1). The method started with a series of 2D registrations of adjacent histological sections to 
stack them into an initial histological volume. The 3D MRI data of the same brain was co-
registered to the initial histological volume. By transforming the MRI volume into the initial 
histological space and considering a linear shrinkage of histological volume, an initial 
estimation of the corresponding MR slice of each histological section was calculated. The 
histological sections were then registered to the corresponding MR slices, and an 
improved histological 3D volume was constructed, from which more accurate 
correspondence between histological sections and MR slices was established. By 
repeating this procedure, after several iterations, the method converged when there was 
no improvement in the 3D registration between the histological and MR volumes, yielding 
the final 3D reconstruction of histological volume in the same reference space as MR 
volume. The transform matrices of the 2D and 3D registrations were then applied to the 
manually segmented basal forebrain structure to form a 3D segmentation in the same 
reference space. 
The 3D registrations between histological and MR volumes were performed in MIPAV 
(http://mipav.cit.nih.gov/). The 2D histology-histology and histology-MRI registrations were 
performed in MatLab(r) (MathWorks). 
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Figure 1: Iterative methods used to establish the correspondence between MR 
slices and histological sections.  
Abbreviations: HtoH = histology to histology, HtoM = histology to MRI, MtoH = MRI to 
histology.  
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6.3 Results 
 
Segmentation 
 
The manual segmentation of basal forebrain structures over the anterior-posterior extent 
can be seen in Figure 2 at five different levels for mouse 2. Mouse brain sections from 
Bregma 2.10 mm to Bregma -2.92 mm were collected for segmentation purposes, with the 
final basal forebrain segmentation extending from Bregma 1.49 mm to Bregma -2.06 mm. 
 
Vertical diagonal band of Broca 
 
The vertical diagonal band of Broca appears first medially (Fig. 2; red/green, top row) at 
Bregma 1.49 mm and then extends dorsally and laterally over subsequent sections. The 
vertical diagonal band of Broca is then bordered ventrally by the horizontal diagonal band 
of Broca from Bregma 0.86 mm. On the following sections the medial septum and 
horizontal diagonal band of Broca areas take up increasingly more space, thereby 
reducing the vertical diagonal band of Broca area. The horizontal diagonal band of Broca 
then splits ventrolaterally from the vertical diagonal band of Broca and the vertical diagonal 
band of Broca finally diminishes at Bregma 0.38 mm.  
 
Medial septum 
 
The first cells belonging to the medial septum appear dorsal to the vertical diagonal band 
of Broca (Fig. 2; blue/yellow, top row) at about Bregma 1.20 mm at the level of the anterior 
commissure, and increasingly cells appear dorsal to the level of the anterior commissure 
over the following sections. In later sections (Fig. 2; blue/yellow, second row) the medial 
septum area also extends ventral to the anterior commissure. The medial septum is 
continuously bordered ventrally by the vertical diagonal band of Broca until the vertical 
diagonal band of Broca disappears and the medial septum then continues up to the point, 
where the anterior commissure crosses the midline at Bregma 0.14 mm. 
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Horizontal diagonal band of Broca 
 
Cell aggregates representing the horizontal diagonal band of Broca commence 
ventrolateral to the vertical diagonal band of Broca from Bregma 0.86 mm and continue as 
far as Bregma -0.82 mm. Over the anterior-posterior extent, the horizontal diagonal band 
of Broca at first increases in size along the ventral surface of the brain (Fig. 2; teal/pink, 
second row) and then increasingly extends laterally, with the whole horizontal diagonal 
band of Broca structure deviating from the dorsally located vertical diagonal band of Broca 
and migrating laterally while at the same time declining in size (Fig. 2; teal/pink, third row). 
From Bregma 0.14 mm, cells of the horizontal diagonal band of Broca remain in the same 
location (Fig. 2; teal/pink, fourth row), mediolateral to the lateral diagonal band of Broca 
and ventral to the substantia innominata. The most posterior cells segmented as horizontal 
diagonal band of Broca were located at Bregma -0.82 mm (Fig. 2; teal/pink, fifth row). 
 
Lateral diagonal band of Broca 
 
Formerly known as the magnocellular preoptic nucleus, the lateral diagonal band of Broca 
is located lateral to the horizontal diagonal band of Broca throughout the brain (Fig. 2; 
white/blue, third to fifth row). The first cell aggregates belonging to the lateral diagonal 
band of Broca appear as early as Bregma 0.50 mm and extend to Bregma -1.06 mm. In 
the posterior parts, a few scattered cells of the nucleus basalis of Meynert (Fig. 2; 
brown/beige, fifth row) are located dorsally to the lateral diagonal band of Broca. 
 
Nucleus basalis of Meynert 
 
Cells belonging to the nucleus basalis of Meynert initially appear between the internal 
capsule and the globus pallidus at Bregma -0.34 mm, and with a small population also 
appearing dorsal to the lateral diagonal band of Broca and ventral to the ventral pallidum 
(Fig. 2; brown/beige, fifth row) at the same level. Whereas the latter cell population 
diminishes after a few slices, the former, more dorsally located population increases in 
number and spreads in all directions, thereby taking up larger areas within the internal 
capsule/globus pallidus areas (Fig. 2; brown/beige, fifth to sixth row) over the anterior-
posterior extent of the structure. Cells that are part of the nucleus basalis of Meynert 
complex are more spread out than the other above mentioned nuclei. Cell numbers start 
progressively to decrease, as the optic tract starts moving from the ventral brain surface 
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towards the internal capsule area. After the most posterior parts of the diagonal band 
complex, the lateral diagonal band of Broca, have disappeared, the nucleus basalis of 
Meynert continues on and then diminishes as the most posteriorly located structure of the 
basal forebrain at Bregma -2.06 mm, when the fasciculus retroflexus starts to deviate from 
the habenular nucleus. 
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Figure 2: Representative images of the process of transferring the manual basal 
forebrain segmentation from histological images to the corresponding MRI space. 
The different steps are shown in columns in the processing order from left to right, and, 
different levels of the basal forebrain are shown in rows from anterior (A) to posterior (P). 
VDB = vertical diagonal band of Broca, MS = medial septum, LDB = lateral diagonal band 
of broca, HDB = horizontal diagonal band of broca, NBM = nucleus basalis of Meynert. 
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Histological volume measurements 
 
After the 2D histological sections of each mouse were restacked using the MR-guided 
registration protocol, the volumes of each basal forebrain structure were calculated for all 
three mice. The individual measurements for each mouse can be seen in Table 1 together 
with the average volume measurements across all animals. These data also demonstrate 
the anatomical variability of each structure between animals, as well as between the left 
and right hemispheres. For example, mouse 2 displayed a larger horizontal diagonal band 
of Broca and lateral diagonal band of Broca as compared to mice 1 and 3. On the other 
hand, mice 1 and 3 showed larger vertical diagonal band of Broca volumes compared to 
mouse 2. There was no significant interhemispheric volume difference for any structure. 
Amongst the basal forebrain compartments, the horizontal diagonal band of Broca and 
nucleus basalis of Meynert had the largest volumes, whereas the lateral diagonal band of 
Broca was found to have the smallest volume. 
 
  
140
  
Volume (mm3) 
Structure Mouse 1 Mouse 2 Mouse 3 Average 
VDB left 0.1408 0.1009 0.1747 0.1388 ± 0.030 
VDB right 0.1398 0.1049 0.1721 0.1388 ± 0.027 
MS left 0.1321 0.1930 0.1418 0.1556 ± 0.027 
MS right 0.1280 0.1969 0.1380 0.1543 ± 0.030 
HDB left 0.1721 0.2602 0.1410 0.1911 ± 0.050 
HDB right 0.1360 0.2755 0.1458 0.1858 ± 0.064 
LDB left 0.0602 0.1352 0.0280 0.0745 ± 0.045 
LDB right 0.0425 0.1307 0.0318 0.0683 ± 0.044 
NBM left 0.1885 0.3375 0.2456 0.2572 ± 0.061 
NBM right 0.2317 0.3196 0.2534 0.2682 ± 0.037 
 
 
Table 1: Histological volumes of segmented structures of the basal forebrain in 
three adult (P90), male, ChAT-eGFP mice.  
The structures are ordered according to their initial appearance in the brain from anterior 
(top) to posterior (bottom). Average volumes are expressed as mean ± standard deviation. 
Abbreviations: VDB = vertical diagonal band of Broca, MS = medial septum, HDB = 
horizontal diagonal band of Broca, LDB = lateral diagonal band of Broca, NBM = nucleus 
basalis of Meynert. 
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3D basal forebrain map 
 
The final basal forebrain 3D map of mouse 2 is shown as a rendered surface (Fig. 3). 
From the images showing different angles of the final basal forebrain volume, the spatial 
distribution of the different structures and also the complex shape of the basal forebrain 
can be appreciated. Whereas medial septum and diagonal band of Broca areas merge 
into each other over the anterio-posterior extent of the basal forebrain, the 3D rendering 
clearly shows that the nucleus basalis of Meynert structure is not fully connected to the 
other structures (Fig. 3A-C). Furthermore the medial septum/diagonal band of Broca 
compartments together represent an overall band-like structure on the ventral surface of 
the mouse brain. 
 
 
 
Figure 3: Surface rendering of 3D basal forebrain structures from mouse 2.  
The view angle is indicated by a A-P (anterior-posterior) axis. Abbreviations: VDB = 
vertical diagonal band of Broca, MS = medial septum, HDB = horizontal diagonal band of 
Broca, LDB = lateral diagonal band of Broca, NBM = nucleus basalis of Meynert. 
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6.4 Discussion and implication of findings 
 
Here we present a map of the mouse basal forebrain created from histological 
segmentation, which can be applied for image analysis of large mouse cohorts using 
methods such as MRI and PET aimed at measuring particular features of the basal 
forebrain such as volume (MRI), retention of tracers (PET), or activity (functional MRI). 
Furthermore the detailed segmentation introduced here will enable measures of the whole 
basal forebrain area in the left and right hemispheres, as well as individual nuclei. 
The work introduced in this chapter is still in progress. So far three mice have been 
imaged at high resolution and subsequent histology of the basal forebrain sections has 
been completed. However, only one of the histological volumes has so far been registered 
to MRI space. Nevertheless the end result of the 3D basal forebrain maps in 
histological/MRI space can be seen from the single mouse for which the complete 
registration and stacking process was performed. 
In the future the complete averaged histology as well as MRI volume of the three mice will 
be available and the final average basal forebrain MRI volume will be able to be applied to 
any MRI modality of interest. As the background strain of the ChAT-eGFP mice is the 
C57BL/6J mouse, the masks will be able to be applied to one of the most commonly used 
mouse strains in current research. The maps developed here will be particularly useful for 
the study of large cohorts of mice, where MRI study templates can be created with 
sufficient animal numbers. 
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Chapter 7: Conclusions and general discussion 
 
7.1 Summary of findings and conclusions 
 
The results presented in this thesis provide new insight into the pathophysiology of basal 
forebrain degeneration during the development of Alzheimer’s disease and have 
contributed to our understanding of the pathological processes underlying this disease. It 
was shown for the first time that basal forebrain atrophy is associated with amyloid 
accumulation and tau aggregation in humans in vivo. Furthermore basal forebrain volume 
was correlated with overall cognitive decline in controls, amnestic mild cognitive 
impairment and Alzheimer’s disease subjects and we demonstrated that basal forebrain 
volumetric reductions reflect impairment of navigation skills in Alzheimer’s disease 
patients. In addition we introduced new ways of imaging basal forebrain dysfunction using 
a mouse model of basal forebrain degeneration, which have the potential to be translated 
into application in humans in the future. 
The basal forebrain is divided into a number of different nuclei situated in the medioventral 
aspects of the brain and these nuclei project to almost the entire neocortex, the amygdala 
as well as the hippocampus, thereby creating a complex network of efferent connections. 
In healthy subjects, who show no signs of cognitive impairment but who have an amyloid 
burden comparable to that of Alzheimer’s disease subjects, the volume of the posterior 
basal forebrain nucleus, which is affected early in Alzheimer’s disease and its prodromal 
stages, was correlated to global amyloid load. As the posterior basal forebrain neurons 
project to a collection of structures, including the frontal cortex, parietal cortex and 
temporal lobe, which show heavy amyloid deposition during the course of Alzheimer’s 
disease, the interaction seen in healthy subjects might represent the earliest 
neurodegenerative events occurring in the posterior basal forebrain neurons such as 
cellular shrinkage, axonal degeneration and synaptic dysfunction. However at this, 
possibly earliest, stage of Alzheimer’s disease, cognitive and morphological reserves are 
sufficient to prevent any functional cognitive impairment.  
Next it was shown that in amnestic mild cognitively impaired subjects with high amyloid 
burden and Alzheimer’s disease subjects, the anterior basal forebrain volume rather than 
the posterior volume correlates with amyloid burden. As amyloid increases over time and 
exerts its toxic effect on the brain, including the basal forebrain neurons, thereby causing 
mild (amnestic mild cognitive impairment) to severe cognitive impairment (Alzheimer’s 
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disease), it is reasonable to assume that volumetric changes in the anterior basal forebrain 
regions might become more pronounced. 
In addition to correlations with amyloid burden, it was revealed that anterior and posterior 
basal forebrain volumes of control and Alzheimer’s disease subjects were correlated to tau 
burden in brain regions known to be predominantly affected by NFT pathology and which 
are anatomically connected to the basal forebrain, in controls and Alzheimer’s disease 
subjects. By measuring tau and amyloid burden in the same subjects and correlating these 
levels to basal forebrain volumes, it was demonstrated that the basal forebrain-tau 
correlation was stronger than the basal forebrain-amyloid interaction. Thus tau toxicity 
might be more detrimental to the function of basal forebrain neurons than amyloid. 
Consistent with this, tau levels have been shown to be correlated to cognitive decline, 
whereas amyloid levels are not (Villemagne et al., 2014). 
Indeed, it was demonstrated herein that basal forebrain volumes correlate with cognitive 
scores and composite episodic memory scores. Moreover, it was discovered that basal 
forebrain volume is correlated to navigation performance specifically involving allocentric 
but not egocentric paradigms. In healthy subjects and amnestic mild cognitively impaired 
patients, the contribution of the basal forebrain degeneration appears to be indirect, and 
primarily mediated through modulation of the hippocampus. However in Alzheimer’s 
disease patients, basal forebrain atrophy may have directly mediated the observed 
impairment in spatial navigation, independent of any hippocampal involvement. In 
particular, degeneration of the anterior basal forebrain, which sends projections to the 
hippocampus, was associated with both lower cognitive scores as well as navigation 
dysfunction in Alzheimer’s disease. 
Finally, it was demonstrated in mice that the integrity of the connections between the 
anterior basal forebrain and the hippocampus can be assessed by tractography. Lesion of 
a single neuronal type, namely cholinergic neurons, induced changes in diffusion 
parameters within the basal forebrain area, as well as causing changes to streamline 
parameters connecting the basal forebrain with the hippocampus. As the basal forebrain 
consists of many other cell types, this lesion did not affect the overall volume of the area. 
Hence this diffusion MRI technique could be a more sensitive method of detecting basal 
forebrain dysfunction in Alzheimer’s disease compared with traditional structural MRI 
methods used elsewhere in this study. However this needs to be evaluated in human 
subjects. 
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The fact that basal forebrain integrity correlates with the major hallmarks of Alzheimer’s 
disease pathology, namely deposition of amyloid and tau proteins as well as cognitive 
decline, demonstrating the potential of basal forebrain integrity measures for aiding the 
future diagnosis of subjects at risk of, or with, Alzheimer’s disease.  
 
7.2 General discussion 
 
7.2.1 The basal forebrain selectively degenerates in Alzheimer’s disease and is 
dysfunctional in its prodromal stage 
 
The measurement of the basal forebrain volume using MRI in several independent patient 
cohorts from Australia (chapter 2; AIBL study; healthy controls n=141; amnestic mild 
cognitive impairment n=40; Alzheimer’s disease n=38), the United States of America 
(chapter 2; ADNI study; healthy controls n=69; amnestic mild cognitive impairment n=127; 
Alzheimer’s disease n=30) and Europe (chapter 4; healthy controls n=17; amnestic mild 
cognitive impairment n=27; Alzheimer’s disease n=22), consistently revealed significant 
reductions of either the whole basal forebrain area and/or subregions (anterior, posterior) 
of the basal forebrain for both the amnestic mild cognitive impairment and Alzheimer’s 
disease subject groups when compared to the control groups in each cohort (chapters 2, 
4). This finding is in accordance with a number of other studies published during the time 
period of the thesis, which also used MRI to assess the basal forebrain volume. Although 
these studies employed various different methods of delineating the basal forebrain 
region, they similarly reported volumetric reductions in the basal forebrain area in amnestic 
mild cognitive impairment and Alzheimer’s disease patients (George et al., 2011; Grothe et 
al., 2012; Grothe et al., 2011; Grothe et al., 2010; Teipel et al., 2005; Zhang et al., 2011). 
With the exception of the European cohort, we found that the Alzheimer’s disease groups  
had significantly smaller basal forebrain volumes. In the European cohort neither whole 
nor anterior/posterior basal forebrain volumes were significantly reduced in the Alzheimer’s 
disease cohort, which might have been due to the slightly smaller subject number in that 
group compared with the amnestic mild cognitively impaired group, which did display 
significant atrophy. In comparison, in the AIBL study we found a clear reduction in basal 
forebrain volume in both the amnestic mild cognitive impairment and Alzheimer’s disease 
subject groups; however this is perhaps not surprising as the masks used to calculate 
basal forebrain volumes of subjects were originally developed based on Alzheimer’s 
disease-related atrophy (defined by comparing Alzheimer’s disease and healthy control 
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subjects) in this cohort. On the other hand, in the American ADNI cohort, Alzheimer’s 
disease subjects showed significant basal forebrain atrophy, whereas amnestic mild 
cognitively impaired subjects did not.  
This finding in the ADNI cohort was confirmed by a recent study (George et al., 2011), 
based on manual segmentation of the substantia innominata of the basal forebrain in the 
same patient cohort, which demonstrated significant reductions in this basal forebrain 
nucleus in Alzheimer’s disease but not amnestic mild cognitively impaired subjects. The 
fact that the ADNI analysis included a significantly larger amnestic mild cognitively 
impaired subject number than the European and the AIBL cohorts combined limits our 
conclusion of a consistent significant basal forebrain volumetric reduction in amnestic mild 
cognitively impaired subjects overall. One factor may be that a single clinic performed the 
diagnosis for all subjects in the AIBL and European cohorts, whereas data from ADNI 
subjects were derived from a large number of disparate clinics. Indeed amnestic mild 
cognitive impairment subject groups are in general considered to be heterogeneous in 
nature, with ~24% of subjects converting to a diagnosis of probable Alzheimer’s disease 
and ~5% of subjects reverting to healthy control status over a 18 month time period in the 
present sample of the AIBL cohort. In line with this we consistently found a large range of 
basal forebrain volumes in the amnestic mild cognitive impairment group in all cohorts 
examined in this work (chapters 2, 4). This could reflect the presence of other dementias in 
this group as well as compensatory mechanisms occurring in the brains of amnestic mild 
cognitively impaired patients, where some subjects show greater morphological reserve 
than others (Guo et al., 2013). In fact all eight amnestic mild cognitively impaired subjects 
who subsequently converted to a clinical diagnosis of probable Alzheimer’s disease (five 
amnestic mild cognitively impaired patients in the AIBL study and three amnestic mild 
cognitively impaired patients in the ADNI study) had reduced basal forebrain volumes and 
therefore reduced morphological and cognitive reserve, prior to conversion (chapter 2). 
Evidence for compensatory metabolic events in basal forebrain neurons was recently 
demonstrated by measuring glucose uptake using PET (Kim et al., 2012). The authors of 
the study showed increased glucose uptake in the basal forebrain in mild cognitively 
impaired patients compared to controls. This in turn might reflect compensatory 
mechanisms masking the neuronal dysfunction and degeneration in these subjects, which, 
in Alzheimer’s disease subjects, are then revealed by further degeneration that is reflected 
by increased atrophy. Indeed, when we calculated the annual rate of atrophy of basal 
forebrain and hippocampus (Fig. 7.1) in the AIBL study we found that Alzheimer’s disease 
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subjects had a significantly higher rate of atrophy (p<0.05; determined by calculating the 
volumetric difference between time points and dividing by the follow-up time in years) 
compared to the healthy control groups (annual rates of atrophy: Alzheimer’s disease 
1.88%; amnestic mild cognitive impairment 0.71%; healthy controls PiB+ 0.58%; healthy 
controls PiB- 0.66%). Basal forebrain rates of atrophy were also similar to hippocampal 
rates of atrophy in the AIBL cohort (annual rates of atrophy: Alzheimer’s disease 2.03%; 
amnestic mild cognitive impairment 1.59%; healthy controls PiB+ 0.51%; healthy controls 
PiB- 0.56%), with the hippocampal rate of atrophy also being significantly higher in the 
Alzheimer’s disease subjects (p<0.001) and amnestic mild cognitive impairment group 
(p<0.01) as compared to healthy control groups. The absence of a significantly higher 
basal forebrain rate of atrophy in the mild cognitively impaired group might be due to the 
fact that basal forebrain volumetric measures generally display greater variance than, for 
example, hippocampal volume measures, but this does not exclude the possibility of 
higher basal forebrain atrophy being present in this group. Consistent with these findings, 
almost identical rates of atrophy for the basal forebrain and hippocampus were recently 
found by Grothe et al. (2012) in an independent patient cohort of healthy elderly and 
Alzheimer’s disease subjects.  
Overall the volumetric findings presented in this work showing significant and consistent 
basal forebrain volumetric atrophy in Alzheimer’s disease, and to a lesser extent in 
amnestic mild cognitive impairment, is independent of global neocortical grey matter 
atrophy (chapter 2), is consistent with histological studies (chapter 1, section 1.4) showing 
no difference in cholinergic neuron numbers in mild cognitively impaired subjects, but 
significant reductions in Alzheimer’s disease patients. 
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Figure 7.1: Annual rates of atrophy of hippocampus and basal forebrain volumes 
calculated over an ~18 months time frame.  
The volumetric difference was calculated between two time points of the AIBL study 
(chapter 2) for each structure and divided by the follow-up time in years. The resulting 
annual rates of change for the subjects were then averaged across clinical groups. * 
p<0.05, ** p<0.01, *** p<0.001 compared to HC PiB+/HC PiB-. Whiskers represent 
min/max values except data points (circles) more than 1.5 interquartile ranges away from 
the 75th percentile. 
 
 
 
7.2.2 Basal forebrain degeneration is correlated to Alzheimer’s disease-related cognitive 
decline and mediates spatial navigation impairments 
 
The current work revealed that basal forebrain volume is correlated to an impairment in 
cognitive ability in Alzheimer’s disease. Correlations of whole, anterior and posterior basal 
forebrain volumes with various cognitive scores in different cohorts revealed significant 
associations between these modalities. For example in the AIBL study this was apparent 
when we found significant correlations between basal forebrain volumes (whole, anterior 
and posterior) and MMSE scores in the whole sample (whole r=0.35, p<0.001; anterior 
r=0.33, p<0.001; posterior r=0.33, p<0.001). In addition clinical dementia rating (CDR) 
scores were significantly correlated to basal forebrain volume (whole r=0.41, p<0.001; 
anterior r=0.41, p<0.001; posterior r=0.36, p<0.001) and CDR sum of boxes (SoB) scores 
also showed significant associations with basal forebrain volumes (whole r=0.43, p<0.001; 
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anterior r=0.39, p<0.001; posterior r=0.41, p<0.001) in the AIBL cohort. However the 
above interactions did not persist at an individual group level and were therefore partly 
driven by the differences between groups.  
The influence of the basal forebrain on overall cognitive state of subjects is also indirect 
and occurs primarily through modulation of activity as well as neuronal plasticity of target 
projection areas such as neocortical regions and the hippocampus (chapter 1, Figure 1.1). 
Therefore early degeneration and atrophy of the basal forebrain in aging as well as 
predementia stages does not directly result in cognitive deficits. However the severe basal 
forebrain cell loss occurring at later stages of Alzheimer’s disease has more direct 
ramifications on the cognitive state of patients. Nevertheless we recently replicated the 
above findings in the smaller independent European cohort, showing a significant 
correlation between anterior basal forebrain volume and CDR, CDR SoB as well as 
composite episodic memory score (chapter 3). 
Moreover, we found that basal forebrain atrophy contributes to the functional impairment 
of subjects as measured by their ability to perform specific navigation tasks (chapter 4). 
Regression analyses in this study indicated that navigation performance in the whole 
cohort is only indirectly correlated to basal forebrain volume but that performance is 
strongly associated with hippocampal volume. In this case, the involvement of the basal 
forebrain in navigation performance in healthy subjects might occur predominantly through 
its contribution to modulating hippocampal function. However in Alzheimer’s disease 
subjects, basal forebrain atrophy and therefore severe dysfunction of basal forebrain 
neurons was identified as solely mediating navigation impairments, independent of 
hippocampal contribution (chapter 4).  
 
7.2.3 Basal forebrain atrophy is linked to amyloid and tau accumulation during the 
development of Alzheimer’s disease 
 
Reductions in basal forebrain volumes were shown to be associated with amyloid 
pathology measured by PiB-PET (chapter 2) as well as AV45 (florbetapir) PET (Grothe et 
al., 2014; Teipel et al., 2013) in Alzheimer’s disease, amnestic mild cognitive impairment 
and control subjects. Interestingly, we found that while anterior basal forebrain volume 
correlated with neocortical amyloid burden in amnestic mild cognitively impaired and 
Alzheimer’s disease patients, posterior basal forebrain volume was associated with 
amyloid burden in controls (chapter 2). This interaction of the basal forebrain with amyloid 
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accumulation is selective and independent of hippocampal and neocortical involvement, 
as neither hippocampal nor neocortical volumes were correlated to global amyloid load. 
Furthermore we found that there was no difference in the rate of basal forebrain atrophy of 
amyloid accumulators vs. non-accumulators (Fig. 7.2; as defined by Villain et al., 2012) 
within any of the subject groups over the 18 month time period in the AIBL study. Similarly, 
a recent study found no relationship between hippocampal rate of atrophy and amyloid 
accumulation (Jack et al., 2014). Another study demonstrated that there is no correlation 
between amyloid burden and the rate of brain atrophy or ventricular expansion (Josephs et 
al., 2008). However, we found a relationship between absolute amyloid burden and basal 
forebrain volume, and although amyloid-beta may not drive basal forebrain degeneration, 
degeneration could contribute to increasing amyloid-beta load within innervated brain 
areas. 
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Figure 7.2: Basal forebrain annual rate of atrophy of subject groups that were 
subdivided into PiB accumulators and non-accumulators.  
There was no effect of amyloid accumulation status on basal forebrain rate of atrophy in 
any of the clinical groups. Linear regression between rate of PiB retention over time 
(independent of accumulation status) and basal forebrain rate of atrophy in individual 
subject groups did not reveal any significant associations. Whiskers represent min/max 
values except data points (circles) more than 1.5 interquartile ranges away from the 75th 
percentile. 
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Our findings are equally consistent with accumulating levels of amyloid affecting basal 
forebrain neuronal terminals in their respective target areas (Auld et al., 2002; Yan and 
Feng, 2004). It has been suggested that amyloid oligomers have the potential to exert a 
wide range of effects on the function of basal forebrain neuronal networks, such as the 
depression of acetylcholine and muscarinic signalling, and enhancement of glutamate 
release (Auld et al., 2002). The correlations reported here might therefore represent the 
downstream consequences of some of the abovementioned processes. 
Tau NFTs, on the other hand, which occur in brain regions that are innervated by basal 
forebrain neurons as well as within basal forebrain neurons themselves (Braak et al., 
2006), were shown to exert a potentially stronger effect on basal forebrain neurons in vivo 
than that induced by amyloid accumulation (chapter 3). However the small sample size in 
the study limits the strength of our conclusions in this regard, and larger studies are 
required to verify our findings.  
Nevertheless, we were able to show correlations of regional THK523/THK5105 retention 
with anterior and posterior basal forebrain volumes in two independent cohorts, as well as 
in the respective clinical groups. While anterior basal forebrain was correlated to THK523 
retention in the hippocampus, orbitofrontal cortex and gyrus rectus in cohort 1, no 
significant correlations were found between anterior basal forebrain volume and THK5105 
retention in cohort 2. In contrast, significant correlations were found between posterior 
basal forebrain volume and parietal as well as neocortical THK523 retention in cohort 1, 
and, parietal as well as neocortical THK5105 retention in cohort 2. In addition, significant 
correlations between basal forebrain volumes and THK523 retention were identified at the 
clinical group level in cohort 1, but these interactions were not replicated for THK5105 
retention in cohort 2. Although the results of the analysis of both cohorts only partly 
overlaps, in both cohorts significant interactions were found.  
These differences might be attributed to the minimal sample size in the THK5105 cohort 
as compared to the THK523 cohort or the different pharmacokinetic properties and binding 
profiles of the two tracers (section 3.4; Okamura et al., 2014; Okamura et al., 2013). 
Larger sample sizes and improved tau tracers currently under development will help to 
clarify the different interactions between global and regional tau burden and basal 
forebrain volumes. Despite these limitations we were able to identify significant 
correlations between basal forebrain volume and tau burden in various brain regions in 
two independent cohorts, employing two different PET tracers in control and Alzheimer’s 
disease subjects. Thus we demonstrated that in vivo measures of tau burden also 
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correlates with another hallmark of Alzheimer’s disease pathology, namely basal forebrain 
atrophy, in addition to previously identified interactions with atrophy of regions such as the 
hippocampus and temporal lobe (Okamura et al., 2014; Villemagne et al., 2014). 
Therefore the present findings further support the potential value usefulness of non-
invasive evaluation of tau pathology in vivo in human populations for diagnostic and/or 
prognostic purposes. 
The work presented herein provides evidence that amyloid and tau pathology, cognitive 
impairment and basal forebrain degeneration could be mechanistically linked. It is further 
proposed that amyloid might accumulate early in asymptomatic subjects but is not 
sufficient to cause the development of Alzheimer’s disease. However parallel induction of 
tau pathology, potentially coupled to other secondary events (environmental and/or 
genetic), could be required to trigger basal forebrain and other brain regional 
degeneration, ultimately leading to cognitive decline. The application of a combination of 
both amyloid and tau imaging with structural MRI in large longitudinal studies, including 
amnestic mild cognitively impaired patient groups, will provide crucial insight into the 
interplay of these pathological features in vivo and their precise relationship to brain 
atrophy and cognitive impairment.  
 
7.2.4 Basal forebrain measures and their potential as diagnostic tools of Alzheimer’s 
disease 
 
Measures of basal forebrain neuronal integrity have great potential as reliable biomarkers 
of Alzheimer’s disease and other dementias. It is clear that basal forebrain volumes can be 
used to distinguish between Alzheimer’s disease, amnestic mild cognitively impaired and 
control subjects. We found that amnestic mild cognitively impaired patients had basal 
forebrain volumes below a certain cut-off value prior to conversion to Alzheimer’s disease. 
Subjects with a basal forebrain volume below this value were at a seven times higher risk 
of conversion to greater cognitive impairment than subjects with basal forebrain volumes 
in the range of the cognitively normal cluster (chapter 2). Furthermore diffusion MRI could 
in the future be used to measure disconnection and death of the cholinergic basal 
forebrain neuronal network prior to atrophy (Kerbler et al., 2012). However methods of 
evaluating basal forebrain integrity have only recently been developed (chapter 2; George 
et al., 2011; Kerbler et al., 2012) and before these methods could be considered for 
diagnostic application at the single subject level, significant validation, replication and 
standardization need to be performed. Nevertheless it has been demonstrated that basal 
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forebrain atrophy correlates with the major hallmarks of Alzheimer’s disease pathology, 
namely amyloid accumulation, aggregation of tau and cognitive impairment. 
Basal forebrain regions of interest (ROIs) such as the maximum probability masks 
developed in this work or the probabilistic maps developed by Zaborszky et al. (2008) 
should be used to assess volumetric integrity of the human basal forebrain as they most 
accurately represent the basal forebrain area. It was found that the maximum probability 
masks (which are partly based on the probabilistic maps) show a high overlap (85%; 
chapter 3) with the probabilistic maps developed through combined histological 
segmentation of the basal forebrain of 10 post-mortem brains (Zaborszky et al., 2008), 
verifying the anatomical precision of the maximum probability masks. The use of a 
probabilistic mask based on segmentation of a brain structure from several subjects’ 
brains is crucial when measuring the volume of a highly variable brain region such as the 
basal forebrain, which does not have any visible anatomical boundaries on MR images. 
Therefore manual segmentation (George et al., 2011) of the basal forebrain should be 
avoided, as it is not a reliable way of determining the volume of this structure. 
Using a mask created from histological segmentation of a single post-mortem brain 
(Grothe et al., 2011; Teipel et al., 2005) is equally flawed, as it does not give a reasonable 
estimate of the basal forebrain area in a population setting. For example, when the mask 
used by Teipel and colleagues (2005) was compared to the probabilistic ROI developed by 
Zaborszky et al. (2008), it was found that the Ch4 area of the former mask was about 20 
times larger than that of the latter mask. The mask developed by Teipel et al. was also 
reported to include areas outside the basal forebrain such as the anterior commissure, 
large parts of the ventral globus pallidus and parts of the medioventral putamen, and 
analyses using this ROI could therefore lead to erroneous conclusions (Zaborszky et al., 
2008). However, the masks developed by Zaborszky et al. (2008) are not yet publicly 
available. In a clinical setting with the aim of potential diagnosis of Alzheimer’s disease, 
maximum probability masks would be particularly useful as they represent basal forebrain 
maps of Alzheimer’s disease-specific change within anatomically verified regions of the 
basal forebrain. 
Another reason basal forebrain atrophy should be incorporated into clinical setting is that, 
because basal forebrain volume correlates with the two pathological hallmarks of 
Alzheimer’s disease, namely accumulation of amyloid and aggregation of tau (chapter 2; 
chapter 3) and is associated with cognitive impairment (chapter3; chapter 4), it is an 
excellent correlate of Alzheimer’s disease, a critical attribute of a potential biomarker. 
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Basal forebrain volume measures might also have better predictive power than 
hippocampal volume measures or measures of global neocortical grey matter atrophy, as 
the latter do not correlate to amyloid burden.  
In addition, basal forebrain neurons are amongst the first to develop tau pathology, seen in 
Braak stage I, whereas tau pathology is observed in the hippocampal formation only in 
Braak stage II (Braak et al., 2006). Although our results demonstrate that basal forebrain 
volume does correlate to tau burden in anatomically connected brain regions, it remains to 
be investigated whether the level of tau in the basal forebrain itself is correlated to basal 
forebrain volume. Assessment of glucose metabolism in the basal forebrain using FDG 
(fluorodeoxyglucose) PET was recently demonstrated to detect hypermetabolism in mild 
cognitively impaired patients compared to controls. This suggests that PET measures of 
tau burden in the basal forebrain could be of particular use for diagnosis of Alzheimer’s 
disease due to the early presence of NFTs in this structure. However, the current 
spatiotemporal resolution of tau-PET imaging is not sufficient to measure tau burden in the 
basal forebrain due to the distance that positrons travel before annihilation. With advances 
in PET technology such as the development of new methods of spatial normalization, 
improvements in system geometry and the introduction of novel detectors, the sensitivity 
of PET systems will be enhanced (Kim et al., 2012; Lewellen, 2008; Peng and Levin, 
2010), potentially enabling future studies to address the above issue. 
It was reported herein that measuring diffusion MRI parameters of the basal forebrain 
area, as well as performing tractography of basal forebrain connections could be used to 
detect basal forebrain cholinergic degeneration in the absence of volumetric changes in 
mice, while being associated with histological measures (chapter 5). The changes in 
diffusion parameters in mice that had undergone lesioning of cholinergic neurons were 
comparable with the first results in human studies measuring similar parameter changes in 
either the basal forebrain area or the fornix in mild cognitively impaired and Alzheimer’s 
disease patients as compared to controls (Oishi et al., 2011; Pievani et al., 2010), but in 
the latter studies there was no biological explanation for the findings. Therefore, our study 
demonstrates the potential sensitivity and feasibility of diffusion MRI to detect brain 
regional changes and alterations in connectivity of the basal forebrain specifically, before 
gross structural change can be detected. In the current study we assessed the 
septohippocampal connections; however tractography measurement of posterior basal 
forebrain projections, namely basalocortical connections, which appear to degenerate at 
the earliest stages of disease, might provide the most predictive clinical information. This 
method would also give a more complete picture of the integrity of the whole network of 
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basal forebrain connections. Furthermore tractography could be used to study 
pathophysiology namely the disconnection of basal forebrain neurons from their targets 
during the development of Alzheimer’s disease. This is expected to occur much earlier in 
the disease, possibly in relation to amyloid deposition and tau aggregation. In addition, 
measuring local diffusion MRI parameters in the basal forebrain could provide a more 
sensitive method over volumetric assessment of the basal forebrain for the potential 
diagnosis of Alzheimer’s disease. However this needs to be further evaluated in human 
subjects. 
The methods of assessing basal forebrain integrity developed in this work using MRI are 
particularly useful because of their potential to be translated into future clinical application. 
These methods allow non-invasive assessment of the structural properties of pathological 
processes relevant for a neurological disorder involving basal forebrain dysfunction. If 
used early in the disease course, the analysis could help to identify those subjects who are 
at risk of developing significant basal forebrain dysfunction that could result in cognitive 
impairment and for whom early treatment with current acetyl cholinesterase drugs and 
future pharmacological agents would be most benificial (Knowles et al., 2013; Longo and 
Massa, 2013; Nguyen et al., 2014). Furthermore the human basal forebrain masks 
introduced here could be applied to study not only structural alterations, but also functional 
properties of the basal forebrain using, for example, functional MRI and PET. 
This thesis has reported significant correlations between basal forebrain degeneration and 
hallmarks of Alzheimer’s disease. However, it remains to be determined why basal 
forebrain neurons are particularly vulnerable to neurodegeneration. It is possible that long 
projection neurons have an increased susceptibility to protein deposits and it has been 
suggested that such neurons, which include basal forebrain neurons, might be the first to 
be affected in Alzheimer’s disease, particularly when they are only sparsely myelinated, 
such as the cholinergic neurons (Braak and Del Tredici, 2011a; Braak et al., 2000; Gartner 
et al., 2001; Moceri et al., 2000).  
Finally, this work provides a substantial contribution to the understanding of the process of 
degeneration of the basal forebrain network in Alzheimer’s disease and its prodromal 
stages. The data that form this thesis and that obtained by others over the same time 
frame, now provide a significant body of evidence linking basal forebrain degeneration, tau 
aggregation, amyloid accumulation and cognitive impairment. Although cause and effects 
remain to be determined through both animal and longitudinal studies of clinical human 
cohorts, there is now strong justification to herald measures of basal forebrain dysfunction 
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as a key clinical attribute to be assessed for diagnostic purposes, and potentially for the 
purpose of individualizing the prescription of appropriate drugs. 
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